lomustine has been researched along with Benign Neoplasms, Brain in 488 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Here, we explored the incidence, and the consequences for treatment exposure and survival, of thrombocytopenia induced by lomustine in recurrent glioblastoma." | 9.69 | Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101. ( Brandes, AA; Clement, PM; Golfinopoulos, V; Gorlia, T; Idbaih, A; Le Rhun, E; Oppong, FB; Platten, M; Preusser, M; Taphoorn, MJ; van den Bent, M; Weller, M; Wick, W, 2023) |
| " We investigated Depatux-M in combination with temozolomide or as a single agent in a randomized controlled phase II trial in recurrent EGFR amplified glioblastoma." | 9.34 | INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. ( Ansell, P; Brilhante, J; Chinot, O; Clement, PM; Coens, C; De Vos, F; Dey, J; Dubbink, HJ; Eoli, M; Franceschi, E; French, P; Frenel, JS; Golfinopoulos, V; Gorlia, T; Krause, S; Looman, J; Nuyens, S; Sanghera, P; Sepulveda, JM; Smits, M; Spruyt, M; Van Den Bent, M; Walenkamp, A; Weller, M; Whenham, N, 2020) |
| "Despite somewhat prolonged progression-free survival, treatment with lomustine plus bevacizumab did not confer a survival advantage over treatment with lomustine alone in patients with progressive glioblastoma." | 9.24 | Lomustine and Bevacizumab in Progressive Glioblastoma. ( Bendszus, M; Brandes, AA; Bromberg, JC; Campone, M; Clement, PM; Domont, J; Dubois, F; Fabbro, M; Golfinopoulos, V; Gorlia, T; Harting, I; Idbaih, A; Klein, M; Le Rhun, E; Platten, M; Sahm, F; Stupp, R; Taal, W; Taphoorn, M; van den Bent, MJ; von Deimling, A; Weller, M; Wick, W, 2017) |
| "Adding temozolomide (TMZ) to radiation for patients with newly-diagnosed anaplastic astrocytomas (AAs) is common clinical practice despite the lack of prospective studies demonstrating a survival advantage." | 9.22 | The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide. ( Abuali, I; Grossman, SA; Lu, Y; Strowd, RE; Ye, X, 2016) |
| "The combination of galunisertib, a transforming growth factor (TGF)-β receptor (R)1 kinase inhibitor, and lomustine was found to have antitumor activity in murine models of glioblastoma." | 9.22 | A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. ( Brandes, AA; Capper, D; Carpentier, AF; Cher, L; Chinot, O; Cleverly, A; Desaiah, D; Guba, SC; Gueorguieva, I; Kesari, S; Lahn, MM; Miles, C; Rodon, J; Sepulveda-Sanchez, JM; Smith, C; Specenier, P; Steinbach, JP; Wheeler, HR; Wick, W, 2016) |
| "We conducted a randomized, non-comparative, multi center, phase II clinical trial in order to investigate the efficacy of axitinib, an oral small molecule tyrosine kinase inhibitor with high affinity and specificity for the vascular endothelial growth factor receptors, in patients with recurrent glioblastoma following prior treatment with radiation and temozolomide." | 9.22 | Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma. ( Bouttens, F; D'Haene, N; Du Four, S; Duerinck, J; Everaert, H; Le Mercier, M; Michotte, A; Neyns, B; Salmon, I; Van Binst, AM; Vandervorst, F; Verschaeve, V, 2016) |
| "Following maximal surgical resection, newly diagnosed children with nonmetastatic high-grade glioma underwent involved field radiotherapy with concurrent temozolomide." | 9.22 | Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study. ( Brat, DJ; Burger, PC; Buxton, A; Cohen, KJ; Eckel, SP; Hamilton, RL; Jakacki, RI; Krailo, MD; Lavey, RS; Pollack, IF; Rosenblum, MK; Zhou, T, 2016) |
| " This trial evaluated the efficacy of low dose bevacizumab in combination with lomustine (CCNU) compared to standard dose bevacizumab in patients with recurrent glioblastoma." | 9.22 | A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma. ( Colen, RR; Conrad, CA; de Groot, JF; Gilbert, MR; Han, X; Liu, DD; Loghin, ME; O'Brien, BJ; Penas-Prado, M; Puduvalli, VK; Tremont-Lukats, I; Weathers, SP; Yung, WKA, 2016) |
| "In this side study of the BELOB trial, 141 patients with recurrent glioblastoma were randomised to receive single-agent bevacizumab or lomustine, or bevacizumab plus lomustine." | 9.20 | Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial. ( Beerepoot, L; Beije, N; de Vos, FY; Gratama, JW; Hanse, M; Kraan, J; Oosterkamp, HM; Otten, A; Sleijfer, S; Taal, W; van den Bent, MJ; van der Holt, B; van Linde, ME; Vernhout, RM; Walenkamp, AM, 2015) |
| " Adult patients (≥18 years of age) with a first recurrence of a glioblastoma after temozolomide chemoradiotherapy were randomly allocated by a web-based program to treatment with oral lomustine 110 mg/m(2) once every 6 weeks, intravenous bevacizumab 10 mg/kg once every 2 weeks, or combination treatment with lomustine 110 mg/m(2) every 6 weeks and bevacizumab 10 mg/kg every 2 weeks." | 9.19 | Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. ( Beerepoot, LV; Boerman, D; Brandsma, D; Bromberg, JE; Buter, J; de Vos, FY; Dinjens, WN; Dubbink, HJ; Enting, RH; Hanse, MC; Honkoop, AH; Jansen, RL; Oosterkamp, HM; Taal, W; Taphoorn, MJ; van den Bent, MJ; van den Berkmortel, FW; van der Holt, B; van Heuvel, I; Vernhout, RM; Walenkamp, AM, 2014) |
| "A randomized, phase III, placebo-controlled, partially blinded clinical trial (REGAL [Recent in in Glioblastoma Alone and With Lomustine]) was conducted to determine the efficacy of cediranib, an oral pan-vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, either as monotherapy or in combination with lomustine versus lomustine in patients with recurrent glioblastoma." | 9.17 | Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. ( Ashby, LS; Batchelor, TT; Campone, M; Cher, L; Degroot, J; Gattamaneni, R; Jain, RK; Jürgensmeier, JM; Liu, Q; Mason, W; Mikkelsen, T; Mulholland, P; Nabors, LB; Neyns, B; Payer, F; Phuphanich, S; Rosenthal, M; Sorensen, AG; van den Bent, M; Wick, A; Xu, J, 2013) |
| "This phase III open-label study compared the efficacy and safety of enzastaurin versus lomustine in patients with recurrent glioblastoma (WHO grade 4)." | 9.14 | Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. ( Carpentier, AF; Chamberlain, MC; Cher, LM; Fine, HA; Hong, S; Liepa, AM; Mason, W; Musib, L; Puduvalli, VK; Thornton, DE; van den Bent, MJ; Weller, M; Wick, W, 2010) |
| "A phase I trial was conducted to determine the maximum tolerated dose (MTD) of temozolomide given in combination with lomustine in newly diagnosed pediatric patients with high-grade gliomas." | 9.13 | A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood. ( Adamson, PC; Blaney, SM; Flom, L; Ingle, AM; Jakacki, RI; Pollack, IF; Prados, MD; Timmerman, R; Yates, A; Zhou, T, 2008) |
| "To evaluate toxicity and efficacy of the combination of lomustine, temozolomide (TMZ) and involved-field radiotherapy in patients with newly diagnosed glioblastoma (GBM)." | 9.12 | Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. ( Bamberg, M; Blaschke, B; Herrlinger, U; Hundsberger, T; Koch, D; Kortmann, RD; Loeser, S; Meyermann, R; Reifenberger, G; Rieger, J; Sommer, C; Steinbach, JP; Tan, TC; Weller, M; Wick, W, 2006) |
| "Temozolomide is an alkylating agent with activity in the treatment of melanoma metastatic to the brain." | 9.12 | A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma. ( Bate, SC; Beirne, DA; Eisen, TG; Gibbens, IM; Gore, ME; Hughes, SA; Larkin, JM; Patel, PM; Thomas, K, 2007) |
| "The authors investigated the results of PCV chemotherapy within a cohort of 24 patients treated within the EORTC study 26971 on temozolomide chemotherapy in recurrent oligodendroglioma." | 9.11 | Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas. ( Allgeier, A; Brandes, AA; Enting, RH; Frenay, M; Kros, JM; Menten, J; Stege, EB; Taphoorn, MJ; Tosoni, A; Triebels, VH; van den Bent, MJ; van Heuvel, I, 2004) |
| "To conduct a Phase II study to evaluate the long-term efficacy and safety of high-dose 5'-bromodeoxyuridine (BrdU) and accelerated radiotherapy followed by procarbazine, lomustine (CCNU), and vincristine (PCV) chemotherapy in patients with glioblastoma multiforme." | 9.09 | A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme. ( Bruner, JM; Groves, MD; Hess, K; Jaeckle, KA; Kyritsis, AP; Levin, VA; Maor, MH; Meyers, C; Peterson, P; Sawaya, RE; Yung, WK, 1999) |
| "Although the efficacy of the nitrosourea-based combination chemotherapy procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, and vincristine (PCV) has been previously demonstrated in the setting of anaplastic/intermediate-grade gliomas, the benefit for glioblastoma patients remains unproven." | 9.09 | Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. ( Bruner, JM; Chang, SM; Choucair, A; Flynn, PJ; Gleason, MJ; Hess, KR; Jaeckle, KA; Kyritsis, AP; Levin, VA; Prados, MD; Uhm, JH, 2000) |
| "To conduct a Phase II one-arm study to evaluate the long-term efficacy and safety of accelerated fractionated radiotherapy combined with intravenous carboplatin for patients with previously untreated glioblastoma multiforme tumors." | 9.08 | Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme. ( Bruner, J; Kyritsis, AP; Leeds, N; Levin, VA; Maor, MH; Rodriguez, L; Sawaya, R; Thall, PF; Woo, S; Yung, WK, 1995) |
| "There is no benefit to the treatment of high-grade astrocytomas in children with eight-drugs-in-1-day chemotherapy compared with CCNU, vincristine, and prednisone." | 9.08 | Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens Cancer Group. ( Bertolone, SJ; Boyett, JM; Cherlow, JM; Finlay, JL; Geyer, JR; McGuire, P; Milstein, JM; Tefft, M; Wisoff, JH; Yates, AJ, 1995) |
| "A prospective phase II study of paclitaxel was performed in adult patients with recurrent hemispheric oligodendrogliomas." | 9.08 | Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas. ( Chamberlain, MC; Kormanik, PA, 1997) |
| "The regimen of procarbazine, CCNU, and vincristine is active against gliomas." | 9.08 | Dose-intensification of procarbazine, CCNU (lomustine), vincristine (PCV) with peripheral blood stem cell support in young patients with gliomas. ( Cornetta, K; Dropcho, E; Heilman, DK; Jakacki, RI; Jamison, C; Macdonald, DR; Mathews, VP; Williams, DA, 1998) |
| "In a study activated in 1983 and closed in 1987, the Brain Tumor Research Center of the University of California and the Northern California Cancer Center evaluated the effect of bromodeoxyuridine in the treatment of glioblastoma multiforme." | 9.07 | Evaluation of bromodeoxyuridine in glioblastoma multiforme: a Northern California Cancer Center Phase II study. ( Ahn, DK; Davis, RL; Flam, MS; Gutin, PH; Levin, VA; Phillips, TL; Prados, MD; Wara, WM; Wilson, CB, 1991) |
| " The protocol called for a randomized trial that compared the effects of following 60 Gy radiation/oral hydroxyurea treatment with either carmustine (BCNU) or the combination of procarbazine, lomustine (CCNU), and vincristine (PCV) for two histologic strata: glioblastoma multiforme and other anaplastic gliomas." | 9.06 | Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. ( Davis, RL; Gutin, PH; Hannigan, J; Levin, VA; Silver, P; Wara, WM; Wilson, CB, 1990) |
| "The majority of patients with high-risk lower grade gliomas (LGG) are treated with single-agent temozolomide (TMZ) and radiotherapy despite three randomized trials showing a striking overall survival benefit with adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy and radiotherapy." | 9.05 | Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV. ( Atkins, KM; Dietrich, J; Loeffler, JS; McDuff, SGR; Oh, KS; Shih, HA, 2020) |
| "To assess the effectiveness and safety of procarbazine, lomustine, and vincristine (PCV) chemotherapy with other interventions in adults with recurrent high-grade glioma." | 8.95 | Procarbazine, lomustine and vincristine for recurrent high-grade glioma. ( Guo, J; Parasramka, S; Rosenfeld, M; Talari, G; Villano, JL, 2017) |
| "The methylhydrazine derivative Procarbazine (PCZ) as monotherapy or in combination with CCNU and vincristine (PCV) was evaluated in a vast number of clinical trials and is still used in patients with high-grade and low-grade gliomas." | 8.84 | Procarbazine--a traditional drug in the treatment of malignant gliomas. ( Bogdahn, U; Goerne, R; Hau, P, 2008) |
| "We evaluated O-(2-[18F]fluoroethyl)-l-tyrosine (FET) PET and MRI for early response assessment in recurrent glioma patients treated with lomustine-based chemotherapy." | 8.31 | Prediction of response to lomustine-based chemotherapy in glioma patients at recurrence using MRI and FET PET. ( Bauer, EK; Ceccon, GS; Fink, GR; Galldiks, N; Goldbrunner, R; Kabbasch, C; Langen, KJ; Lohmann, P; Stoffels, G; Tscherpel, C; Werner, JM; Wollring, MM, 2023) |
| " TTFields therapy is approved for treatment of newly-diagnosed glioblastoma (GBM) concurrent with maintenance temozolomide (TMZ)." | 8.31 | Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines. ( Dor-On, E; Fishman, H; Giladi, M; Haber, A; Kinzel, A; Monin, R; Palti, Y; Weinberg, U, 2023) |
| " Here we describe the occurrence of pseudoprogression in patients with anaplastic oligodendrogliomas treated with postoperative procarbazine, lomustine and vincristine (PCV) chemotherapy alone." | 8.31 | T2-Fluid-attenuated inversion recovery (FLAIR) pseudoprogression in patients with anaplastic oligodendrogliomas treated with procarbazine, lomustine and vincristine (PCV) chemotherapy alone. ( Boutet, C; Carpentier, C; Dehais, C; Di Stefano, AL; Ducray, F; Esparragosa Vazquez, I; Figarella-Branger, D; Forest, F; Larrieu-Ciron, D; Meyronet, D; Ndiaye, M; Picart, T; Rivoirard, R; Seyve, A; Vassal, F; Younan, N, 2023) |
| "Glioblastomas (GBM) often acquire resistance against temozolomide (TMZ) after continuous treatment and recur as TMZ-resistant GBM (TMZ-R-GBM)." | 8.02 | Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance. ( Fujii, T; Ichimura, K; Kawauchi, D; Kobayashi, T; Kondo, A; Nakano, T; Narita, Y; Sasaki, N; Satomi, K; Takahashi, M; Tomiyama, A; Uchida, E; Wada, K; Yamamuro, S; Yoshino, A, 2021) |
| "IDH-mutant anaplastic astrocytomas (AAs) are chemosensitive tumors for which the best choice of adjuvant chemotherapy between procarbazine, lomustine, and vincristine (PCV) or temozolomide (TMZ) after radiotherapy (RT) remains unclear." | 8.02 | Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for IDH-Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort. ( Bronniman, C; Carpentier, C; Ciron, DL; Dehais, C; Ducray, F; Esteyrie, V; Figarella-Branger, D; Martin, E; Moyal, EC; Network, P; Pouessel, D; Uro-Coste, E, 2021) |
| "Following optimal local therapy, adjuvant Procarbazine, Lomustine and Vincristine (PCV) improves overall survival (OS) in low-grade glioma (LGG)." | 8.02 | One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre. ( Aslam, R; Breathnach, OS; Coyne, Z; Grogan, L; Hennessy, BT; Hennessy, MA; Keogh, RJ; Morris, PG, 2021) |
| "In the EF-14 trial for newly diagnosed glioblastoma (ndGBM) patients addition of Tumour Treating Fields (TTFields) to temozolomide treatment resulted in a significantly improved overall survival (OS)." | 7.96 | Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma. ( Blau, T; Deuschl, C; Glas, M; Herrlinger, U; Kebir, S; Keyvani, K; Kleinschnitz, C; Lazaridis, L; Oster, C; Pierscianek, D; Schäfer, N; Scheffler, B; Schmidt, T; Stuschke, M; Sure, U; Teuber-Hanselmann, S; Tzaridis, T; Weller, J, 2020) |
| "Systematic evaluation of the effectiveness and safety of combined procarbazine, lomustine, and vincristine for treating recurrent high-grade glioma." | 7.96 | A comparative study of the effectiveness and safety of combined procarbazine, lomustine, and vincristine as a therapeutic method for recurrent high-grade glioma: A protocol for systematic review and meta-analysis. ( Cai, Y; Jiang, YG; Jiang, ZH; Tan, ZG; Wang, M, 2020) |
| "Radiotherapy with procarbazine, lomustine, and vincristine (PCV) improves overall survival in patients with anaplastic oligodendroglioma 1p19q codeleted." | 7.88 | Radiotherapy plus temozolomide or PCV in patients with anaplastic oligodendroglioma 1p19q codeleted. ( Castro-Martinez, E; Gonzalez-Aguilar, A; Guerrero-Juarez, V; Gutierrez-Aceves, A; Hernandez-Hernandez, A; Lopez-Martinez, M; Peiro-Osuna, RP; Reyes-Moreno, I; Santos-Zambrano, J, 2018) |
| "Taken together, these data suggest a potential role for a combination therapy of lomustine and DHA for the treatment of glioblastomas." | 7.81 | Enhanced anticancer properties of lomustine in conjunction with docosahexaenoic acid in glioblastoma cell lines. ( Cohen-Gadol, AA; Harvey, KA; Pollok, K; Saaddatzadeh, MR; Siddiqui, RA; Wang, H; Xu, Z, 2015) |
| "In this retrospective study, we identified adult patients with histologically confirmed glioblastoma (WHO grade IV) who were treated with lomustine or carmustine in combination with bevacizumab as a second or third regimen after failing an alternative initial bevacizumab-containing regimen." | 7.80 | Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab. ( Alexander, BM; Beroukhim, R; Doherty, L; Hempfling, K; Huang, RY; LaFrankie, D; Lee, EQ; Nayak, L; Norden, AD; Rahman, R; Rai, A; Reardon, DA; Rifenburg, J; Rinne, ML; Ruland, S; Wen, PY, 2014) |
| " The validated method has been successfully applied to a pharmacokinetic study of thermosensitive liposome-encapsulated lomustine containing iohexol and lomustine solution after intravenous administration to C6 glioma rats." | 7.77 | HPLC method validation for the quantification of lomustine to study pharmacokinetics of thermosensitive liposome-encapsulated lomustine containing iohexol for CT imaging in C6 glioma rats. ( Derendorf, H; Gao, J; Li, M; Liu, C; Yu, F; Zeng, Y; Zhang, B; Zhuang, L, 2011) |
| " Among these tumors, a high percentage of low-grade oligodendrogliomas (ODG) are sensitive to chemotherapy with procarbazine, CCNU, and vincristine (PCV)." | 7.73 | Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma. ( Branle, F; De Witte, O; Goldman, S; Sadeghi, N; Tang, BN; Wikler, D, 2005) |
| "We have reported that carmustine (BCNU) and cisplatin administered before, during, and after radiotherapy did not improve the survival of patients with high-grade astrocytomas and were associated with more serious toxicities than radiotherapy plus BCNU." | 7.73 | Combination chemotherapy with carmustine and cisplatin followed by procarbazine, lomustine, and vincristine for adult high-grade astrocytoma. ( Jung, SM; Liau, CT; Tseng, CK; Wei, KC, 2005) |
| "To re-evaluate the cost effectiveness and median overall survival (OS) achieved in patients with recurrent malignant gliomas treated with temozolomide in British Columbia, as compared to previous lomustine use in the same patient population based on updated outcomes data." | 7.73 | Re-evaluation of the cost effectiveness of temozolomide for malignant gliomas in British Columbia. ( Mabasa, VH; Taylor, SC, 2006) |
| "The aim of this study was to evaluate the toxicity, response, and survival of patients with relapsed high-grade gliomas after radiation therapy (RT) combined with lomustine (CCNU)." | 7.70 | Reirradiation and lomustine in patients with relapsed high-grade gliomas. ( Arcicasa, M; Bidoli, E; Dedkov, A; Gigante, M; Roncadin, M; Trovò, MG, 1999) |
| "The authors reviewed the results of neoadjuvant (preradiation) procarbazine, CCNU, and vincristine chemotherapy for anaplastic oligodendrogliomas because, increasingly, chemotherapy is prescribed before radiation for oligodendroglial neoplasms." | 7.70 | Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma. ( Cairncross, JG; Macdonald, DR; Paleologos, NA; Vick, NA, 1999) |
| "Our results indicate that chemotherapy with a combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea is active for patients with recurrent anaplastic gliomas and glioblastomas not previously treated with nitrosourea-based chemotherapy but is inactive for patients with glioblastomas previously treated with chemotherapy." | 7.69 | Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas. ( Bruner, J; Flowers, A; Gleason, MJ; Ictech, SE; Jaeckle, KA; Kyritsis, AP; Levin, VA; Yung, WK, 1996) |
| "Effective chemotherapy using PCV (procarbazine, lomustine and vincristine) has been documented in anaplastic oligodendrogliomas and oligoastrocytomas." | 7.69 | [Assessment of procarbazine, vincristine and lomustine association (PCV protocol) in oligodendroglioma and mixed glioma]. ( Bouffet, E; Bret, P; Helfre, S; Jouvet, A; Mertens, P; Mornex, F; Sindou, M; Thiesse, P, 1997) |
| "Twenty-eight evaluable children with the diagnosis of brain stem glioma were treated with 5-fluorouracil and CCNU before posterior fossa irradiation (5500 rads); during irradiation, the children received hydroxyurea and misonidazole." | 7.67 | 5-Fluorouracil and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) followed by hydroxyurea, misonidazole, and irradiation for brain stem gliomas: a pilot study of the Brain Tumor Research Center and the Childrens Cancer Group. ( Allen, J; Edwards, MS; Levin, VA; Ortega, J; Vestnys, P; Wara, WM, 1984) |
| "Twenty-one patients with recurrent malignant central nervous system gliomas were treated with a combination of 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine." | 7.67 | Treatment of recurrent brain stem gliomas and other central nervous system tumors with 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine. ( Edwards, MS; Fulton, D; Levin, V; Prados, M; Rodriguez, LA; Silver, P, 1988) |
| "Fourteen consecutive melanoma patients with evaluable metastatic disease were treated with combination chemotherapy including procarbazine, vincristine and lomustine (POC)." | 7.67 | Metastatic malignant melanoma treated with procarbazine, vincristine and lomustine (POC). ( Ardizzoni, A; Grimaldi, A; Repetto, L; Rosso, R; Sertoli, MR, 1987) |
| "Twenty consecutive patients with supratentorial Grade III and IV astrocytomas were treated with postoperative radiotherapy, and a simultaneous induction chemotherapy with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU), procarbazine, bleomycin, and maintenance chemotherapy with CCNU." | 7.66 | Radiotherapy combined with procarbazine, bleomycin, and CCNU in the treatment of high-grade supratentorial astrocytomas. ( Greiner, RH; Markwalder, H; Seiler, RW; Zimmerman, A, 1978) |
| "Seven patients were treated with a combination of intraventricular methotrexate (MTX) and oral CCNU after resection and whole CNS irradiation of medulloblastomas." | 7.66 | Adjuvant chemotherapy with intraventricular methotrexate and CCNU after surgery and radiotherapy of medulloblastomas. ( Imbach, P; Seiler, RW; Vassella, F; Wagner, HP, 1978) |
| "Seventeen patients with recurrent medulloblastoma were treated with a combination of three drugs: procarbazine, CCNU, and vincristine (PCV)." | 7.66 | Chemotherapy of recurrent medulloblastoma with combined procarbazine, CCNU, and vincristine. ( Crafts, DC; Edwards, MS; Levin, VA; Pischer, TL; Wilson, CB, 1978) |
| "Axitinib is a small molecule tyrosine kinase inhibitor with high affinity and specificity for the family of vascular endothelial growth factor receptors." | 6.87 | Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma. ( Andre, C; Bouttens, F; Chaskis, C; D'Haene, N; Du Four, S; Duerinck, J; Le Mercier, M; Michotte, A; Neyns, B; Rogiers, A; Salmon, I; Van Fraeyenhove, F; Verschaeve, V, 2018) |
| "Anaplastic oligodendroglioma are chemotherapy-sensitive tumors." | 6.78 | Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. ( Allgeier, A; Bernsen, HJ; Brandes, AA; Delattre, JY; Dinjens, WN; Enting, RH; Frenay, M; French, PJ; Gorlia, T; Grisold, W; Hoang-Xuan, K; Kouwenhoven, MC; Kros, JM; Lacombe, D; Sipos, L; Taphoorn, MJ; Tijssen, CC; van den Bent, MJ; Vecht, CJ, 2013) |
| "Intrinsic subtypes are highly prognostic in EORTC 26951 and improve outcome prediction when combined with other prognostic factors." | 6.78 | Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC stu ( de Rooi, J; den Dunnen, WF; Eilers, PH; Erdem-Eraslan, L; French, PJ; Gorlia, T; Gravendeel, LA; Idbaih, A; Kros, JM; Sillevis Smitt, PA; Spliet, WG; Teepen, JL; van den Bent, MJ; Wesseling, P, 2013) |
| " The safety component reported here, which also investigated pharmacokinetics and preliminary clinical activity, required expansion and is therefore considered a phase I part to establish a recommended dosing regimen of the combination of CCNU (90-110 mg/m(2)) and dasatinib (100-200 mg daily)." | 6.77 | EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma. ( Allgeier, A; Brandes, AA; Franceschi, E; Gorlia, T; Hegi, M; Lacombe, D; Laigle Donadey, F; Lhermitte, B; Strauss, LC; Stupp, R; van den Bent, MJ; van Herpen, C, 2012) |
| "Anaplastic oligodendrogliomas are more responsive to chemotherapy than high-grade astrocytomas." | 6.72 | Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer p ( Allgeier, A; Bernsen, HJ; Brandes, AA; Carpentier, AF; Frenay, M; Gorlia, T; Grisold, W; Haaxma-Reiche, H; Kros, JM; Lacombe, D; Sanson, M; Sipos, L; Taphoorn, MJ; Tijssen, CC; van den Bent, MJ; van Kouwenhoven, MC; Vecht, CJ, 2006) |
| "Temozolomide was in general well tolerated; the most frequent side-effects were hematological." | 6.71 | Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. ( Baron, B; Boogerd, W; Bravo Marques, J; Chinot, O; De Beule, N; Kros, JM; Taphoorn, MJ; van den Bent, MJ; van der Rijt, CC; Vecht, CJ, 2003) |
| "Nine patients had brain metastases, and seven patients were systemically pretreated." | 6.68 | Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study. ( de Mulder, PH; Jansen, RL; Muller, EW; Punt, CJ; van Herpen, CM; Vreugdenhil, G, 1997) |
| "Glioblastomas are the most common malignant primary intrinsic brain tumors." | 6.66 | How did lomustine become standard of care in recurrent glioblastoma? ( Le Rhun, E; Weller, M, 2020) |
| " Here, we explored the incidence, and the consequences for treatment exposure and survival, of thrombocytopenia induced by lomustine in recurrent glioblastoma." | 5.69 | Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101. ( Brandes, AA; Clement, PM; Golfinopoulos, V; Gorlia, T; Idbaih, A; Le Rhun, E; Oppong, FB; Platten, M; Preusser, M; Taphoorn, MJ; van den Bent, M; Weller, M; Wick, W, 2023) |
| "In the randomized phase III trial CeTeG/NOA-09, temozolomide (TMZ)/lomustine (CCNU) combination therapy was superior to TMZ in newly diagnosed MGMT methylated glioblastoma, albeit reporting more frequent hematotoxicity." | 5.69 | Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial. ( Brehmer, S; Bullinger, L; Giordano, FA; Glas, M; Goldbrunner, R; Grauer, O; Hau, P; Herrlinger, U; Kowalski, T; Krex, D; Potthoff, AL; Ringel, F; Sabel, M; Schäfer, N; Schaub, C; Schmidt-Graf, F; Schneider, M; Schnell, O; Seidel, C; Steinbach, JP; Tabatabai, G; Tonn, JC; Tzaridis, T; Vajkoczy, P; Vatter, H; Weller, J; Zeiner, PS; Zeyen, T, 2023) |
| "The EORTC-26101 study was a randomized phase II and III clinical trial of bevacizumab in combination with lomustine versus lomustine alone in progressive glioblastoma." | 5.69 | Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial. ( Bendszus, M; Brandes, AA; Campone, M; Clement, PM; Doerner, L; Dômont, J; Hai, L; Idbaih, A; Ito, J; Kaulen, LD; Kessler, T; Platten, M; Sahm, F; Schrimpf, D; Taphoorn, M; van den Bent, M; von Deimling, A; Wick, A; Wick, W, 2023) |
| "NOA-18 aims at improving qualified overall survival (qOS) for adult patients with CNS WHO grade 2 and 3 oligodendrogliomas by randomizing between standard chemoradiation with up to six six-weekly cycles with PCV and six six-weekly cycles with lomustine and temozolomide (CETEG) (n = 182 patients per group accrued over 4 years) thereby delaying radiotherapy and adding the chemoradiotherapy concept at progression after initial radiation-free chemotherapy, allowing for effective salvage treatment and delaying potentially deleterious side effects." | 5.51 | Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial. ( Baumann, L; Bendszus, M; Combs, S; Dormann, A; Haut, T; Kessler, T; Kieser, M; Koch, M; Limprecht, R; Merkle-Lock, J; Pertz, M; Platten, M; Sahm, F; Sander, A; Schlegel, U; Selkrig, N; Walter, S; Wick, A; Wick, W; Winkler, F, 2022) |
| "Intracranial gliomas are a common malignancy in dogs, and are associated with a poor prognosis due to their aggressive nature and a lack of clinically effective treatments." | 5.48 | Survival times in dogs with presumptive intracranial gliomas treated with oral lomustine: A comparative retrospective study (2008-2017). ( Cohen, PW; Dewey, CW; Moirano, SJ; Wright, KZ, 2018) |
| "Lomustine is a treatment option for patients with high-grade glioma." | 5.43 | Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models. ( Gruber, HE; Huang, TT; Ibañez, CE; Jolly, DJ; Lopez Espinoza, F; Mendoza, D; Robbins, JM; Yagiz, K, 2016) |
| "Myoinositol (MI) is an organic osmolyte, with intracellular concentration changes depending on the extracellular osmolality." | 5.43 | Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A 1H-Magnetic Resonance Spectroscopy Study. ( Bähr, O; Hattingen, E; Pilatus, U; Ronellenfitsch, MW; Steidl, E; Steinbach, JP; Zanella, F, 2016) |
| " We investigated Depatux-M in combination with temozolomide or as a single agent in a randomized controlled phase II trial in recurrent EGFR amplified glioblastoma." | 5.34 | INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. ( Ansell, P; Brilhante, J; Chinot, O; Clement, PM; Coens, C; De Vos, F; Dey, J; Dubbink, HJ; Eoli, M; Franceschi, E; French, P; Frenel, JS; Golfinopoulos, V; Gorlia, T; Krause, S; Looman, J; Nuyens, S; Sanghera, P; Sepulveda, JM; Smits, M; Spruyt, M; Van Den Bent, M; Walenkamp, A; Weller, M; Whenham, N, 2020) |
| "Despite somewhat prolonged progression-free survival, treatment with lomustine plus bevacizumab did not confer a survival advantage over treatment with lomustine alone in patients with progressive glioblastoma." | 5.24 | Lomustine and Bevacizumab in Progressive Glioblastoma. ( Bendszus, M; Brandes, AA; Bromberg, JC; Campone, M; Clement, PM; Domont, J; Dubois, F; Fabbro, M; Golfinopoulos, V; Gorlia, T; Harting, I; Idbaih, A; Klein, M; Le Rhun, E; Platten, M; Sahm, F; Stupp, R; Taal, W; Taphoorn, M; van den Bent, MJ; von Deimling, A; Weller, M; Wick, W, 2017) |
| "Adding temozolomide (TMZ) to radiation for patients with newly-diagnosed anaplastic astrocytomas (AAs) is common clinical practice despite the lack of prospective studies demonstrating a survival advantage." | 5.22 | The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide. ( Abuali, I; Grossman, SA; Lu, Y; Strowd, RE; Ye, X, 2016) |
| "The combination of galunisertib, a transforming growth factor (TGF)-β receptor (R)1 kinase inhibitor, and lomustine was found to have antitumor activity in murine models of glioblastoma." | 5.22 | A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. ( Brandes, AA; Capper, D; Carpentier, AF; Cher, L; Chinot, O; Cleverly, A; Desaiah, D; Guba, SC; Gueorguieva, I; Kesari, S; Lahn, MM; Miles, C; Rodon, J; Sepulveda-Sanchez, JM; Smith, C; Specenier, P; Steinbach, JP; Wheeler, HR; Wick, W, 2016) |
| "We conducted a randomized, non-comparative, multi center, phase II clinical trial in order to investigate the efficacy of axitinib, an oral small molecule tyrosine kinase inhibitor with high affinity and specificity for the vascular endothelial growth factor receptors, in patients with recurrent glioblastoma following prior treatment with radiation and temozolomide." | 5.22 | Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma. ( Bouttens, F; D'Haene, N; Du Four, S; Duerinck, J; Everaert, H; Le Mercier, M; Michotte, A; Neyns, B; Salmon, I; Van Binst, AM; Vandervorst, F; Verschaeve, V, 2016) |
| "Following maximal surgical resection, newly diagnosed children with nonmetastatic high-grade glioma underwent involved field radiotherapy with concurrent temozolomide." | 5.22 | Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study. ( Brat, DJ; Burger, PC; Buxton, A; Cohen, KJ; Eckel, SP; Hamilton, RL; Jakacki, RI; Krailo, MD; Lavey, RS; Pollack, IF; Rosenblum, MK; Zhou, T, 2016) |
| " This trial evaluated the efficacy of low dose bevacizumab in combination with lomustine (CCNU) compared to standard dose bevacizumab in patients with recurrent glioblastoma." | 5.22 | A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma. ( Colen, RR; Conrad, CA; de Groot, JF; Gilbert, MR; Han, X; Liu, DD; Loghin, ME; O'Brien, BJ; Penas-Prado, M; Puduvalli, VK; Tremont-Lukats, I; Weathers, SP; Yung, WKA, 2016) |
| "Patients with anaplastic oligodendrogliomas (n = 288) who were randomized (EORTC 26951) to radiotherapy (RT) alone or RT plus procarbazine, lomustine, and vincristine (PCV) chemotherapy were analyzed." | 5.20 | Joint modeling of longitudinal health-related quality of life data and survival. ( Bottomley, A; Coens, C; Dirven, L; Ediebah, DE; Galindo-Garre, F; Reijneveld, JC; Ringash, J; Taphoorn, MJ; Uitdehaag, BM; van den Bent, MJ; Zikos, E, 2015) |
| "The BELOB study, a randomised controlled phase 2 trial comparing lomustine, bevacizumab and combined lomustine and bevacizumab in patients with recurrent glioblastoma, showed that the 9-month overall survival rate was most promising in the combination arm." | 5.20 | The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial. ( Beerepoot, LV; Bottomley, A; Bromberg, JE; de Vos, FY; Dirven, L; Hanse, MC; Otten, A; Reijneveld, JC; Smits, M; Taal, W; Taphoorn, MJ; van den Bent, MJ; van der Holt, B; van der Meer, N; Vos, MJ; Walenkamp, AM, 2015) |
| "In this side study of the BELOB trial, 141 patients with recurrent glioblastoma were randomised to receive single-agent bevacizumab or lomustine, or bevacizumab plus lomustine." | 5.20 | Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial. ( Beerepoot, L; Beije, N; de Vos, FY; Gratama, JW; Hanse, M; Kraan, J; Oosterkamp, HM; Otten, A; Sleijfer, S; Taal, W; van den Bent, MJ; van der Holt, B; van Linde, ME; Vernhout, RM; Walenkamp, AM, 2015) |
| "The addition of PCV (procarbazine, lomustine, and vincristine) chemotherapy to radiotherapy (RT) for patients with WHO grade 2 glioma improves progression-free survival (PFS)." | 5.19 | Effect of the addition of chemotherapy to radiotherapy on cognitive function in patients with low-grade glioma: secondary analysis of RTOG 98-02. ( Barger, GR; Brachman, DG; Brown, PD; Buckner, JC; Gilbert, MR; Hu, C; Mehta, MP; Prabhu, RS; Shaw, EG; Stelzer, KJ; Won, M, 2014) |
| "The purpose of this prospective phase II/III trial was to study the effect of therapy intensification when combining procarbazine, lomustine, and vincristine (PCV) chemotherapy with a standard course of radiation therapy (RT) on cognitive functioning for patients with World Health Organization grade 2 low-grade gliomas (LGGs)." | 5.19 | Patients with primary brain tumors. ( Behrend, SW, 2014) |
| "We evaluated the prognostic and predictive value of a range of molecular changes in the setting of a randomised trial comparing standard PCV (procarbazine, CCNU (1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea) and vincristine) chemotherapy with the standard temozolomide (TMZ) 5-day (200 mg/m2/day) schedule and a 21-day (100 mg/m2/day) schedule in chemo-naïve, high-grade glioma (non-oligodendroglial tumours; WHO (World Health Organisation) grades III and IV) patients at first progression following radiotherapy." | 5.19 | Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial. ( Brada, M; Chan, R; Collins, VP; Di, Y; Gabe, R; Ichimura, K; Pearson, D; Stenning, SP; Thompson, LC, 2014) |
| " Adult patients (≥18 years of age) with a first recurrence of a glioblastoma after temozolomide chemoradiotherapy were randomly allocated by a web-based program to treatment with oral lomustine 110 mg/m(2) once every 6 weeks, intravenous bevacizumab 10 mg/kg once every 2 weeks, or combination treatment with lomustine 110 mg/m(2) every 6 weeks and bevacizumab 10 mg/kg every 2 weeks." | 5.19 | Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. ( Beerepoot, LV; Boerman, D; Brandsma, D; Bromberg, JE; Buter, J; de Vos, FY; Dinjens, WN; Dubbink, HJ; Enting, RH; Hanse, MC; Honkoop, AH; Jansen, RL; Oosterkamp, HM; Taal, W; Taphoorn, MJ; van den Bent, MJ; van den Berkmortel, FW; van der Holt, B; van Heuvel, I; Vernhout, RM; Walenkamp, AM, 2014) |
| "A randomized, phase III, placebo-controlled, partially blinded clinical trial (REGAL [Recent in in Glioblastoma Alone and With Lomustine]) was conducted to determine the efficacy of cediranib, an oral pan-vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, either as monotherapy or in combination with lomustine versus lomustine in patients with recurrent glioblastoma." | 5.17 | Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. ( Ashby, LS; Batchelor, TT; Campone, M; Cher, L; Degroot, J; Gattamaneni, R; Jain, RK; Jürgensmeier, JM; Liu, Q; Mason, W; Mikkelsen, T; Mulholland, P; Nabors, LB; Neyns, B; Payer, F; Phuphanich, S; Rosenthal, M; Sorensen, AG; van den Bent, M; Wick, A; Xu, J, 2013) |
| "Thirteen patients with temozolomide-refractory anaplastic oligodendroglioma (11 patients) or oligoastrocytoma (2 patients) underwent blood-brain barrier disruption with carboplatin (IA, 200 mg/m(2)/d), etoposide phosphate (IV, 200 mg/m(2)/d), and melphalan (IA, dose escalation) every 4 weeks, for up to 1 year." | 5.14 | Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study. ( Delashaw, JB; Doolittle, ND; Gahramanov, S; Guillaume, DJ; Hedrick, NA; Neuwelt, EA, 2010) |
| "This phase III open-label study compared the efficacy and safety of enzastaurin versus lomustine in patients with recurrent glioblastoma (WHO grade 4)." | 5.14 | Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. ( Carpentier, AF; Chamberlain, MC; Cher, LM; Fine, HA; Hong, S; Liepa, AM; Mason, W; Musib, L; Puduvalli, VK; Thornton, DE; van den Bent, MJ; Weller, M; Wick, W, 2010) |
| " We determined the effect of IDH1 mutations on progression-free survival and overall survival (OS), and its correlation with other clinical and molecular features in the prospective randomized European Organization for Research and Treatment of Cancer study 26951 on adjuvant procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea, and vincristine (PCV) in anaplastic oligodendroglioma." | 5.14 | IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. ( Brandes, AA; Dinjens, WN; Dubbink, HJ; Frenay, M; Gorlia, T; Idbaih, A; Kros, JM; Lacombe, D; Marie, Y; Sanson, M; Taphoorn, MJ; Tijssen, CC; van den Bent, MJ; van Marion, R; Wesseling, P, 2010) |
| "A phase I trial was conducted to determine the maximum tolerated dose (MTD) of temozolomide given in combination with lomustine in newly diagnosed pediatric patients with high-grade gliomas." | 5.13 | A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood. ( Adamson, PC; Blaney, SM; Flom, L; Ingle, AM; Jakacki, RI; Pollack, IF; Prados, MD; Timmerman, R; Yates, A; Zhou, T, 2008) |
| "The authors administered procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU, lomustine), and vincristine (PCV) to 86 patients with recurrent glioblastoma." | 5.12 | PCV chemotherapy for recurrent glioblastoma. ( Dichgans, J; Dietz, K; Fischer, J; Herrlinger, U; Schmidt, F; Weller, M, 2006) |
| "We previously reported a phase 2 trial of 69 patients with newly diagnosed anaplastic or aggressive oligodendroglioma who were treated with intensive procarbazine, CCNU (lomustine), and vincristine (PCV) followed by high-dose thiotepa with autologous stem cell rescue." | 5.12 | High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up. ( Abrey, LE; Bayer, R; Cairncross, JG; Childs, BH; DeAngelis, LM; Finlay, JL; Forsyth, P; Gardner, S; Hu, W; Kaminer, L; Macdonald, DR; Nimer, SD; Paleologos, N; Peterson, K; Ramsay, DA; Rosenfeld, S; Salzman, D; Smith, AM; Stewart, D; Swinnen, L; Weaver, S, 2006) |
| "Anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA) are treated with surgery and radiotherapy (RT) at diagnosis, but they also respond to procarbazine, lomustine, and vincristine (PCV), raising the possibility that early chemotherapy will improve survival." | 5.12 | Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. ( Berkey, B; Brachman, D; Buckner, J; Cairncross, G; Curran, W; Fink, K; Jenkins, R; Laperierre, N; Mehta, M; Scheithauer, B; Shaw, E; Souhami, L, 2006) |
| "To evaluate toxicity and efficacy of the combination of lomustine, temozolomide (TMZ) and involved-field radiotherapy in patients with newly diagnosed glioblastoma (GBM)." | 5.12 | Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. ( Bamberg, M; Blaschke, B; Herrlinger, U; Hundsberger, T; Koch, D; Kortmann, RD; Loeser, S; Meyermann, R; Reifenberger, G; Rieger, J; Sommer, C; Steinbach, JP; Tan, TC; Weller, M; Wick, W, 2006) |
| "Temozolomide is an alkylating agent with activity in the treatment of melanoma metastatic to the brain." | 5.12 | A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma. ( Bate, SC; Beirne, DA; Eisen, TG; Gibbens, IM; Gore, ME; Hughes, SA; Larkin, JM; Patel, PM; Thomas, K, 2007) |
| "Twenty-three patients with recurrent or progressive oligodendrogliomas or oligoastrocytomas after first-line PCV (procarbazine, lomustine, and vincristine) chemotherapy were enrolled in a single-institution Phase II study of second-line carboplatin chemotherapy." | 5.11 | Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study. ( Borgognone, M; Costanza, A; Laguzzi, E; Mutani, R; Nobile, M; Rudà, R; Soffietti, R, 2004) |
| "The authors investigated the results of PCV chemotherapy within a cohort of 24 patients treated within the EORTC study 26971 on temozolomide chemotherapy in recurrent oligodendroglioma." | 5.11 | Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas. ( Allgeier, A; Brandes, AA; Enting, RH; Frenay, M; Kros, JM; Menten, J; Stege, EB; Taphoorn, MJ; Tosoni, A; Triebels, VH; van den Bent, MJ; van Heuvel, I, 2004) |
| "The aim of this study was to compare tolerance of a nitrosurea-based regime with 'standard' therapy of vincristine (VCR) and carboplatin for low-grade gliomas." | 5.10 | Tolerance of nitrosurea-based multiagent chemotherapy regime for low-grade pediatric gliomas. ( Hoddes, JA; Lancaster, DL; Michalski, A, 2003) |
| "To conduct a Phase II study to evaluate the long-term efficacy and safety of high-dose 5'-bromodeoxyuridine (BrdU) and accelerated radiotherapy followed by procarbazine, lomustine (CCNU), and vincristine (PCV) chemotherapy in patients with glioblastoma multiforme." | 5.09 | A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme. ( Bruner, JM; Groves, MD; Hess, K; Jaeckle, KA; Kyritsis, AP; Levin, VA; Maor, MH; Meyers, C; Peterson, P; Sawaya, RE; Yung, WK, 1999) |
| " Here we report our experience with adjuvant postirradiation and preirradiation chemotherapy using procarbazine, lomustine, and vincristine (PCV) in 27 patients with WHO grade II or III oligodendroglioma or oligoastrocytoma." | 5.09 | A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors. ( Bamberg, M; Dichgans, J; Grote, EH; Meyermann, R; Schabet, M; Streffer, J; Voigt, K; Weller, M, 2000) |
| "Although the efficacy of the nitrosourea-based combination chemotherapy procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, and vincristine (PCV) has been previously demonstrated in the setting of anaplastic/intermediate-grade gliomas, the benefit for glioblastoma patients remains unproven." | 5.09 | Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. ( Bruner, JM; Chang, SM; Choucair, A; Flynn, PJ; Gleason, MJ; Hess, KR; Jaeckle, KA; Kyritsis, AP; Levin, VA; Prados, MD; Uhm, JH, 2000) |
| "To conduct a Phase II one-arm study to evaluate the long-term efficacy and safety of accelerated fractionated radiotherapy combined with intravenous carboplatin for patients with previously untreated glioblastoma multiforme tumors." | 5.08 | Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme. ( Bruner, J; Kyritsis, AP; Leeds, N; Levin, VA; Maor, MH; Rodriguez, L; Sawaya, R; Thall, PF; Woo, S; Yung, WK, 1995) |
| "There is no benefit to the treatment of high-grade astrocytomas in children with eight-drugs-in-1-day chemotherapy compared with CCNU, vincristine, and prednisone." | 5.08 | Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens Cancer Group. ( Bertolone, SJ; Boyett, JM; Cherlow, JM; Finlay, JL; Geyer, JR; McGuire, P; Milstein, JM; Tefft, M; Wisoff, JH; Yates, AJ, 1995) |
| "A prospective phase II study of paclitaxel was performed in adult patients with recurrent hemispheric oligodendrogliomas." | 5.08 | Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas. ( Chamberlain, MC; Kormanik, PA, 1997) |
| "The regimen of procarbazine, CCNU, and vincristine is active against gliomas." | 5.08 | Dose-intensification of procarbazine, CCNU (lomustine), vincristine (PCV) with peripheral blood stem cell support in young patients with gliomas. ( Cornetta, K; Dropcho, E; Heilman, DK; Jakacki, RI; Jamison, C; Macdonald, DR; Mathews, VP; Williams, DA, 1998) |
| "To examine the rate and duration of response of anaplastic oligodendrogliomas to a dose-escalated combination chemotherapy regimen consisting of procarbazine, lomustine (CCNU), and vincristine (PCV) and to evaluate the side effects of this treatment." | 5.07 | Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. ( Buckner, J; Cairncross, G; Cascino, T; Dropcho, E; Fulton, D; Lee, D; Ludwin, S; Macdonald, D; Schold, C; Stewart, D, 1994) |
| "In a study activated in 1983 and closed in 1987, the Brain Tumor Research Center of the University of California and the Northern California Cancer Center evaluated the effect of bromodeoxyuridine in the treatment of glioblastoma multiforme." | 5.07 | Evaluation of bromodeoxyuridine in glioblastoma multiforme: a Northern California Cancer Center Phase II study. ( Ahn, DK; Davis, RL; Flam, MS; Gutin, PH; Levin, VA; Phillips, TL; Prados, MD; Wara, WM; Wilson, CB, 1991) |
| " The protocol called for a randomized trial that compared the effects of following 60 Gy radiation/oral hydroxyurea treatment with either carmustine (BCNU) or the combination of procarbazine, lomustine (CCNU), and vincristine (PCV) for two histologic strata: glioblastoma multiforme and other anaplastic gliomas." | 5.06 | Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. ( Davis, RL; Gutin, PH; Hannigan, J; Levin, VA; Silver, P; Wara, WM; Wilson, CB, 1990) |
| "The majority of patients with high-risk lower grade gliomas (LGG) are treated with single-agent temozolomide (TMZ) and radiotherapy despite three randomized trials showing a striking overall survival benefit with adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy and radiotherapy." | 5.05 | Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV. ( Atkins, KM; Dietrich, J; Loeffler, JS; McDuff, SGR; Oh, KS; Shih, HA, 2020) |
| "The association of radiotherapy and procarbazine, lomustine (CCNU), vincristine chemotherapy in low-grade oligodendrogliomas is definitely superior over radiotherapy alone, and yields median progression-free survival and overall survival values exceeding by far 10 years." | 5.05 | Is chemotherapy alone an option as initial treatment for low-grade oligodendrogliomas? ( Rudà, R; Soffietti, R; Touat, M, 2020) |
| "Forty-three patients with inoperable and/or recurring malignant gliomas and 30 patients with multiple recurring brain metastases were treated with a combination of adriamycine (45 mg/m 2 and 4-dimethyl-epipodophyllotoxin D-thenylidene (VM 26) (60 mg/m 2 for 2 days) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitroso-urea (CCNU) (60 mg/m 2 for 2 days)." | 5.04 | Treatment of malignant gliomas and brain metastases in adults using a combination of adriamycine, VM 26, and CCNU. Results of a type II trial. ( Gautier, H; Huguenin, P; Lheritier, J; Mathé, G; Morin, P; Palangie, T; Parrot, R; Poisson, M; Pouillart, P, 1977) |
| "Forty-three patients with inoperable and/or recurring malignant gliomas, and 30 patients with multiple recurring brain metastases were treated with a combination of adriamycine (45 mg/m2) and 4-dimethyl-epipodophyllotoxin D-thenylidene (VM 26) (60 mg/m2 for 2 days) with 1-(2-chloroethyl) -3-cyclohexyl-1-nitroso-urea (CCNU) (60 mg/m2 for two days)." | 5.04 | [Trial treatment of glioblastomas in adults and cerebral metastais by adriamycin, VM 26 and CCNU combination. Result of a type II trial]. ( Buge, A; Gautier, H; Huguenin, P; Lheritier, J; Mathé, G; Morin, P; Parrot, R; Poisson, M; Pouillart, P; Thy, HT, 1976) |
| "To assess the effectiveness and safety of procarbazine, lomustine, and vincristine (PCV) chemotherapy with other interventions in adults with recurrent high-grade glioma." | 4.95 | Procarbazine, lomustine and vincristine for recurrent high-grade glioma. ( Guo, J; Parasramka, S; Rosenfeld, M; Talari, G; Villano, JL, 2017) |
| "Anaplastic oligodendrogliomas (AOs) are rare brain tumors responsive to chemotherapy with procarbazine, lomustine (CCNU) and vincristine (PCV), especially when harboring 1p19q codeletion." | 4.91 | Procarbazine, lomustine and vincristine or temozolomide: which is the better regimen? ( Lassman, AB, 2015) |
| "The long-term follow-up of the RTOG 9802 trial that compared 54 Gy of radiotherapy (RT) with the same RT followed by adjuvant procarbazine, CCNU, and vincristine (PCV) chemotherapy in high-risk low-grade glioma shows a major increase in survival after adjuvant PCV chemotherapy." | 4.90 | Practice changing mature results of RTOG study 9802: another positive PCV trial makes adjuvant chemotherapy part of standard of care in low-grade glioma. ( van den Bent, MJ, 2014) |
| "The methylhydrazine derivative Procarbazine (PCZ) as monotherapy or in combination with CCNU and vincristine (PCV) was evaluated in a vast number of clinical trials and is still used in patients with high-grade and low-grade gliomas." | 4.84 | Procarbazine--a traditional drug in the treatment of malignant gliomas. ( Bogdahn, U; Goerne, R; Hau, P, 2008) |
| "We report two patients with acute myeloid leukemia (AML) following therapy for malignant glioma; one was a young women treated heavily with alkylating agents for glioblastoma and the other a young man treated with high doses of procarbazine, lomustine, and vincristine (PCV) for anaplastic astrocytoma." | 4.80 | Acute leukemia following treatment of malignant glioma. ( Brown, MT; Gockerman, JP; Perry, JR, 1998) |
| "We evaluated O-(2-[18F]fluoroethyl)-l-tyrosine (FET) PET and MRI for early response assessment in recurrent glioma patients treated with lomustine-based chemotherapy." | 4.31 | Prediction of response to lomustine-based chemotherapy in glioma patients at recurrence using MRI and FET PET. ( Bauer, EK; Ceccon, GS; Fink, GR; Galldiks, N; Goldbrunner, R; Kabbasch, C; Langen, KJ; Lohmann, P; Stoffels, G; Tscherpel, C; Werner, JM; Wollring, MM, 2023) |
| " TTFields therapy is approved for treatment of newly-diagnosed glioblastoma (GBM) concurrent with maintenance temozolomide (TMZ)." | 4.31 | Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines. ( Dor-On, E; Fishman, H; Giladi, M; Haber, A; Kinzel, A; Monin, R; Palti, Y; Weinberg, U, 2023) |
| " Here we describe the occurrence of pseudoprogression in patients with anaplastic oligodendrogliomas treated with postoperative procarbazine, lomustine and vincristine (PCV) chemotherapy alone." | 4.31 | T2-Fluid-attenuated inversion recovery (FLAIR) pseudoprogression in patients with anaplastic oligodendrogliomas treated with procarbazine, lomustine and vincristine (PCV) chemotherapy alone. ( Boutet, C; Carpentier, C; Dehais, C; Di Stefano, AL; Ducray, F; Esparragosa Vazquez, I; Figarella-Branger, D; Forest, F; Larrieu-Ciron, D; Meyronet, D; Ndiaye, M; Picart, T; Rivoirard, R; Seyve, A; Vassal, F; Younan, N, 2023) |
| "In the randomized CeTeG/NOA-09 trial, lomustine/temozolomide (CCNU/TMZ) was superior to TMZ therapy regarding overall survival (OS) in MGMT promotor-methylated glioblastoma." | 4.31 | Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses. ( Duffy, C; Galldiks, N; Glas, M; Goldbrunner, R; Grauer, O; Hattingen, E; Hau, P; Herrlinger, U; Krex, D; Nitsch, L; Paech, D; Potthoff, AL; Radbruch, A; Schäfer, N; Schaub, C; Schlegel, U; Schneider, M; Seidel, C; Steinbach, JP; Stummer, W; Tabatabai, G; Tzaridis, T; Weller, J; Zeiner, PS; Zeyen, T, 2023) |
| "Glioblastomas (GBM) often acquire resistance against temozolomide (TMZ) after continuous treatment and recur as TMZ-resistant GBM (TMZ-R-GBM)." | 4.02 | Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance. ( Fujii, T; Ichimura, K; Kawauchi, D; Kobayashi, T; Kondo, A; Nakano, T; Narita, Y; Sasaki, N; Satomi, K; Takahashi, M; Tomiyama, A; Uchida, E; Wada, K; Yamamuro, S; Yoshino, A, 2021) |
| "IDH-mutant anaplastic astrocytomas (AAs) are chemosensitive tumors for which the best choice of adjuvant chemotherapy between procarbazine, lomustine, and vincristine (PCV) or temozolomide (TMZ) after radiotherapy (RT) remains unclear." | 4.02 | Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for IDH-Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort. ( Bronniman, C; Carpentier, C; Ciron, DL; Dehais, C; Ducray, F; Esteyrie, V; Figarella-Branger, D; Martin, E; Moyal, EC; Network, P; Pouessel, D; Uro-Coste, E, 2021) |
| "Following optimal local therapy, adjuvant Procarbazine, Lomustine and Vincristine (PCV) improves overall survival (OS) in low-grade glioma (LGG)." | 4.02 | One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre. ( Aslam, R; Breathnach, OS; Coyne, Z; Grogan, L; Hennessy, BT; Hennessy, MA; Keogh, RJ; Morris, PG, 2021) |
| "Patients (n = 142) with molecularly defined oligodendroglioma (WHO 2016) were assigned to four cohorts: W&S, wait-and-scan after stereotactic biopsy (n = 59); RES, surgical resection only (n = 27); TMZ, temozolomide after biopsy (n = 26) or PCV (n = 30) after biopsy." | 4.02 | PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression. ( Egensperger, R; Karschnia, P; Katzendobler, S; Lietke, S; Suchorska, B; Thon, N; Tonn, JC; Weller, J; Weller, M, 2021) |
| "In the EF-14 trial for newly diagnosed glioblastoma (ndGBM) patients addition of Tumour Treating Fields (TTFields) to temozolomide treatment resulted in a significantly improved overall survival (OS)." | 3.96 | Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma. ( Blau, T; Deuschl, C; Glas, M; Herrlinger, U; Kebir, S; Keyvani, K; Kleinschnitz, C; Lazaridis, L; Oster, C; Pierscianek, D; Schäfer, N; Scheffler, B; Schmidt, T; Stuschke, M; Sure, U; Teuber-Hanselmann, S; Tzaridis, T; Weller, J, 2020) |
| "Systematic evaluation of the effectiveness and safety of combined procarbazine, lomustine, and vincristine for treating recurrent high-grade glioma." | 3.96 | A comparative study of the effectiveness and safety of combined procarbazine, lomustine, and vincristine as a therapeutic method for recurrent high-grade glioma: A protocol for systematic review and meta-analysis. ( Cai, Y; Jiang, YG; Jiang, ZH; Tan, ZG; Wang, M, 2020) |
| "Imaging necrosis on MRI scans was assessed and compared to outcome measures of the European Organisation for Research and Treatment of Cancer 26101 phase III trial that compared single-agent lomustine with lomustine plus bevacizumab in patients with progressive glioblastoma." | 3.91 | Imaging necrosis during treatment is associated with worse survival in EORTC 26101 study. ( Bendszus, M; Brandes, AA; Bromberg, JEC; Campone, M; Clement, PM; Domont, J; Fabbro, M; Golfinopoulos, V; Gorlia, T; Harting, I; Idbaih, A; Kickingereder, P; Le Rhun, E; Nowosielski, M; Platten, M; Sahm, F; Taal, W; Taphoorn, MJB; van den Bent, MJ; Weller, M; Wick, W, 2019) |
| "Radiotherapy with procarbazine, lomustine, and vincristine (PCV) improves overall survival in patients with anaplastic oligodendroglioma 1p19q codeleted." | 3.88 | Radiotherapy plus temozolomide or PCV in patients with anaplastic oligodendroglioma 1p19q codeleted. ( Castro-Martinez, E; Gonzalez-Aguilar, A; Guerrero-Juarez, V; Gutierrez-Aceves, A; Hernandez-Hernandez, A; Lopez-Martinez, M; Peiro-Osuna, RP; Reyes-Moreno, I; Santos-Zambrano, J, 2018) |
| "The addition of procarbazine, lomustine, vincristine (PCV) chemotherapy to radiotherapy (RT) for patients with high-risk (≥40 y old or subtotally resected) low-grade glioma (LGG) results in an absolute median survival benefit of over 5 years." | 3.85 | Cost-effectiveness of radiation and chemotherapy for high-risk low-grade glioma. ( Bendavid, E; Chang, DT; Chin, AL; Durkee, BY; Harris, JP; Kim, H; Kumar, KA; Maruyama, S; Owens, DK; Pitt, A; Pollom, EL; Qian, Y; Soltys, SG, 2017) |
| "Taken together, these data suggest a potential role for a combination therapy of lomustine and DHA for the treatment of glioblastomas." | 3.81 | Enhanced anticancer properties of lomustine in conjunction with docosahexaenoic acid in glioblastoma cell lines. ( Cohen-Gadol, AA; Harvey, KA; Pollok, K; Saaddatzadeh, MR; Siddiqui, RA; Wang, H; Xu, Z, 2015) |
| "While procarbazine with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (PC) added to vincristine (PCV) was proven beneficial in the treatment of co-deleted anaplastic oligodendroglioma (AO), the question of whether PC alone is sufficient is important, as vincristine adds toxicity with uncertain benefit." | 3.81 | PC or PCV, That Is the Question: Primary Anaplastic Oligodendroglial Tumors Treated with Procarbazine and CCNU With and Without Vincristine. ( De Groot, J; Liu, D; Shonka, N; Smith, L; Webre, C, 2015) |
| "We previously developed a mathematical model capturing tumor size dynamics of adult low-grade gliomas (LGGs) before and after treatment either with PCV (Procarbazine, CCNU, and Vincristine) chemotherapy alone or with radiotherapy (RT) alone." | 3.81 | Increasing the Time Interval between PCV Chemotherapy Cycles as a Strategy to Improve Duration of Response in Low-Grade Gliomas: Results from a Model-Based Clinical Trial Simulation. ( Ducray, F; Honnorat, J; Mazzocco, P; Ribba, B, 2015) |
| "In this retrospective study, we identified adult patients with histologically confirmed glioblastoma (WHO grade IV) who were treated with lomustine or carmustine in combination with bevacizumab as a second or third regimen after failing an alternative initial bevacizumab-containing regimen." | 3.80 | Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab. ( Alexander, BM; Beroukhim, R; Doherty, L; Hempfling, K; Huang, RY; LaFrankie, D; Lee, EQ; Nayak, L; Norden, AD; Rahman, R; Rai, A; Reardon, DA; Rifenburg, J; Rinne, ML; Ruland, S; Wen, PY, 2014) |
| " This has changed with the long-term follow-up analysis of the EORTC and RTOG trials on procarbazine, lomustine, and vincristine (PCV) chemotherapy in anaplastic oligodendroglioma." | 3.79 | How to use molecular markers when caring for a patient with brain cancer: 1P/19Q as a predictive and prognostic marker in the neuro-oncology clinic. ( van den Bent, MJ, 2013) |
| " The validated method has been successfully applied to a pharmacokinetic study of thermosensitive liposome-encapsulated lomustine containing iohexol and lomustine solution after intravenous administration to C6 glioma rats." | 3.77 | HPLC method validation for the quantification of lomustine to study pharmacokinetics of thermosensitive liposome-encapsulated lomustine containing iohexol for CT imaging in C6 glioma rats. ( Derendorf, H; Gao, J; Li, M; Liu, C; Yu, F; Zeng, Y; Zhang, B; Zhuang, L, 2011) |
| " Among these tumors, a high percentage of low-grade oligodendrogliomas (ODG) are sensitive to chemotherapy with procarbazine, CCNU, and vincristine (PCV)." | 3.73 | Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma. ( Branle, F; De Witte, O; Goldman, S; Sadeghi, N; Tang, BN; Wikler, D, 2005) |
| "We have reported that carmustine (BCNU) and cisplatin administered before, during, and after radiotherapy did not improve the survival of patients with high-grade astrocytomas and were associated with more serious toxicities than radiotherapy plus BCNU." | 3.73 | Combination chemotherapy with carmustine and cisplatin followed by procarbazine, lomustine, and vincristine for adult high-grade astrocytoma. ( Jung, SM; Liau, CT; Tseng, CK; Wei, KC, 2005) |
| "Accidentally, we observed a complete response (CR) in a patient undergoing chemotherapy with bleomycin, vincristine or Oncovin, CCNU or lomustine, dacarbazine (BOLD) regimen for metastatic melanoma including brain metastases, who was also treated with G-CSF to manage a concomitant leukopenia." | 3.73 | Complete remission of brain metastases in three patients with stage IV melanoma treated with BOLD and G-CSF. ( Bonaccorsi, P; Borroni, RG; Bottoni, U; Calvieri, S; Clerico, R; Devirgiliis, V; Panasiti, V; Trasimeni, G, 2005) |
| "To re-evaluate the cost effectiveness and median overall survival (OS) achieved in patients with recurrent malignant gliomas treated with temozolomide in British Columbia, as compared to previous lomustine use in the same patient population based on updated outcomes data." | 3.73 | Re-evaluation of the cost effectiveness of temozolomide for malignant gliomas in British Columbia. ( Mabasa, VH; Taylor, SC, 2006) |
| "We report the long-term follow-up, 71 months, of seven patients treated by procarbazine, lomustine and vincristine (PCV) therapy for a symptomatic low-grade oligodendrogliomatous tumor." | 3.73 | [Long-term outcome in patients with symptomatic low-grade oligodendrogliomatous tumors treated by cytotoxic agents]. ( Cartalat-Carel, S; Catenoix, H; Chapuis, F; Honnorat, J; Nighoghossian, N; Trouillas, P, 2006) |
| "We collected 6 case-reports of symptomatric non removable low grade fibrillary astrocytoma of adults treated with a procarbazine-CCNU-vincristine chemotherapy regimen." | 3.72 | [Neoadjuvant chemotherapy for symptomatic non operable grade II fibrillary astrocytoma in adults]. ( Alchaar, H; Bleuse, A; Bondiau, PY; Bourg, V; Brunetto, JL; Chanalet, S; Chatel, M; Courdi, A; Darcourt, J; Fauchon, F; Fontaine, D; Frénay, M; Grellier, P; Guibert, F; Lanteri-Minet, M; Lebrun, C; Lonjon, M; Michiels, JF; Paquis, P; Paquis, V; Ramaioli, A; Rasendrarijao, D; Vandenbos, F, 2004) |
| " In glioblastomas (histological grade 4, n = 257) the same chemotherapy was evaluated versus two cycles 4 weeks apart of 160 mg lomustine (CCNU) orally instead of BCNU, combined with vincristine and procarbazine (PCV) versus no chemotherapy." | 3.70 | A retrospective study of the value of chemotherapy as adjuvant therapy to surgery and radiotherapy in grade 3 and 4 gliomas. ( Gundersen, S; Lote, K; Watne, K, 1998) |
| "The aim of this study was to evaluate the toxicity, response, and survival of patients with relapsed high-grade gliomas after radiation therapy (RT) combined with lomustine (CCNU)." | 3.70 | Reirradiation and lomustine in patients with relapsed high-grade gliomas. ( Arcicasa, M; Bidoli, E; Dedkov, A; Gigante, M; Roncadin, M; Trovò, MG, 1999) |
| "The authors reviewed the results of neoadjuvant (preradiation) procarbazine, CCNU, and vincristine chemotherapy for anaplastic oligodendrogliomas because, increasingly, chemotherapy is prescribed before radiation for oligodendroglial neoplasms." | 3.70 | Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma. ( Cairncross, JG; Macdonald, DR; Paleologos, NA; Vick, NA, 1999) |
| "We treated 54 patients, newly diagnosed for glioblastoma, with systemic chemotherapy (carmustine (BCNU) 100 mg/m2 and cisplatin 90 mg/m2 every 6 weeks) and radiotherapy soon after surgery." | 3.70 | Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients. ( Boiardi, A; Broggi, G; Eoli, M; Pozzi, A; Salmaggi, A; Silvani, A, 1999) |
| "Carmustine and lomustine are nitrosourea antitumor chemotherapeutic agents which were used to determine whether or not they could affect arylamine N-acetyltransferase (NAT) activity and DNA-2-aminofluorene adducts in rat glial tumor cell line (C6 glioma)." | 3.70 | Effects of carmustine and lomustine on arylamine N-acetyltransferase activity and 2-aminofluorene-DNA adducts in rat glial tumor cells. ( Hung, CF, 2000) |
| "The aim of this study was to examine the range of sensitivity of a panel of short-term cultures derived from different types of malignant childhood brain tumours including medulloblastoma, ependymoma and glioblastoma multiforme to three cytotoxic drugs, lomustine (CCNU), vincristine (VCR) and procarbazine (PCB)." | 3.70 | Chemosensitivity in childhood brain tumours in vitro: evidence of differential sensitivity to lomustine (CCNU) and vincristine. ( Darling, JL; Harding, B; Harkness, W; Hayward, R; Lewandowicz, GM; Thomas, DG, 2000) |
| "To report a lomustine overdose in a patient with anaplastic astrocytoma." | 3.69 | Multiorgan failure associated with lomustine overdose. ( Moreb, J; Myers, L; Trent, KC, 1995) |
| "We report a patient who developed aplastic anemia after three courses of cyclohexylchloroethylnitrousurea (CCNU), procarbazine and oncovine administered after craniotomy and irradiation for brain astrocytoma." | 3.69 | Aplastic anemia induced by cyclohexylchloroethylnitrousurea. ( Elis, A; Lishner, M; Ravid, M; Savin, H, 1994) |
| "We administered chemotherapy in standard and intensified formulations of procarbazine, lomustine (CCNU), and vincristine to nine symptomatic patients with low-grade oligodendroglioma." | 3.69 | Low-grade oligodendroglioma responds to chemotherapy. ( DeAngelis, LM; Krol, GS; Mason, WP, 1996) |
| "Our results indicate that chemotherapy with a combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea is active for patients with recurrent anaplastic gliomas and glioblastomas not previously treated with nitrosourea-based chemotherapy but is inactive for patients with glioblastomas previously treated with chemotherapy." | 3.69 | Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas. ( Bruner, J; Flowers, A; Gleason, MJ; Ictech, SE; Jaeckle, KA; Kyritsis, AP; Levin, VA; Yung, WK, 1996) |
| "Effective chemotherapy using PCV (procarbazine, lomustine and vincristine) has been documented in anaplastic oligodendrogliomas and oligoastrocytomas." | 3.69 | [Assessment of procarbazine, vincristine and lomustine association (PCV protocol) in oligodendroglioma and mixed glioma]. ( Bouffet, E; Bret, P; Helfre, S; Jouvet, A; Mertens, P; Mornex, F; Sindou, M; Thiesse, P, 1997) |
| "Twenty-eight evaluable children with the diagnosis of brain stem glioma were treated with 5-fluorouracil and CCNU before posterior fossa irradiation (5500 rads); during irradiation, the children received hydroxyurea and misonidazole." | 3.67 | 5-Fluorouracil and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) followed by hydroxyurea, misonidazole, and irradiation for brain stem gliomas: a pilot study of the Brain Tumor Research Center and the Childrens Cancer Group. ( Allen, J; Edwards, MS; Levin, VA; Ortega, J; Vestnys, P; Wara, WM, 1984) |
| "Twenty-one patients with recurrent malignant central nervous system gliomas were treated with a combination of 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine." | 3.67 | Treatment of recurrent brain stem gliomas and other central nervous system tumors with 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine. ( Edwards, MS; Fulton, D; Levin, V; Prados, M; Rodriguez, LA; Silver, P, 1988) |
| "Fourteen consecutive melanoma patients with evaluable metastatic disease were treated with combination chemotherapy including procarbazine, vincristine and lomustine (POC)." | 3.67 | Metastatic malignant melanoma treated with procarbazine, vincristine and lomustine (POC). ( Ardizzoni, A; Grimaldi, A; Repetto, L; Rosso, R; Sertoli, MR, 1987) |
| "One hundred and seventeen patients with cerebral glioma (Kernohan grades III and IV) were treated with adjuvant chemotherapy using procarbazine (PCB), CCNU and vincristine (VCR) following whole head irradiation." | 3.67 | Assay of anti-cancer drugs in tissue culture: relationship of relapse free interval (RFI) and in vitro chemosensitivity in patients with malignant cerebral glioma. ( Bozek, T; Capra, LG; Collins, CD; Darling, JL; Godlee, JN; Mooney, C; Mott, TJ; Paul, EA; Thomas, DG; Tobias, JS, 1985) |
| "A patient is presented who developed nephrotoxicity after therapy with lomustine (CCNU) for astrocytoma of the brain." | 3.67 | Nephrotoxicity of lomustine. A case report and literature review. ( Ellis, ME; Kuperminc, M; Weiss, RB, 1985) |
| "Twenty consecutive patients with supratentorial Grade III and IV astrocytomas were treated with postoperative radiotherapy, and a simultaneous induction chemotherapy with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU), procarbazine, bleomycin, and maintenance chemotherapy with CCNU." | 3.66 | Radiotherapy combined with procarbazine, bleomycin, and CCNU in the treatment of high-grade supratentorial astrocytomas. ( Greiner, RH; Markwalder, H; Seiler, RW; Zimmerman, A, 1978) |
| "A patient with a mixed malignant glioma metastatic to the bones and lungs failed to respond to two different broad-spectrum combination chemotherapy regimens which included Adriamycin, methotrexate, cyclophosphamide, CCNU and cis-dichlorodiammineplatinum(II)." | 3.66 | Combination chemotherapy for extracranial metastases of a primary malignant cerebral neoplasm. ( Oster, MW, 1979) |
| "Seven patients were treated with a combination of intraventricular methotrexate (MTX) and oral CCNU after resection and whole CNS irradiation of medulloblastomas." | 3.66 | Adjuvant chemotherapy with intraventricular methotrexate and CCNU after surgery and radiotherapy of medulloblastomas. ( Imbach, P; Seiler, RW; Vassella, F; Wagner, HP, 1978) |
| "Seventeen patients with recurrent medulloblastoma were treated with a combination of three drugs: procarbazine, CCNU, and vincristine (PCV)." | 3.66 | Chemotherapy of recurrent medulloblastoma with combined procarbazine, CCNU, and vincristine. ( Crafts, DC; Edwards, MS; Levin, VA; Pischer, TL; Wilson, CB, 1978) |
| "Forty-three patients with inoperable or recurring malignant gliomas, and 30 patients with multiple recurring brain metastases were treated with a combination of Adriamycin (45 mg/m2) and 4-dimethyl-epipodophyllotoxin D-thenylidene (VM 26) (60 mg/m2 for 2 days) with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) (60 mg/m2 for 2 days)." | 3.65 | Treatment of malignant gliomas and brain metastases in adults with a combination of adriamycin, VM 26, and CCNU. Results of a phase II trail. ( Gauthier, H; Huguenin, P; Lheritier, J; Mathe, G; Morin, P; Parrot, R; Poisson, M; Pouillart, P; Thy, TH, 1976) |
| "Axitinib is a small molecule tyrosine kinase inhibitor with high affinity and specificity for the family of vascular endothelial growth factor receptors." | 2.87 | Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma. ( Andre, C; Bouttens, F; Chaskis, C; D'Haene, N; Du Four, S; Duerinck, J; Le Mercier, M; Michotte, A; Neyns, B; Rogiers, A; Salmon, I; Van Fraeyenhove, F; Verschaeve, V, 2018) |
| "The prognosis of patients with anaplastic oligodendrogliomas (AOD) and oligoastrocytomas (AOA) is variable." | 2.78 | New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brai ( Bernsen, HJ; Brandes, AA; Delattre, JY; Frénay, M; Gorlia, T; Kouwenhoven, MC; Kros, JM; Lacombe, D; Taphoorn, MJ; Tijssen, CC; van den Bent, MJ, 2013) |
| "Anaplastic oligodendroglioma are chemotherapy-sensitive tumors." | 2.78 | Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. ( Allgeier, A; Bernsen, HJ; Brandes, AA; Delattre, JY; Dinjens, WN; Enting, RH; Frenay, M; French, PJ; Gorlia, T; Grisold, W; Hoang-Xuan, K; Kouwenhoven, MC; Kros, JM; Lacombe, D; Sipos, L; Taphoorn, MJ; Tijssen, CC; van den Bent, MJ; Vecht, CJ, 2013) |
| "Intrinsic subtypes are highly prognostic in EORTC 26951 and improve outcome prediction when combined with other prognostic factors." | 2.78 | Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC stu ( de Rooi, J; den Dunnen, WF; Eilers, PH; Erdem-Eraslan, L; French, PJ; Gorlia, T; Gravendeel, LA; Idbaih, A; Kros, JM; Sillevis Smitt, PA; Spliet, WG; Teepen, JL; van den Bent, MJ; Wesseling, P, 2013) |
| " The safety component reported here, which also investigated pharmacokinetics and preliminary clinical activity, required expansion and is therefore considered a phase I part to establish a recommended dosing regimen of the combination of CCNU (90-110 mg/m(2)) and dasatinib (100-200 mg daily)." | 2.77 | EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma. ( Allgeier, A; Brandes, AA; Franceschi, E; Gorlia, T; Hegi, M; Lacombe, D; Laigle Donadey, F; Lhermitte, B; Strauss, LC; Stupp, R; van den Bent, MJ; van Herpen, C, 2012) |
| "RT alone for anaplastic oligodendroglioma." | 2.75 | Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. ( Brachman, D; Buckner, J; Cairncross, G; Curran, W; Fink, K; Jenkins, R; Laperriere, N; Mehta, M; Scheithauer, B; Shaw, E; Souhami, L; Wang, M, 2010) |
| "AOA tumors with necrosis are to be considered WHO grade IV tumors (GBM)." | 2.74 | Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951. ( Allgeier, A; Brandes, AA; Bromberg, JE; Gorlia, T; Grisold, W; Ibdaih, A; Kouwenhoven, MC; Kros, JM; Lacombe, D; Mirimanoff, R; Mokhtari, K; Sipos, L; Teepen, JL; van den Bent, MJ; van Duinen, SG; Vandenbos, F; Vecht, CJ; Wesseling, P, 2009) |
| "Based on studies relating to anaplastic oligodendroglioma (OG) chemosensitivity and benefit of time to progression or overall survival, chemotherapy for pure OG has been proposed." | 2.73 | Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy. ( Bourg, V; Chanalet, S; Fauchon, F; Fontaine, D; Frenay, M; Lebrun, C; Lonjon, M; Paquis, P; Ramaioli, A; Vandenbos, F, 2007) |
| "Adult patients with anaplastic oligodendrogliomas received RT alone or RT plus PCV chemotherapy." | 2.73 | Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial. ( Allgeier, A; Bernsen, HJ; Bottomley, A; Brandes, AA; Coens, C; Delattre, JY; Frénay, M; Lacombe, D; Mauer, ME; Sillevis Smitt, PA; Taphoorn, MJ; Tijssen, CC; van den Bent, MJ, 2007) |
| "Anaplastic oligodendrogliomas are more responsive to chemotherapy than high-grade astrocytomas." | 2.72 | Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer p ( Allgeier, A; Bernsen, HJ; Brandes, AA; Carpentier, AF; Frenay, M; Gorlia, T; Grisold, W; Haaxma-Reiche, H; Kros, JM; Lacombe, D; Sanson, M; Sipos, L; Taphoorn, MJ; Tijssen, CC; van den Bent, MJ; van Kouwenhoven, MC; Vecht, CJ, 2006) |
| "Temozolomide was in general well tolerated; the most frequent side-effects were hematological." | 2.71 | Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. ( Baron, B; Boogerd, W; Bravo Marques, J; Chinot, O; De Beule, N; Kros, JM; Taphoorn, MJ; van den Bent, MJ; van der Rijt, CC; Vecht, CJ, 2003) |
| "Anaplastic oligodendroglioma is a chemosensitive glial neoplasm." | 2.71 | High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma. ( Abrey, LE; Bayer, R; Cairncross, JG; Childs, BH; DeAngelis, LM; Finlay, JL; Forsyth, P; Gardner, S; Hu, W; Kaminer, L; Macdonald, DR; Nimer, SD; Paleologos, N; Peterson, K; Ramsey, DA; Rosenfeld, S; Salzman, D; Smith, AM; Stewart, D; Swinnen, L; Weaver, S, 2003) |
| "Because of the diffuse nature of gliomatosis cerebri (GC), surgery is not suitable, and large field radiotherapy carries the risk of severe toxicity." | 2.71 | Initial chemotherapy in gliomatosis cerebri. ( Carpentier, A; Cartalat-Carel, S; Chinot, O; Cougnard, J; Delattre, JY; Djafari, L; Duffau, H; Gervais, H; Hoang-Xuan, K; Honnorat, J; Laigle, F; Mokhtari, K; Napolitano, M; Sanson, M; Taillandier, L; Taillibert, S, 2004) |
| "Histologically, 69 had anaplastic astrocytoma; 14, anaplastic oligoastrocytoma; and 7, anaplastic oligodendroglioma." | 2.70 | Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas. ( Bruner, J; Chang, E; Gleason, MJ; Hess, KR; Ictech, SA; Kyritsis, A; Leeds, N; Levin, VA; Maor, MH; Meyers, CA; Yung, WK, 2002) |
| "Estimated 4-year survival for the anaplastic astrocytoma (AA) stratum (n = 116) is 46%." | 2.68 | Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas. ( Davis, RL; Gutin, PH; Lamborn, K; Levin, VA; Phillips, TL; Prados, MR; Wara, WM; Wilson, CB, 1995) |
| "Nine patients had brain metastases, and seven patients were systemically pretreated." | 2.68 | Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study. ( de Mulder, PH; Jansen, RL; Muller, EW; Punt, CJ; van Herpen, CM; Vreugdenhil, G, 1997) |
| "Those treated for glioblastoma multiforme had a mean Karnofsky Performance Score of 86% (range 60-100%) at 1 month and 75% (range 60-100%) at 24 months." | 2.67 | External irradiation followed by an interstitial high activity iodine-125 implant "boost" in the initial treatment of malignant gliomas: NCOG study 6G-82-2. ( Gutin, PH; Larson, DA; Leibel, SA; Levin, VA; Phillips, TL; Prados, MD; Silver, P; Sneed, PK; Wara, WM; Weaver, KA, 1991) |
| " Nevertheless, regimen B resulted in significantly more leukopenic patients, septicemic episodes, and blood transfusions, and the dosage of etoposide was more often reduced in arm B than in arm A." | 2.67 | Combination chemotherapy of limited-stage small-cell lung cancer. A controlled trial on 221 patients comparing two alternating regimens. ( Dombernowsky, P; Hansen, HH; Hansen, M; Hirsch, FR; Osterlind, K; Pedersen, AG; Sörenson, S, 1991) |
| "Glioblastomas are the most common malignant primary intrinsic brain tumors." | 2.66 | How did lomustine become standard of care in recurrent glioblastoma? ( Le Rhun, E; Weller, M, 2020) |
| " Nor did the analysis of life quality and of changes in clinical performance show any benefit in supplementing surgery and radiation therapy with CCNU chemotherapy at the dosage used." | 2.66 | Quality of survival of patients with brain gliomas treated with postoperative CCNU and radiation therapy. ( Bendarzewska, B; Bielawski, A; Dabrowska, A; Gościński, I; Lopatkiewicz, J; Markiewicz, P; Peszyński, J; Szymona, J; Trojanowski, T; Turowski, K, 1989) |
| "Misonidazole 1." | 2.66 | Combined modality treatment of operated astrocytomas grade 3 and 4. A prospective and randomized study of misonidazole and radiotherapy with two different radiation schedules and subsequent CCNU chemotherapy. Stage II of a prospective multicenter trial of ( Ganz, JC; Hagen, S; Hatlevoll, R; Kristiansen, K; Lindegaard, KF; Mella, O; Nesbakken, R; Ringkjöb, R; Rosengren, B; Torvik, A, 1985) |
| "Thirty-one patients with metastatic brain tumors were treated with Radiotherapy (RT) and CCNU or with RT, CCNU and Levamisole (LMS) in a randomized clinical trial." | 2.65 | Radio-chemo-immunotherapy (CCNU plus levamisole) for treatment of metastatic brain tumors. A pilot study. ( Knerich, R; Paoletti, P; Pavesi, L; Preti, P; Robustelli della Cuna, G, 1984) |
| " On the other side, dosage and the interval between cycles of chemotherapy appear to be a determining factor in the activity, but the limits are very narrow." | 2.64 | [A study of the use of sequential chemotherapy in 176 cases of glioblastoma (author's transl)]. ( Buge, A; Poisson, M; Pouillart, P, 1978) |
| "Brain metastasis occurred in 0/14 patients in the PCI and 4/15 in the non-PCI (P less than or equal to ." | 2.64 | Prophylactic cranial irradiation in small cell carcinoma of the lung. A randomized study. ( Cooper, MR; Ferree, C; Jackson, DV; Muss, HB; Richards, F; Spurr, CL; White, DR, 1977) |
| "Glioblastomas are rich in blood vessels (i." | 2.58 | Anti-angiogenic therapy for high-grade glioma. ( Ameratunga, M; Grant, R; Khasraw, M; Pavlakis, N; Simes, J; Wheeler, H, 2018) |
| "Gliomas are the most frequent primary brain tumors." | 2.50 | [Management of gliomas]. ( Chapet, S; Lévy, S; Mazeron, JJ, 2014) |
| " Alternative dosing regimens, such as 1-week on/1-week off, or 3-week on/1-week off, that deliver more prolonged exposure have been observed to result in higher cumulative doses than the standard 5-day regimen and may deplete tumor-derived O6-methylguanine-DNA methyltransferase (MGMT) in tumor cells, thus sensitizing tumor cells to the effects of TMZ." | 2.45 | [Treatment of glioma with temozolomide]. ( Nishikawa, R, 2009) |
| "The incidence of oligodendroglioma is increasing, most likely due to its improved recognition." | 2.42 | Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis. ( Engelhard, HH; Mundt, A; Stelea, A, 2003) |
| "Procarbazine was stopped after 2 cycles because of the development of a rash." | 2.42 | The role of PCV chemotherapy in the treatment of central neurocytoma: illustration of a case and review of the literature. ( Berger, MS; Chang, SM; Schmidt, MH; Uyehara-Lock, JH; von Koch, CS, 2003) |
| "Because oligodendroglioma are infiltrative tumors, the Mac Donald's response criteria, usually used for solid and contrast-enhanced tumors, seem not to be adapted." | 2.41 | PCV chemotherapy for oligodendroglioma: response analyzed on T2 weighted-MRI. ( Diabira, S; Gamelin, E; Jadaud, E; Menei, P; Rousselet, MC; Soulier, P, 2001) |
| " Since no epidemiological data in man are available, extrapolation of animal data to man are important as well as dose-response studies in risk evaluations." | 2.37 | Carcinogenic N-nitroso compounds and their environmental significance. ( Preussmann, R, 1984) |
| "Temozolomide-based treatment was administered to 64 of 68 (94." | 1.72 | Early Postoperative Treatment versus Initial Observation in CNS WHO Grade 2 and 3 Oligodendroglioma: Clinical Outcomes and DNA Methylation Patterns. ( Aichholzer, M; Berghoff, AS; Dieckmann, K; Furtner, J; Goldberger, S; Hatziioannou, T; Heller, G; Leibetseder, A; Mair, MJ; Pichler, J; Preusser, M; Puhr, R; Tomasich, E; von Oertzen, T; Weis, S; Widhalm, G; Wöhrer, A, 2022) |
| "Glioblastoma is a malignant primary brain tumor that affects approximately 250,000 new patients per year worldwide." | 1.72 | Current therapeutic options for glioblastoma and future perspectives. ( Aquilanti, E; Wen, PY, 2022) |
| "Intracranial gliomas are a common malignancy in dogs, and are associated with a poor prognosis due to their aggressive nature and a lack of clinically effective treatments." | 1.48 | Survival times in dogs with presumptive intracranial gliomas treated with oral lomustine: A comparative retrospective study (2008-2017). ( Cohen, PW; Dewey, CW; Moirano, SJ; Wright, KZ, 2018) |
| "The study included 26 patients with anaplastic astrocytoma and 37 patients with glioblastoma; all patients were aged ≤18 years." | 1.43 | High-grade glioma in children and adolescents: a single-center experience. ( Akalan, N; Akyuz, C; Cengiz, M; Eren, G; Gurkaynak, M; Ozyigit, G; Varan, A; Yazici, G; Yüce, D; Zorlu, F, 2016) |
| "Mice were dosed with either intravenous lomustine Molecular Envelope Technology (MET) nanoparticles (13 mg kg(-1)) or ethanolic lomustine (6." | 1.43 | Lomustine Nanoparticles Enable Both Bone Marrow Sparing and High Brain Drug Levels - A Strategy for Brain Cancer Treatments. ( Chooi, KW; Fisusi, FA; Garrett, N; Lalatsa, K; Moger, J; Okubanjo, O; Satchi-Fainaro, R; Schätzlein, AG; Serrano, D; Siew, A; Stapleton, P; Summers, I; Uchegbu, IF, 2016) |
| "Lomustine is a treatment option for patients with high-grade glioma." | 1.43 | Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models. ( Gruber, HE; Huang, TT; Ibañez, CE; Jolly, DJ; Lopez Espinoza, F; Mendoza, D; Robbins, JM; Yagiz, K, 2016) |
| "Lomustine was administered, but 1 year after surgery, the dog exhibited cluster seizures and died." | 1.43 | Case of a miniature dachshund with a primitive neuroectodermal tumor confined to the forebrain region treated with a combination of surgery and chemotherapy. ( Matsunaga, S; Nakamoto, Y; Ozawa, T; Uchida, K; Yamada, A, 2016) |
| "Myoinositol (MI) is an organic osmolyte, with intracellular concentration changes depending on the extracellular osmolality." | 1.43 | Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A 1H-Magnetic Resonance Spectroscopy Study. ( Bähr, O; Hattingen, E; Pilatus, U; Ronellenfitsch, MW; Steidl, E; Steinbach, JP; Zanella, F, 2016) |
| "Our results of combined treatment of brain metastases are presented and available approaches to brain irradiation and chemotherapy are discussed." | 1.37 | [Brain metastasis in breast cancer]. ( Ivanov, VG; Korytova, LI; Masliukova, EA; Meshechkin, AV; Zhabuna, RM, 2011) |
| "Malignant gliomas are the most common primary intrinsic brain tumors and are highly lethal." | 1.35 | Nitrosoureas inhibit the stathmin-mediated migration and invasion of malignant glioma cells. ( Choi, Y; Liang, XJ; Park, JK; Sackett, DL, 2008) |
| "12 months." | 1.35 | [Clinical features and combined treatment of the central nervous system in Hodgkin's disease]. ( Filatova, LV; Gershanovich, ML, 2008) |
| "Identification of synchronous brain tumors prompted genetic testing for predisposition to malignancy." | 1.35 | De novo germline TP53 mutation presenting with synchronous malignancies of the central nervous system. ( Brat, DJ; Esiashvili, N; Janss, AJ; Schniederjan, MJ; Shehata, B, 2009) |
| "Epilepsy was the most important risk factor for disability." | 1.32 | Long-term sequelae in children treated for brain tumors: impairments, disability, and handicap. ( Jereb, B; Macedoni-Luksic, M; Todorovski, L, 2003) |
| "We describe a case of anaplastic astrocytoma in a 14-year-old boy arising at the site of a dysembryoplastic neuroepithelial tumor (DNT) 3 years after combined radiation and chemotherapy." | 1.32 | Malignant transformation of a dysembryoplastic neuroepithelial tumor after radiation and chemotherapy. ( Mena, H; Rushing, EJ; Thompson, LD, 2003) |
| "Secondary anaplastic oligodendroglioma patients were younger than patients with de novo anaplastic oligodendrogliomas." | 1.32 | Long-term outcome of oligodendrogliomas. ( Bourg, V; Chanalet, S; Chatel, M; Fontaine, D; Frenay, M; Lebrun, C; Lonjon, M; Michiels, JF; Paquis, P; Ramaioli, A; Vandenbos, F, 2004) |
| "Several protocols for the adjuvant treatment of glioblastoma multiforme (GBM) are currently being evaluated." | 1.31 | Distinct radiochemotherapy protocols differentially influence cellular proliferation and expression of p53 and Bcl-2 in glioblastoma multiforme relapses in vivo. ( Deininger, MH; Grote, E; Meyermann, R; Wickboldt, J, 2000) |
| "Oligodendroglioma is a rare central nervous system tumor which may occur in pure or mixed histology." | 1.30 | Radiation and chemotherapy improve outcome in oligodendroglioma. ( Allison, RR; Barry, T; Schulsinger, A; Shin, KH; Vongtama, V, 1997) |
| "Intracranial Hodgkin's disease is very rare and is often a terminal event." | 1.30 | Intracranial Hodgkin's disease in two patients with familial Hodgkin's disease. ( Agarwal, V; Ashigbi, MY; Bello, J; Venkatraj, U; Wiernik, PH, 1997) |
| "004), the elimination half-life was 35% shorter (12." | 1.30 | Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. ( Joensuu, H; Kivistö, KT; Mäenpää, H; Neuvonen, PJ; Villikka, K, 1999) |
| "The rate of brain metastases was significantly lower in patients treated with methotrexate and nitrosurea containing schedules and PCI, compared to those who were treated with other schedules (irrespective of PCI)." | 1.29 | Consolidative thoracic radiotherapy and prophylactic cranial irradiation in limited disease small cell lung cancer. ( de Jonge, A; Karim, AB; Meyer, OW; Njo, KH; Slotman, BJ, 1993) |
| "Malignant oligodendrogliomas have been shown to be responsive to chemotherapy." | 1.28 | The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. ( Glass, J; Gruber, ML; Hochberg, FH; Louis, DN; Rattner, B; Smith, D, 1992) |
| "Procarbazine was ineffective." | 1.28 | The chemotherapeutic response of a murine (VM) model of human glioma. ( Bradford, R; Darling, JL; Thomas, DG, 1990) |
| "12 patients with brain tumors were treated with a combination of procarbazine, CCNU (bis-2-chloroethyl-3-cyclohexyl-1-nitrosourea) and vincristine." | 1.27 | Procarbazine, CCNU and vincristine (PCV) combination chemotherapy for brain tumors. ( Biran, S; Brufman, G; Catane, R; Halpern, J; Sulkes, A, 1984) |
| " The shapes of the dose-response curves indicated complete cross-resistance between BCNU and CCNU, i." | 1.27 | In vitro analysis of BCNU-sensitivity in human malignant gliomas. II. Cross-resistance studies with cisplatinum and nitrosoureas. ( Bricolo, A; Della Corte, V; Gerosa, MA; Licata, C; Marcon, C; Rosenblum, ML; Stevanoni, G; Tridente, G, 1986) |
| "The disease appeared to be a diffuse encephalopathy frequently affecting the higher cortical functions." | 1.27 | Neurologic dysfunction in patients treated for small cell carcinoma of the lung: a clinical and radiological study. ( Chak, LY; Cox, RS; Kushlan, PD; Porzig, KJ; Sikic, BI; Wasserstein, P; Zatz, LM, 1986) |
| " The radiation dose ranged from 3000 to 4650 rad and the oral CCNU dosage from 300 mg to 1050 mg." | 1.27 | Sudden onset of blindness in patients treated with oral CCNU and low-dose cranial irradiation. ( Kleinschmidt-Demasters, BK; Perez, GM; Wilson, WB, 1987) |
| "5 g/M2 every six weeks, with dosage adjustments for myelotoxicity." | 1.27 | Misonidazole and CCNU chemotherapy for recurrent primary brain tumor. ( Fulton, DS; McKinnon, S; Tanasichuk, H; Urtasun, RC, 1987) |
| "Malignant oligodendroglioma is a uniquely chemosensitive glial tumor." | 1.27 | Successful chemotherapy for recurrent malignant oligodendroglioma. ( Cairncross, JG; Macdonald, DR, 1988) |
| "Bone marrow myelofibrosis may be another delayed treatment effect of this class of drugs." | 1.27 | Myelofibrosis following treatment with a nitrosourea for malignant glioma. ( Fehir, KM; McKenney, SA, 1986) |
| "Six of them had tumor metastasis with in 6 months after the initial treatment(s)." | 1.27 | [Brain tumors in infants and children--factors affecting prognosis, (Part-3). Mode of metastasis and prognosis in medulloblastoma]. ( Matsumoto, S; Oi, S; Raimondi, AJ, 1985) |
| "A dose-response relation for the cytotoxic activity of chloroethylnitrosourea cancer chemotherapeutic agents in cell culture has been developed." | 1.26 | Quantitative dose-response relations for the cytotoxic activity of chloroethylnitrosoureas in cell culture. ( Deen, DF; Weinkam, RJ, 1982) |
| "Three cases of pseudocysts following surgery and chemotherapy for glioblastomas are reported." | 1.26 | Cerebral pseudocysts following chemotherapy of glioblastomas. ( Philippon, J; Poisson, M; Racadot, J; Sichez, JP; van Effenterre, R, 1977) |
| " The depression of platelets and white blood cells was mild after a single dosage of 40 mg/kg CCNU which recovered on about the 6th day." | 1.26 | Brain tumor chemotherapy using a rat glioma model. ( Mennel, HD; Tamura, M; Zülch, KJ, 1979) |
| "34 patients operated on for malignant gliomas were successively treated by combination chemotherapy with VM26 and CCNU and conventional radiation therapy with an average dosage of 5,800 Rads, six months after surgery." | 1.26 | Malignant gliomas treated after surgery by combination chemotherapy and delayed radiation therapy. Part II. Tolerance to irradiation after chemotherapy. ( Bataini, JP; Hauw, JJ; Mashaly, R; Metzger, J; Pertuiset, BF; Poisson, M; Pouillart, P, 1979) |
| "Three patients developed CNS metastasis while on treatment." | 1.26 | Adriamycin and 1-(2-chlorethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in the treatment of metastatic breast cancer. ( Blumenschein, GR; Burgess, MA; Buzdar, AU; Hortobagyi, GN; Tashima, CK; Waterfield, WC, 1978) |
| "Pretreatment with phenytoin, sodium methylprednisolone succinate and dexamethasone had little or no effect." | 1.26 | The effect of phenobarbital pretreatment on the antitumor activity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl-1-nitrosourea (PCNU), and on the plasma p ( Byrd, A; Finn, A; Levin, VA; Stearns, J; Weinkam, RJ, 1979) |
| " However, with certain dosage schedules such as every 2 hr for 5 injections daily on 2 consecutive days, i." | 1.26 | Chemotherapy of an experimental glioma with nitrosoureas. ( Day, A; Liberman, L; Ng, R; Tator, CH, 1977) |
| "Untreated meningeal carcinomatosis is a uniformly fatal type of metastatic disease presenting with many protean signs and symptoms." | 1.26 | Meningeal carcinomatosis. Case report and review of the literature. ( Bender, J; Bramlet, D; Giliberti, J, 1976) |
| " In the first phase, 14 patients (Group A) with progressive neurologic dysfunction following primary treatment were treated with DTIC alone (8 patients) or in combination with CCNU or methyl CCNU (6 patients) and evaluated for change in neurologic status." | 1.25 | Treatment of grade III and IV astrocytoma with dimethyl triazeno imidazole carboxamide (DTIC, NSC-45388) alone and in combination with CCNU (NSC-79037) or methyl CCNU (MeCCNU, NSC-95441). ( Baxter, D; Cunningham, TJ; Horton, J; Nelson, L; Olson, KB; Rosenbaum, C; Sponzo, RW; Taylor, SG, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 176 (36.07) | 18.7374 |
| 1990's | 78 (15.98) | 18.2507 |
| 2000's | 101 (20.70) | 29.6817 |
| 2010's | 98 (20.08) | 24.3611 |
| 2020's | 35 (7.17) | 2.80 |
| Authors | Studies |
|---|---|
| Yamamuro, S | 1 |
| Takahashi, M | 1 |
| Satomi, K | 1 |
| Sasaki, N | 1 |
| Kobayashi, T | 2 |
| Uchida, E | 1 |
| Kawauchi, D | 1 |
| Nakano, T | 1 |
| Fujii, T | 1 |
| Narita, Y | 1 |
| Kondo, A | 1 |
| Wada, K | 1 |
| Yoshino, A | 1 |
| Ichimura, K | 2 |
| Tomiyama, A | 1 |
| McBain, C | 1 |
| Lawrie, TA | 1 |
| Rogozińska, E | 1 |
| Kernohan, A | 1 |
| Robinson, T | 1 |
| Jefferies, S | 1 |
| Lavogina, D | 1 |
| Laasfeld, T | 1 |
| Vardja, M | 1 |
| Lust, H | 1 |
| Jaal, J | 1 |
| Wick, A | 4 |
| Sander, A | 1 |
| Koch, M | 1 |
| Bendszus, M | 5 |
| Combs, S | 1 |
| Haut, T | 1 |
| Dormann, A | 1 |
| Walter, S | 1 |
| Pertz, M | 1 |
| Merkle-Lock, J | 1 |
| Selkrig, N | 1 |
| Limprecht, R | 1 |
| Baumann, L | 1 |
| Kieser, M | 1 |
| Sahm, F | 5 |
| Schlegel, U | 4 |
| Winkler, F | 2 |
| Platten, M | 8 |
| Wick, W | 16 |
| Kessler, T | 3 |
| Mair, MJ | 1 |
| Leibetseder, A | 1 |
| Heller, G | 1 |
| Puhr, R | 1 |
| Tomasich, E | 1 |
| Goldberger, S | 1 |
| Hatziioannou, T | 1 |
| Wöhrer, A | 1 |
| Widhalm, G | 1 |
| Dieckmann, K | 3 |
| Aichholzer, M | 1 |
| Weis, S | 1 |
| von Oertzen, T | 1 |
| Furtner, J | 1 |
| Pichler, J | 1 |
| Preusser, M | 4 |
| Berghoff, AS | 1 |
| Aquilanti, E | 1 |
| Wen, PY | 5 |
| Wollring, MM | 1 |
| Werner, JM | 2 |
| Bauer, EK | 2 |
| Tscherpel, C | 2 |
| Ceccon, GS | 1 |
| Lohmann, P | 2 |
| Stoffels, G | 2 |
| Kabbasch, C | 2 |
| Goldbrunner, R | 4 |
| Fink, GR | 2 |
| Langen, KJ | 3 |
| Galldiks, N | 3 |
| Le Rhun, E | 6 |
| Oppong, FB | 3 |
| van den Bent, M | 10 |
| Brandes, AA | 18 |
| Taphoorn, MJ | 15 |
| Idbaih, A | 10 |
| Clement, PM | 7 |
| Golfinopoulos, V | 6 |
| Gorlia, T | 17 |
| Weller, M | 21 |
| Weller, J | 6 |
| Schäfer, N | 6 |
| Schaub, C | 4 |
| Tzaridis, T | 4 |
| Zeyen, T | 2 |
| Schneider, M | 3 |
| Potthoff, AL | 2 |
| Giordano, FA | 1 |
| Steinbach, JP | 6 |
| Zeiner, PS | 2 |
| Kowalski, T | 1 |
| Sabel, M | 2 |
| Hau, P | 5 |
| Krex, D | 4 |
| Grauer, O | 3 |
| Schnell, O | 2 |
| Tabatabai, G | 2 |
| Ringel, F | 1 |
| Schmidt-Graf, F | 2 |
| Brehmer, S | 1 |
| Tonn, JC | 3 |
| Bullinger, L | 1 |
| Vajkoczy, P | 1 |
| Glas, M | 6 |
| Vatter, H | 2 |
| Herrlinger, U | 9 |
| Seidel, C | 3 |
| Ellingson, BM | 1 |
| Chang, SM | 3 |
| Vogelbaum, MA | 2 |
| Li, G | 1 |
| Li, S | 1 |
| Kim, J | 1 |
| Youssef, G | 1 |
| Lassman, AB | 3 |
| Gilbert, MR | 7 |
| de Groot, JF | 2 |
| Galanis, E | 1 |
| Cloughesy, TF | 3 |
| Fishman, H | 1 |
| Monin, R | 1 |
| Dor-On, E | 1 |
| Kinzel, A | 1 |
| Haber, A | 1 |
| Giladi, M | 1 |
| Weinberg, U | 1 |
| Palti, Y | 1 |
| Esparragosa Vazquez, I | 1 |
| Ndiaye, M | 1 |
| Di Stefano, AL | 1 |
| Younan, N | 1 |
| Larrieu-Ciron, D | 1 |
| Seyve, A | 1 |
| Picart, T | 1 |
| Meyronet, D | 2 |
| Boutet, C | 1 |
| Vassal, F | 1 |
| Carpentier, C | 3 |
| Figarella-Branger, D | 2 |
| Dehais, C | 2 |
| Forest, F | 1 |
| Rivoirard, R | 1 |
| Ducray, F | 8 |
| Schrimpf, D | 1 |
| Doerner, L | 1 |
| Hai, L | 1 |
| Kaulen, LD | 1 |
| Ito, J | 1 |
| Taphoorn, M | 3 |
| Dômont, J | 3 |
| Campone, M | 4 |
| von Deimling, A | 4 |
| Paech, D | 1 |
| Duffy, C | 1 |
| Nitsch, L | 1 |
| Stummer, W | 1 |
| Hattingen, E | 2 |
| Radbruch, A | 1 |
| Krugman, J | 1 |
| Patel, K | 1 |
| Cantor, A | 1 |
| Snuderl, M | 1 |
| Cooper, B | 1 |
| Zan, E | 1 |
| Radmanesh, A | 1 |
| Hidalgo, ET | 1 |
| Nicolaides, T | 1 |
| McDuff, SGR | 1 |
| Dietrich, J | 1 |
| Atkins, KM | 1 |
| Oh, KS | 1 |
| Loeffler, JS | 2 |
| Shih, HA | 1 |
| Mukherjee, S | 1 |
| Wood, J | 1 |
| Liaquat, I | 1 |
| Stapleton, SR | 1 |
| Martin, AJ | 1 |
| Eoli, M | 3 |
| Sepulveda, JM | 1 |
| Smits, M | 3 |
| Walenkamp, A | 2 |
| Frenel, JS | 1 |
| Franceschi, E | 3 |
| Chinot, O | 4 |
| De Vos, F | 1 |
| Whenham, N | 1 |
| Sanghera, P | 1 |
| Dubbink, HJ | 4 |
| French, P | 2 |
| Looman, J | 1 |
| Dey, J | 1 |
| Krause, S | 1 |
| Ansell, P | 1 |
| Nuyens, S | 1 |
| Spruyt, M | 1 |
| Brilhante, J | 1 |
| Coens, C | 3 |
| Lazaridis, L | 1 |
| Teuber-Hanselmann, S | 1 |
| Blau, T | 1 |
| Schmidt, T | 1 |
| Oster, C | 1 |
| Pierscianek, D | 1 |
| Keyvani, K | 1 |
| Kleinschnitz, C | 1 |
| Stuschke, M | 1 |
| Scheffler, B | 1 |
| Deuschl, C | 1 |
| Sure, U | 1 |
| Kebir, S | 2 |
| Lobbous, M | 1 |
| Nabors, LB | 2 |
| Indraccolo, S | 1 |
| De Salvo, GL | 1 |
| Verza, M | 1 |
| Caccese, M | 1 |
| Esposito, G | 1 |
| Piga, I | 1 |
| Del Bianco, P | 1 |
| Pizzi, M | 1 |
| Gardiman, MP | 1 |
| Rudà, R | 3 |
| Ibrahim, T | 1 |
| Rizzato, S | 1 |
| Lolli, I | 1 |
| Zagonel, V | 1 |
| Lombardi, G | 1 |
| Raswoli, M | 1 |
| Nobre, L | 1 |
| Hawkins, C | 1 |
| Bartels, UK | 1 |
| Tabori, U | 1 |
| Bouffet, E | 3 |
| Alrohaibani, A | 1 |
| Swetnam, LA | 1 |
| Andeen, NK | 1 |
| Kickingereder, P | 2 |
| Brugnara, G | 1 |
| Hansen, MB | 1 |
| Nowosielski, M | 2 |
| Pflüger, I | 1 |
| Schell, M | 1 |
| Isensee, F | 1 |
| Foltyn, M | 1 |
| Neuberger, U | 1 |
| Heiland, S | 1 |
| Maier-Hein, KH | 1 |
| Østergaard, L | 1 |
| van den Bent, MJ | 29 |
| Cai, Y | 1 |
| Jiang, YG | 1 |
| Wang, M | 5 |
| Jiang, ZH | 1 |
| Tan, ZG | 1 |
| Touat, M | 1 |
| Soffietti, R | 2 |
| Seidel, S | 1 |
| Coch, C | 1 |
| Fimmers, R | 1 |
| Pietsch, T | 3 |
| Reifenberger, G | 4 |
| Felsberg, J | 3 |
| Petrecca, K | 1 |
| Walbert, T | 2 |
| Butowski, N | 1 |
| Salacz, M | 1 |
| Perry, J | 1 |
| Damek, D | 1 |
| Bota, D | 1 |
| Bettegowda, C | 1 |
| Zhu, JJ | 1 |
| Iwamoto, F | 1 |
| Placantonakis, D | 1 |
| Kim, L | 2 |
| Elder, B | 1 |
| Kaptain, G | 1 |
| Cachia, D | 1 |
| Moshel, Y | 1 |
| Brem, S | 2 |
| Piccioni, D | 1 |
| Landolfi, J | 1 |
| Chen, CC | 1 |
| Gruber, H | 1 |
| Rao, AR | 1 |
| Hogan, D | 1 |
| Accomando, W | 1 |
| Ostertag, D | 1 |
| Montellano, TT | 1 |
| Kheoh, T | 1 |
| Kabbinavar, F | 1 |
| Esteyrie, V | 1 |
| Martin, E | 1 |
| Uro-Coste, E | 1 |
| Bronniman, C | 1 |
| Pouessel, D | 1 |
| Ciron, DL | 1 |
| Moyal, EC | 1 |
| Network, P | 1 |
| Keogh, RJ | 1 |
| Aslam, R | 1 |
| Hennessy, MA | 1 |
| Coyne, Z | 1 |
| Hennessy, BT | 1 |
| Breathnach, OS | 1 |
| Grogan, L | 1 |
| Morris, PG | 1 |
| Katzendobler, S | 1 |
| Karschnia, P | 1 |
| Lietke, S | 1 |
| Egensperger, R | 1 |
| Thon, N | 1 |
| Suchorska, B | 1 |
| Ceccon, G | 1 |
| Baues, C | 1 |
| Celik, E | 1 |
| Marnitz, S | 1 |
| Gielen, GH | 1 |
| Lin, P | 1 |
| Jiang, H | 1 |
| Zhao, YJ | 1 |
| Pang, JS | 1 |
| Liao, W | 1 |
| He, Y | 1 |
| Lin, ZY | 1 |
| Yang, H | 1 |
| Castro, M | 1 |
| Pampana, A | 1 |
| Alam, A | 1 |
| Parashar, R | 1 |
| Rajagopalan, S | 1 |
| Lala, DA | 1 |
| Roy, KGG | 1 |
| Basu, S | 1 |
| Prakash, A | 1 |
| Nair, P | 1 |
| Joseph, V | 1 |
| Agarwal, A | 1 |
| G, P | 1 |
| Behura, L | 1 |
| Kulkarni, S | 1 |
| Choudhary, NR | 1 |
| Kapoor, S | 1 |
| Qian, Y | 1 |
| Maruyama, S | 1 |
| Kim, H | 2 |
| Pollom, EL | 1 |
| Kumar, KA | 1 |
| Chin, AL | 1 |
| Harris, JP | 1 |
| Chang, DT | 1 |
| Pitt, A | 1 |
| Bendavid, E | 1 |
| Owens, DK | 1 |
| Durkee, BY | 1 |
| Soltys, SG | 1 |
| Parasramka, S | 1 |
| Talari, G | 1 |
| Rosenfeld, M | 1 |
| Guo, J | 1 |
| Villano, JL | 2 |
| Belcher, SM | 1 |
| Burton, CC | 1 |
| Cookman, CJ | 1 |
| Kirby, M | 1 |
| Miranda, GL | 1 |
| Saeed, FO | 1 |
| Wray, KE | 1 |
| Duerinck, J | 3 |
| Du Four, S | 3 |
| Bouttens, F | 2 |
| Andre, C | 1 |
| Verschaeve, V | 2 |
| Van Fraeyenhove, F | 1 |
| Chaskis, C | 1 |
| D'Haene, N | 2 |
| Le Mercier, M | 2 |
| Rogiers, A | 1 |
| Michotte, A | 3 |
| Salmon, I | 2 |
| Neyns, B | 4 |
| Harting, I | 2 |
| Taal, W | 9 |
| Stupp, R | 5 |
| Fabbro, M | 2 |
| Dubois, F | 1 |
| Bromberg, JC | 1 |
| Klein, M | 1 |
| Staberg, M | 2 |
| Rasmussen, RD | 2 |
| Michaelsen, SR | 2 |
| Pedersen, H | 1 |
| Jensen, KE | 1 |
| Villingshøj, M | 2 |
| Skjoth-Rasmussen, J | 1 |
| Brennum, J | 1 |
| Vitting-Seerup, K | 1 |
| Poulsen, HS | 2 |
| Hamerlik, P | 2 |
| Moirano, SJ | 1 |
| Dewey, CW | 1 |
| Wright, KZ | 1 |
| Cohen, PW | 1 |
| Grube, S | 1 |
| Ewald, C | 1 |
| Kögler, C | 1 |
| Lawson McLean, A | 1 |
| Kalff, R | 1 |
| Walter, J | 1 |
| Rodrigues-Junior, DM | 1 |
| Biassi, TP | 1 |
| Carlin, V | 1 |
| Buri, MV | 1 |
| Torrecilhas, AC | 1 |
| Bortoluci, KR | 1 |
| Vettore, AL | 1 |
| Gonzalez-Aguilar, A | 1 |
| Reyes-Moreno, I | 1 |
| Peiro-Osuna, RP | 1 |
| Hernandez-Hernandez, A | 1 |
| Gutierrez-Aceves, A | 1 |
| Santos-Zambrano, J | 1 |
| Guerrero-Juarez, V | 1 |
| Lopez-Martinez, M | 1 |
| Castro-Martinez, E | 1 |
| Ameratunga, M | 1 |
| Pavlakis, N | 2 |
| Wheeler, H | 2 |
| Grant, R | 2 |
| Simes, J | 1 |
| Khasraw, M | 2 |
| Lukas, RV | 1 |
| Hegi, ME | 1 |
| Killock, D | 1 |
| Norden, AD | 2 |
| Korytowsky, B | 1 |
| You, M | 1 |
| Kim Le, T | 1 |
| Dastani, H | 1 |
| Bobiak, S | 1 |
| Singh, P | 1 |
| Bromberg, JEC | 1 |
| Taphoorn, MJB | 1 |
| Lee, EQ | 2 |
| Nayak, L | 2 |
| Reardon, DA | 2 |
| Rosenfeld, MR | 1 |
| Delattre, JY | 6 |
| Kros, JM | 16 |
| Kouwenhoven, MC | 3 |
| Bernsen, HJ | 4 |
| Frénay, M | 10 |
| Tijssen, CC | 6 |
| Lacombe, D | 8 |
| Roth, P | 3 |
| Batchelor, TT | 1 |
| Mulholland, P | 1 |
| Mason, W | 2 |
| Mikkelsen, T | 2 |
| Phuphanich, S | 2 |
| Ashby, LS | 2 |
| Degroot, J | 1 |
| Gattamaneni, R | 1 |
| Cher, L | 2 |
| Rosenthal, M | 1 |
| Payer, F | 1 |
| Jürgensmeier, JM | 1 |
| Jain, RK | 1 |
| Sorensen, AG | 1 |
| Xu, J | 1 |
| Liu, Q | 1 |
| Prabhu, RS | 1 |
| Won, M | 2 |
| Shaw, EG | 4 |
| Hu, C | 1 |
| Brachman, DG | 2 |
| Buckner, JC | 6 |
| Stelzer, KJ | 1 |
| Barger, GR | 2 |
| Brown, PD | 3 |
| Mehta, MP | 4 |
| Kaloshi, G | 2 |
| Rroji, A | 2 |
| Petrela, M | 2 |
| Cairncross, JG | 14 |
| Jenkins, RB | 2 |
| Giannini, C | 1 |
| Fink, KL | 1 |
| Souhami, L | 4 |
| Laperriere, NJ | 1 |
| Huse, JT | 1 |
| Curran, WJ | 4 |
| Behrend, SW | 1 |
| Tonder, M | 1 |
| Eisele, G | 1 |
| Weiss, T | 1 |
| Hofer, S | 2 |
| Seystahl, K | 1 |
| Valavanis, A | 1 |
| Collins, VP | 1 |
| Di, Y | 1 |
| Pearson, D | 1 |
| Chan, R | 1 |
| Thompson, LC | 1 |
| Gabe, R | 1 |
| Brada, M | 1 |
| Stenning, SP | 2 |
| Rahman, R | 1 |
| Hempfling, K | 1 |
| Rinne, ML | 1 |
| Beroukhim, R | 1 |
| Doherty, L | 1 |
| Ruland, S | 1 |
| Rai, A | 1 |
| Rifenburg, J | 1 |
| LaFrankie, D | 1 |
| Alexander, BM | 1 |
| Huang, RY | 1 |
| Oosterkamp, HM | 3 |
| Walenkamp, AM | 3 |
| Beerepoot, LV | 4 |
| Hanse, MC | 3 |
| Buter, J | 3 |
| Honkoop, AH | 2 |
| Boerman, D | 1 |
| de Vos, FY | 3 |
| Dinjens, WN | 5 |
| Enting, RH | 4 |
| van den Berkmortel, FW | 1 |
| Jansen, RL | 2 |
| Brandsma, D | 1 |
| Bromberg, JE | 4 |
| van Heuvel, I | 4 |
| Vernhout, RM | 4 |
| van der Holt, B | 5 |
| Villanueva, MT | 2 |
| Lévy, S | 1 |
| Chapet, S | 1 |
| Mazeron, JJ | 2 |
| Ameratunga, MS | 1 |
| Raza, S | 1 |
| Firwana, B | 1 |
| Doll, DC | 1 |
| Ediebah, DE | 1 |
| Galindo-Garre, F | 1 |
| Uitdehaag, BM | 2 |
| Ringash, J | 1 |
| Reijneveld, JC | 2 |
| Dirven, L | 2 |
| Zikos, E | 1 |
| Bottomley, A | 3 |
| van der Rijt, CC | 2 |
| Sillevis Smitt, PA | 6 |
| Wertenbroek, AA | 1 |
| Harvey, KA | 1 |
| Xu, Z | 1 |
| Saaddatzadeh, MR | 1 |
| Wang, H | 1 |
| Pollok, K | 1 |
| Cohen-Gadol, AA | 1 |
| Siddiqui, RA | 1 |
| Chamberlain, MC | 7 |
| Wong, ET | 1 |
| Lok, E | 1 |
| Swanson, KD | 1 |
| Dixit, S | 1 |
| Hingorani, M | 1 |
| Schiff, D | 2 |
| van der Meer, N | 1 |
| Vos, MJ | 2 |
| Otten, A | 2 |
| Levin, VA | 25 |
| Beije, N | 1 |
| Kraan, J | 1 |
| Beerepoot, L | 1 |
| Hanse, M | 2 |
| van Linde, ME | 1 |
| Gratama, JW | 1 |
| Sleijfer, S | 1 |
| Roci, E | 1 |
| Carvalho, BF | 1 |
| Fernandes, AC | 1 |
| Almeida, DS | 1 |
| Sampaio, LV | 1 |
| Costa, A | 1 |
| Caeiro, C | 1 |
| Osório, L | 1 |
| Castro, L | 1 |
| Linhares, P | 1 |
| Damasceno, M | 1 |
| Vaz, RC | 1 |
| Webre, C | 1 |
| Shonka, N | 1 |
| Smith, L | 1 |
| Liu, D | 1 |
| De Groot, J | 1 |
| Sander, W | 1 |
| Van Binst, AM | 2 |
| Everaert, H | 2 |
| Heiland, DH | 1 |
| Masalha, W | 1 |
| Franco, P | 1 |
| Machein, MR | 1 |
| Weyerbrock, A | 1 |
| Yazici, G | 1 |
| Zorlu, F | 1 |
| Cengiz, M | 1 |
| Ozyigit, G | 1 |
| Eren, G | 1 |
| Yüce, D | 1 |
| Varan, A | 2 |
| Akyuz, C | 2 |
| Akalan, N | 2 |
| Gurkaynak, M | 1 |
| Strowd, RE | 1 |
| Abuali, I | 1 |
| Ye, X | 1 |
| Lu, Y | 1 |
| Grossman, SA | 1 |
| Erdem-Eraslan, L | 2 |
| Hoogstrate, Y | 1 |
| Naz-Khan, H | 1 |
| Stubbs, A | 1 |
| van der Spek, P | 1 |
| Böttcher, R | 1 |
| Gao, Y | 1 |
| de Wit, M | 1 |
| French, PJ | 3 |
| Mazzocco, P | 1 |
| Honnorat, J | 4 |
| Ribba, B | 1 |
| Carpentier, AF | 3 |
| Kesari, S | 1 |
| Sepulveda-Sanchez, JM | 1 |
| Wheeler, HR | 1 |
| Capper, D | 1 |
| Specenier, P | 1 |
| Rodon, J | 1 |
| Cleverly, A | 1 |
| Smith, C | 1 |
| Gueorguieva, I | 1 |
| Miles, C | 1 |
| Guba, SC | 1 |
| Desaiah, D | 1 |
| Lahn, MM | 1 |
| Fisusi, FA | 1 |
| Siew, A | 1 |
| Chooi, KW | 1 |
| Okubanjo, O | 1 |
| Garrett, N | 1 |
| Lalatsa, K | 1 |
| Serrano, D | 1 |
| Summers, I | 1 |
| Moger, J | 1 |
| Stapleton, P | 1 |
| Satchi-Fainaro, R | 1 |
| Schätzlein, AG | 1 |
| Uchegbu, IF | 1 |
| Vandervorst, F | 1 |
| Jakacki, RI | 5 |
| Cohen, KJ | 1 |
| Buxton, A | 1 |
| Krailo, MD | 1 |
| Burger, PC | 2 |
| Rosenblum, MK | 2 |
| Brat, DJ | 2 |
| Hamilton, RL | 1 |
| Eckel, SP | 1 |
| Zhou, T | 3 |
| Lavey, RS | 1 |
| Pollack, IF | 4 |
| Pugh, SL | 1 |
| Chakravarti, A | 1 |
| Coons, S | 1 |
| Ricci, P | 1 |
| Bullard, D | 1 |
| Stelzer, K | 1 |
| Brachman, D | 4 |
| Suh, JH | 1 |
| Schultz, CJ | 1 |
| Bahary, JP | 1 |
| Fisher, BJ | 3 |
| Murtha, AD | 1 |
| Bell, EH | 1 |
| Gramatzki, D | 1 |
| Rushing, EJ | 2 |
| Hentschel, B | 1 |
| Westphal, M | 1 |
| Simon, M | 2 |
| Yagiz, K | 1 |
| Huang, TT | 1 |
| Lopez Espinoza, F | 1 |
| Mendoza, D | 1 |
| Ibañez, CE | 1 |
| Gruber, HE | 1 |
| Jolly, DJ | 1 |
| Robbins, JM | 1 |
| Combs, SE | 1 |
| Meyer, B | 1 |
| Weathers, SP | 1 |
| Han, X | 1 |
| Liu, DD | 1 |
| Conrad, CA | 2 |
| Loghin, ME | 1 |
| O'Brien, BJ | 1 |
| Penas-Prado, M | 1 |
| Puduvalli, VK | 3 |
| Tremont-Lukats, I | 1 |
| Colen, RR | 1 |
| Yung, WKA | 1 |
| Nakamoto, Y | 1 |
| Yamada, A | 1 |
| Uchida, K | 1 |
| Matsunaga, S | 1 |
| Ozawa, T | 1 |
| Steidl, E | 1 |
| Pilatus, U | 1 |
| Zanella, F | 1 |
| Ronellenfitsch, MW | 1 |
| Bähr, O | 1 |
| Gahrmann, R | 1 |
| Vos, M | 1 |
| de Groot, JC | 1 |
| Flach, ZH | 1 |
| Jasperse, B | 1 |
| Goerne, R | 1 |
| Bogdahn, U | 1 |
| Liang, XJ | 1 |
| Choi, Y | 1 |
| Sackett, DL | 1 |
| Park, JK | 1 |
| Baumert, BG | 1 |
| Rasch, K | 1 |
| Wiewrodt, D | 1 |
| Kartashev, AV | 1 |
| Vinogradov, VM | 1 |
| Fewer, D | 1 |
| Wilson, CB | 12 |
| Boldrey, EB | 3 |
| Enot, JK | 1 |
| Filatova, LV | 1 |
| Gershanovich, ML | 2 |
| Ibdaih, A | 2 |
| Mokhtari, K | 5 |
| van Duinen, SG | 1 |
| Teepen, JL | 2 |
| Wesseling, P | 4 |
| Vandenbos, F | 4 |
| Grisold, W | 6 |
| Sipos, L | 3 |
| Mirimanoff, R | 1 |
| Vecht, CJ | 4 |
| Allgeier, A | 6 |
| Yang, SH | 2 |
| Hong, YK | 2 |
| Jeun, SS | 2 |
| Kim, IS | 1 |
| Hong, JT | 1 |
| Sung, JH | 1 |
| Son, BC | 1 |
| Lee, SW | 1 |
| Kim, MC | 2 |
| Lee, KS | 2 |
| Vesper, J | 1 |
| Graf, E | 1 |
| Wille, C | 1 |
| Tilgner, J | 1 |
| Trippel, M | 1 |
| Nikkhah, G | 1 |
| Ostertag, C | 1 |
| Nakamura, M | 1 |
| Shimada, K | 1 |
| Nakase, H | 1 |
| Konishi, N | 1 |
| Nishikawa, R | 1 |
| Schniederjan, MJ | 1 |
| Shehata, B | 1 |
| Esiashvili, N | 1 |
| Janss, AJ | 1 |
| Cairncross, G | 5 |
| Shaw, E | 3 |
| Jenkins, R | 4 |
| Scheithauer, B | 2 |
| Buckner, J | 4 |
| Fink, K | 3 |
| Laperriere, N | 2 |
| Mehta, M | 3 |
| Curran, W | 3 |
| DeAngelis, LM | 5 |
| Sanson, M | 7 |
| van der Lee-Haarloo, CR | 1 |
| Hegi, M | 2 |
| Jeuken, JW | 1 |
| Hartmann, C | 1 |
| Engel, C | 1 |
| Stoffels, M | 1 |
| Stockhammer, F | 1 |
| Sabel, MC | 1 |
| Koeppen, S | 1 |
| Ketter, R | 1 |
| Meyermann, R | 4 |
| Rapp, M | 1 |
| Meisner, C | 1 |
| Kortmann, RD | 2 |
| Wiestler, OD | 1 |
| Ernemann, U | 1 |
| Bamberg, M | 4 |
| Guillaume, DJ | 1 |
| Doolittle, ND | 1 |
| Gahramanov, S | 1 |
| Hedrick, NA | 1 |
| Delashaw, JB | 1 |
| Neuwelt, EA | 1 |
| Cher, LM | 1 |
| Hong, S | 1 |
| Musib, L | 1 |
| Liepa, AM | 1 |
| Thornton, DE | 1 |
| Fine, HA | 2 |
| Marie, Y | 1 |
| van Marion, R | 1 |
| Agha, CA | 1 |
| Ibrahim, S | 1 |
| Hassan, A | 1 |
| Elias, DA | 1 |
| Fathallah-Shaykh, HM | 1 |
| Peyre, M | 1 |
| Cartalat-Carel, S | 3 |
| Ricard, D | 1 |
| Jouvet, A | 4 |
| Pallud, J | 1 |
| Guyotat, J | 2 |
| Jouanneau, E | 2 |
| Sunyach, MP | 2 |
| Frappaz, D | 2 |
| Groves, MD | 2 |
| Yung, WK | 7 |
| Bobustuc, GC | 1 |
| Colman, H | 1 |
| Hsu, SH | 1 |
| Bekele, BN | 1 |
| Qiao, W | 1 |
| Kong, DS | 1 |
| Kim, ST | 1 |
| Lee, JI | 1 |
| Suh, YL | 1 |
| Lim, DH | 1 |
| Kim, WS | 1 |
| Kwon, KH | 1 |
| Park, K | 1 |
| Kim, JH | 1 |
| Nam, DH | 1 |
| Dalmasso, C | 1 |
| Kouwenhoven, M | 1 |
| Jeuken, J | 1 |
| Teepen, J | 1 |
| Broët, P | 1 |
| Delattre, O | 1 |
| Hoang-Xuan, K | 4 |
| Zhuang, L | 1 |
| Gao, J | 1 |
| Zeng, Y | 1 |
| Yu, F | 1 |
| Zhang, B | 1 |
| Li, M | 1 |
| Derendorf, H | 1 |
| Liu, C | 1 |
| Iwamoto, FM | 1 |
| Aldape, KD | 1 |
| Rivera, AL | 1 |
| Eichler, AF | 1 |
| Louis, DN | 4 |
| Paleologos, NA | 2 |
| Roldán, GB | 1 |
| Ligon, KL | 1 |
| Robins, HI | 1 |
| Rocque, BG | 1 |
| Mason, WP | 2 |
| Weaver, SA | 1 |
| Green, RM | 1 |
| Kamar, FG | 1 |
| Abrey, LE | 4 |
| Jhanwar, SC | 1 |
| Panageas, KS | 1 |
| Korytova, LI | 1 |
| Meshechkin, AV | 1 |
| Zhabuna, RM | 1 |
| Masliukova, EA | 1 |
| Ivanov, VG | 1 |
| Vauleon, E | 1 |
| Mesbah, H | 1 |
| Gedouin, D | 1 |
| Lecouillard, I | 1 |
| Louvel, G | 1 |
| Hamlat, A | 1 |
| Riffaud, L | 1 |
| Carsin, B | 1 |
| Quillien, V | 1 |
| Audrain, O | 1 |
| Lesimple, T | 1 |
| Ater, JL | 1 |
| Holmes, E | 1 |
| Mazewski, CM | 1 |
| Booth, TN | 1 |
| Freyer, DR | 1 |
| Lazarus, KH | 1 |
| Packer, RJ | 5 |
| Prados, M | 3 |
| Sposto, R | 3 |
| Vezina, G | 1 |
| Wisoff, JH | 2 |
| Stuplich, M | 1 |
| Hadizadeh, DR | 1 |
| Kuchelmeister, K | 1 |
| Scorzin, J | 1 |
| Filss, C | 1 |
| Mack, F | 1 |
| Schüller, H | 1 |
| Urbach, H | 1 |
| Van Meervenne, S | 1 |
| Verhoeven, PS | 1 |
| de Vos, J | 1 |
| Gielen, IM | 1 |
| Polis, I | 1 |
| Van Ham, LM | 1 |
| Viaccoz, A | 1 |
| Lekoubou, A | 1 |
| Printz, C | 1 |
| Szabo, D | 1 |
| Saveraid, TC | 1 |
| Rodenas, S | 1 |
| van Herpen, C | 1 |
| Laigle Donadey, F | 1 |
| Lhermitte, B | 1 |
| Strauss, LC | 1 |
| Dignam, JJ | 1 |
| Zhang, QE | 1 |
| DeGroot, JF | 1 |
| Hunsberger, S | 1 |
| Gravendeel, LA | 1 |
| de Rooi, J | 1 |
| Eilers, PH | 1 |
| Spliet, WG | 1 |
| den Dunnen, WF | 1 |
| Murphy, C | 1 |
| Pickles, T | 1 |
| Knowling, M | 1 |
| Thiesse, B | 1 |
| Zander, T | 1 |
| Nettekoven, W | 1 |
| Kraus, JA | 1 |
| Pels, H | 1 |
| Ko, YD | 1 |
| Vetter, H | 1 |
| Klockgether, T | 1 |
| Baker, MJ | 1 |
| Daniels, S | 1 |
| Sherman, B | 1 |
| Gesme, D | 1 |
| O'Fallon, JR | 1 |
| Hammack, JE | 1 |
| Stafford, S | 1 |
| Hawkins, R | 1 |
| Scheithauer, BW | 1 |
| Erickson, BJ | 1 |
| Levitt, R | 1 |
| Louis, E | 1 |
| Keime-Guibert, F | 1 |
| Macedoni-Luksic, M | 1 |
| Jereb, B | 1 |
| Todorovski, L | 1 |
| Piribauer, M | 3 |
| Fazeny-Dörner, B | 2 |
| Rössler, K | 2 |
| Ungersböck, K | 2 |
| Czech, T | 2 |
| Killer, M | 2 |
| Birner, P | 1 |
| Prayer, D | 2 |
| Hainfellner, J | 1 |
| Muhm, M | 2 |
| Marosi, C | 4 |
| Nieder, C | 1 |
| Looijenga, LH | 2 |
| Langenberg, K | 1 |
| Dinjens, W | 1 |
| Graveland, W | 1 |
| Uytdewilligen, L | 1 |
| Barkhof, F | 1 |
| Heimans, JJ | 3 |
| Baayen, HC | 1 |
| Boogerd, W | 3 |
| Castelijns, JA | 1 |
| Elkhuizen, PH | 1 |
| Postma, TJ | 2 |
| Bravo Marques, J | 1 |
| De Beule, N | 1 |
| Baron, B | 1 |
| Pommier, P | 1 |
| Martel Lafay, I | 1 |
| Ginestet, G | 1 |
| Sindou, M | 3 |
| Bret, P | 2 |
| Carrie, C | 1 |
| Gyries, A | 1 |
| Budinsky, A | 1 |
| Baumgartner, G | 1 |
| Veitl, M | 1 |
| Lancaster, DL | 1 |
| Hoddes, JA | 1 |
| Michalski, A | 1 |
| Thompson, LD | 1 |
| Mena, H | 1 |
| Fouladi, M | 1 |
| Hunt, DL | 1 |
| Dueckers, G | 1 |
| Becker, LE | 1 |
| Yates, AJ | 3 |
| Gilles, FH | 1 |
| Davis, RL | 5 |
| Boyett, JM | 5 |
| Finlay, JL | 7 |
| Engelhard, HH | 1 |
| Stelea, A | 1 |
| Mundt, A | 1 |
| Khil'ko, VA | 1 |
| Khachatrian, VA | 1 |
| Shuleshova, NV | 1 |
| von Koch, CS | 1 |
| Schmidt, MH | 1 |
| Uyehara-Lock, JH | 1 |
| Berger, MS | 1 |
| Lichy, MP | 1 |
| Bachert, P | 1 |
| Henze, M | 1 |
| Lichy, CM | 1 |
| Debus, J | 1 |
| Schlemmer, HP | 1 |
| Childs, BH | 2 |
| Paleologos, N | 4 |
| Kaminer, L | 3 |
| Rosenfeld, S | 3 |
| Salzman, D | 3 |
| Gardner, S | 2 |
| Peterson, K | 3 |
| Hu, W | 3 |
| Swinnen, L | 3 |
| Bayer, R | 3 |
| Forsyth, P | 4 |
| Stewart, D | 5 |
| Smith, AM | 2 |
| Macdonald, DR | 8 |
| Weaver, S | 2 |
| Ramsey, DA | 1 |
| Nimer, SD | 2 |
| Nobile, M | 1 |
| Borgognone, M | 1 |
| Costanza, A | 1 |
| Laguzzi, E | 1 |
| Mutani, R | 1 |
| Prados, MD | 9 |
| Seiferheld, W | 1 |
| Sandler, HM | 1 |
| Phillips, T | 2 |
| Schultz, C | 2 |
| Urtasun, R | 3 |
| Davis, R | 3 |
| Gutin, P | 3 |
| Cascino, TL | 2 |
| Greenberg, HS | 2 |
| Lebrun, C | 3 |
| Fontaine, D | 3 |
| Ramaioli, A | 3 |
| Chanalet, S | 3 |
| Lonjon, M | 3 |
| Michiels, JF | 2 |
| Bourg, V | 3 |
| Paquis, P | 3 |
| Chatel, M | 2 |
| Alchaar, H | 1 |
| Bleuse, A | 1 |
| Bondiau, PY | 1 |
| Brunetto, JL | 1 |
| Courdi, A | 1 |
| Darcourt, J | 1 |
| Fauchon, F | 2 |
| Guibert, F | 1 |
| Grellier, P | 1 |
| Lanteri-Minet, M | 1 |
| Paquis, V | 1 |
| Rasendrarijao, D | 1 |
| Taillibert, S | 1 |
| Napolitano, M | 1 |
| Djafari, L | 1 |
| Cougnard, J | 1 |
| Gervais, H | 1 |
| Laigle, F | 1 |
| Carpentier, A | 1 |
| Taillandier, L | 1 |
| Duffau, H | 1 |
| de Wit, MC | 1 |
| de Bruin, HG | 2 |
| Eijkenboom, W | 1 |
| Triebels, VH | 1 |
| Menten, J | 1 |
| Tosoni, A | 1 |
| Stege, EB | 1 |
| Teng, LH | 1 |
| Gui, QP | 1 |
| Xuan, Q | 1 |
| Lu, DH | 1 |
| Stege, EM | 1 |
| van der Rijt, CD | 1 |
| Smitt, PA | 1 |
| Tang, BN | 1 |
| Sadeghi, N | 1 |
| Branle, F | 1 |
| De Witte, O | 1 |
| Wikler, D | 1 |
| Goldman, S | 1 |
| Liau, CT | 1 |
| Wei, KC | 1 |
| Tseng, CK | 1 |
| Jung, SM | 1 |
| Nomura, K | 1 |
| Oberndorfer, S | 1 |
| Lahrmann, H | 1 |
| Hitzenberger, P | 1 |
| Bottoni, U | 1 |
| Bonaccorsi, P | 1 |
| Devirgiliis, V | 1 |
| Panasiti, V | 1 |
| Borroni, RG | 1 |
| Trasimeni, G | 1 |
| Clerico, R | 1 |
| Calvieri, S | 1 |
| Tafuto, S | 1 |
| Muto, P | 1 |
| Tortoriello, A | 1 |
| Pisano, A | 1 |
| Comella, P | 1 |
| Formato, R | 1 |
| Quattrin, S | 1 |
| Iaffaioli, RV | 1 |
| Ty, AU | 1 |
| See, SJ | 1 |
| Rao, JP | 1 |
| Khoo, JB | 1 |
| Wong, MC | 1 |
| Yimam, MA | 1 |
| Bui, T | 1 |
| Ho, RJ | 2 |
| Jones, R | 1 |
| Kirkup, M | 1 |
| Guglani, S | 1 |
| Hopkins, K | 1 |
| Schmidt, F | 1 |
| Fischer, J | 2 |
| Dietz, K | 1 |
| Dichgans, J | 3 |
| Ramsay, DA | 2 |
| Cornetta, K | 2 |
| Croop, J | 1 |
| Dropcho, E | 3 |
| Abonour, R | 1 |
| Kieran, MW | 1 |
| Kreissman, S | 1 |
| Reeves, L | 1 |
| Erickson, LC | 1 |
| Williams, DA | 2 |
| Walker, C | 2 |
| Haylock, B | 2 |
| Husband, D | 2 |
| Joyce, KA | 2 |
| Fildes, D | 2 |
| Jenkinson, MD | 2 |
| Smith, T | 2 |
| Broome, J | 2 |
| du Plessis, DG | 2 |
| Warnke, PC | 2 |
| Lang, FF | 1 |
| Berkey, B | 1 |
| Laperierre, N | 1 |
| Haaxma-Reiche, H | 1 |
| van Kouwenhoven, MC | 1 |
| Faber, V | 1 |
| Thödtmann, R | 1 |
| Piccirilli, M | 1 |
| Landi, A | 1 |
| Salvati, M | 1 |
| Rieger, J | 1 |
| Koch, D | 1 |
| Loeser, S | 1 |
| Blaschke, B | 1 |
| Hundsberger, T | 1 |
| Tan, TC | 1 |
| Sommer, C | 1 |
| Mabasa, VH | 1 |
| Taylor, SC | 1 |
| Kopitzki, K | 1 |
| Prosser, J | 1 |
| Vinjamuri, S | 1 |
| Atahan, L | 1 |
| Söylemezoglu, F | 1 |
| Selek, U | 1 |
| Yalçin, B | 1 |
| Kutluk, T | 1 |
| Büyükpamukçu, M | 1 |
| Catenoix, H | 1 |
| Chapuis, F | 1 |
| Nighoghossian, N | 1 |
| Trouillas, P | 1 |
| Larkin, JM | 1 |
| Hughes, SA | 1 |
| Beirne, DA | 1 |
| Patel, PM | 1 |
| Gibbens, IM | 1 |
| Bate, SC | 1 |
| Thomas, K | 1 |
| Eisen, TG | 1 |
| Gore, ME | 1 |
| Yoon, SC | 1 |
| Kim, BS | 1 |
| Lee, YS | 1 |
| Lee, TK | 1 |
| Park, CK | 1 |
| Mauer, ME | 1 |
| Wolff, JE | 1 |
| Berrak, S | 1 |
| Koontz Webb, SE | 1 |
| Zhang, M | 1 |
| Choi, JD | 1 |
| Powers, CJ | 1 |
| Vredenburgh, JJ | 1 |
| Friedman, AH | 1 |
| Sampson, JH | 1 |
| Kobiakov, GL | 1 |
| Mohile, NA | 1 |
| Raizer, JJ | 1 |
| Kewalramani, T | 1 |
| Yates, A | 1 |
| Blaney, SM | 1 |
| Timmerman, R | 1 |
| Ingle, AM | 1 |
| Flom, L | 1 |
| Adamson, PC | 1 |
| Edwards, MS | 4 |
| Wara, WM | 6 |
| Allen, J | 1 |
| Ortega, J | 2 |
| Vestnys, P | 1 |
| Eyre, HJ | 2 |
| Quagliana, JM | 2 |
| Eltringham, JR | 2 |
| Frank, J | 1 |
| O'Bryan, RM | 1 |
| McDonald, B | 1 |
| Rivkin, SE | 1 |
| Stridsklev, IC | 1 |
| Hagen, S | 2 |
| Klepp, O | 1 |
| Kessinger, A | 1 |
| Gropp, C | 1 |
| Havemann, K | 1 |
| Seiler, RW | 9 |
| Bleehen, NM | 3 |
| Osieka, R | 1 |
| Glatte, P | 1 |
| Pannenbäcker, R | 1 |
| Schmidt, CG | 2 |
| Cianfriglia, F | 1 |
| Pompili, A | 2 |
| Riccio, A | 2 |
| Grassi, A | 1 |
| Zimmermann, A | 2 |
| Markwalder, H | 4 |
| Jellinger, K | 2 |
| Volc, D | 2 |
| Podreka, I | 2 |
| Böck, F | 1 |
| Schuster, H | 1 |
| Alth, G | 1 |
| Kogelnik, HD | 1 |
| Pomodanov, AP | 1 |
| Sosnov, IuD | 1 |
| Perevodchikova, NI | 2 |
| Dvoĭrin, VV | 1 |
| Assekritova, IV | 1 |
| Aisner, J | 1 |
| Whitacre, M | 1 |
| Van Echo, DA | 1 |
| Wiernik, PH | 2 |
| Smyth, JF | 1 |
| Ford, HT | 1 |
| Conte, PF | 1 |
| Giaccone, G | 1 |
| Musella, R | 1 |
| Calciati, A | 1 |
| Robustelli della Cuna, G | 3 |
| Paoletti, P | 9 |
| Bernardo, G | 1 |
| Knerich, R | 6 |
| Butti, G | 2 |
| Cuzzoni, Q | 1 |
| Kostron, H | 1 |
| Barrere, M | 1 |
| Fanjaud, G | 1 |
| Larrue, V | 1 |
| Geraud, G | 1 |
| Bes, A | 1 |
| Jacque, C | 1 |
| Kujas, M | 1 |
| Raoul, M | 1 |
| Baumann, N | 1 |
| Poisson, M | 10 |
| Afra, D | 2 |
| Kocsis, B | 2 |
| Dobay, J | 1 |
| Eckhardt, S | 2 |
| Seydel, HG | 2 |
| Creech, R | 1 |
| Pagano, M | 1 |
| Salazar, O | 1 |
| Rubin, P | 1 |
| Concannon, J | 1 |
| Carbone, P | 1 |
| Mohuiddin, M | 1 |
| Perez, C | 1 |
| Matthews, M | 1 |
| Mikhina, ZP | 1 |
| Glekov, IV | 1 |
| Voĭnarevich, AO | 1 |
| Ausekar, BV | 1 |
| Pavesi, L | 1 |
| Preti, P | 1 |
| Preussmann, R | 1 |
| Fingert, HJ | 1 |
| Hochberg, FH | 3 |
| Oredsson, SM | 1 |
| Deen, DF | 4 |
| Marton, LJ | 2 |
| Brufman, G | 1 |
| Halpern, J | 1 |
| Sulkes, A | 1 |
| Catane, R | 1 |
| Biran, S | 1 |
| Wheeler, KT | 3 |
| Wallen, CA | 2 |
| Wolf, KL | 1 |
| Siemann, DW | 1 |
| Shapiro, WR | 3 |
| Weiss, RB | 2 |
| Issell, BF | 1 |
| Muller, PJ | 3 |
| Tator, CH | 5 |
| Bloom, ML | 1 |
| Hildebrand, J | 6 |
| Badjou, R | 1 |
| Collard-Ronge, E | 1 |
| Delforge, A | 1 |
| Malarme, M | 1 |
| Spiro, T | 1 |
| Sztern, B | 1 |
| Vandensteene, A | 1 |
| Stryckmans, PA | 1 |
| Hansen, HH | 2 |
| Dombernowsky, P | 2 |
| Hirsch, FR | 2 |
| Hansen, M | 2 |
| Rygård, J | 1 |
| Vestnys, PS | 1 |
| Weinkam, RJ | 2 |
| Ilsen, HW | 1 |
| Petrovici, IN | 1 |
| Mennel, HD | 4 |
| Zülch, KJ | 2 |
| Szymas, J | 1 |
| Vats, TS | 1 |
| Trueworthy, RC | 1 |
| Langston, CM | 1 |
| Huang, Q | 1 |
| Flament, H | 1 |
| Vollmer, R | 1 |
| Weiss, R | 1 |
| Schacht, RG | 1 |
| Feiner, HD | 1 |
| Gallo, GR | 1 |
| Lieberman, A | 1 |
| Baldwin, DS | 1 |
| Bloom, M | 1 |
| Chaurasiya, J | 1 |
| Mohanty, S | 1 |
| Prasad, GC | 1 |
| Berglund, J | 1 |
| Thuning, CA | 1 |
| Bakir, NA | 1 |
| Warren, J | 1 |
| Jandolo, B | 1 |
| Fontana, M | 1 |
| Li, J | 1 |
| Li, L | 1 |
| Kang, S | 1 |
| Açikgöz, S | 1 |
| Bingol, F | 1 |
| offin, S | 1 |
| Açikgöz, B | 1 |
| Cohen, BH | 1 |
| Zeltzer, PM | 2 |
| Geyer, JR | 5 |
| Allen, JC | 4 |
| McGuire-Cullen, P | 1 |
| Milstein, JM | 3 |
| Rorke, LB | 4 |
| Stanley, P | 2 |
| Trent, KC | 1 |
| Myers, L | 1 |
| Moreb, J | 1 |
| Eisenhauer, EA | 1 |
| Maor, MH | 3 |
| Thall, PF | 1 |
| Bruner, J | 3 |
| Sawaya, R | 1 |
| Kyritsis, AP | 5 |
| Leeds, N | 2 |
| Woo, S | 1 |
| Rodriguez, L | 1 |
| Shrieve, DC | 1 |
| Coleman, CN | 1 |
| Turski, PA | 1 |
| Sobol, RE | 1 |
| Fakhrai, H | 1 |
| Shawler, D | 1 |
| Gjerset, R | 1 |
| Dorigo, O | 1 |
| Carson, C | 1 |
| Khaleghi, T | 1 |
| Koziol, J | 1 |
| Shiftan, TA | 1 |
| Royston, I | 1 |
| Prados, MR | 1 |
| Gutin, PH | 8 |
| Phillips, TL | 4 |
| Lamborn, K | 3 |
| Albright, AL | 1 |
| Stevens, KR | 1 |
| Wisoff, J | 1 |
| Schramm, CM | 1 |
| Donahue, BR | 1 |
| Haas, F | 1 |
| Bertolone, SJ | 1 |
| McGuire, P | 1 |
| Cherlow, JM | 1 |
| Tefft, M | 1 |
| Macdonald, D | 3 |
| Ludwin, S | 1 |
| Lee, D | 1 |
| Cascino, T | 1 |
| Fulton, D | 2 |
| Schold, C | 1 |
| Slotman, BJ | 1 |
| Njo, KH | 1 |
| de Jonge, A | 1 |
| Meyer, OW | 1 |
| Karim, AB | 1 |
| Elis, A | 1 |
| Lishner, M | 1 |
| Savin, H | 1 |
| Ravid, M | 1 |
| Goldwein, JW | 1 |
| Radcliffe, J | 1 |
| Sutton, LN | 3 |
| Lange, B | 1 |
| D'Angio, GJ | 1 |
| Crowley, JJ | 1 |
| Townsend, JJ | 1 |
| Morantz, RA | 1 |
| Schulman, SF | 1 |
| al-Sarraf, M | 1 |
| Krol, GS | 1 |
| Ilveskoski, I | 1 |
| Saarinen, UM | 1 |
| Wiklund, T | 1 |
| Perkkiö, M | 1 |
| Salmi, TT | 1 |
| Lanning, M | 1 |
| Mäkipernaa, A | 1 |
| Pihko, H | 1 |
| Evans, AE | 4 |
| Anderson, JR | 1 |
| Lefkowitz-Boudreaux, IB | 1 |
| Thornton, AF | 1 |
| Harsh, GR | 1 |
| Patel, H | 1 |
| Finkelstein, D | 1 |
| Schlegel, J | 1 |
| Stumm, G | 1 |
| Ruschoff, J | 1 |
| Jaeckle, KA | 5 |
| Gleason, MJ | 3 |
| Ictech, SE | 1 |
| Flowers, A | 1 |
| Rabbitt, J | 2 |
| Kaba, SE | 1 |
| Hess, K | 2 |
| Mercier, R | 1 |
| Dakhil, S | 1 |
| Allison, RR | 1 |
| Schulsinger, A | 1 |
| Vongtama, V | 1 |
| Barry, T | 1 |
| Shin, KH | 1 |
| Ashigbi, MY | 1 |
| Venkatraj, U | 1 |
| Agarwal, V | 1 |
| Bello, J | 1 |
| Colleoni, M | 1 |
| Graiff, C | 1 |
| Nelli, P | 1 |
| Vicario, G | 1 |
| Sgarbossa, G | 1 |
| Pancheri, F | 1 |
| Manente, P | 1 |
| Punt, CJ | 2 |
| van Herpen, CM | 1 |
| Vreugdenhil, G | 1 |
| Muller, EW | 1 |
| de Mulder, PH | 1 |
| Hayat, K | 1 |
| Jones, B | 1 |
| Bisbrown, G | 1 |
| Baria, K | 1 |
| Pigott, T | 1 |
| El-Deredy, W | 1 |
| Ashmore, SM | 1 |
| Branston, NM | 1 |
| Darling, JL | 7 |
| Williams, SR | 1 |
| Thomas, DG | 5 |
| Kormanik, PA | 1 |
| Mornex, F | 1 |
| Thiesse, P | 2 |
| Mertens, P | 1 |
| Helfre, S | 1 |
| van Groeningen, CJ | 2 |
| Witjes, RJ | 1 |
| Weerts, JG | 1 |
| Kralendonk, JH | 1 |
| Bauman, GS | 2 |
| Abele, M | 1 |
| Leonhardt, M | 1 |
| Urban, C | 1 |
| Benesch, M | 1 |
| Pakisch, B | 1 |
| Lackner, H | 1 |
| Kerbl, R | 1 |
| Schwinger, W | 1 |
| Oberbauer, R | 1 |
| Pronk, LC | 1 |
| Krouwer, HG | 1 |
| Zonnenberg, BA | 1 |
| Twijnstra, A | 1 |
| Jamison, C | 1 |
| Mathews, VP | 1 |
| Heilman, DK | 1 |
| Perry, JR | 1 |
| Brown, MT | 1 |
| Gockerman, JP | 1 |
| Gundersen, S | 1 |
| Lote, K | 1 |
| Watne, K | 1 |
| Celik, I | 1 |
| Erman, M | 1 |
| Kars, A | 1 |
| Tekuzman, G | 1 |
| Arcicasa, M | 1 |
| Roncadin, M | 1 |
| Bidoli, E | 1 |
| Dedkov, A | 1 |
| Gigante, M | 1 |
| Trovò, MG | 1 |
| Sankar, A | 1 |
| Meyers, C | 1 |
| Sawaya, RE | 1 |
| Bruner, JM | 2 |
| Peterson, P | 1 |
| Vick, NA | 1 |
| Jeremic, B | 2 |
| Shibamoto, Y | 1 |
| Gruijicic, D | 1 |
| Milicic, B | 1 |
| Stojanovic, M | 1 |
| Nikolic, N | 1 |
| Dagovic, A | 1 |
| Aleksandrovic, J | 1 |
| Scott, C | 1 |
| Sandler, H | 1 |
| Villikka, K | 1 |
| Kivistö, KT | 1 |
| Mäenpää, H | 1 |
| Joensuu, H | 1 |
| Neuvonen, PJ | 1 |
| Källén, K | 1 |
| Geijer, B | 1 |
| Malmström, P | 1 |
| Andersson, AM | 1 |
| Holtås, S | 1 |
| Ryding, E | 1 |
| Rosén, I | 1 |
| Streffer, J | 1 |
| Schabet, M | 1 |
| Grote, EH | 1 |
| Voigt, K | 1 |
| Boiardi, A | 2 |
| Pozzi, A | 1 |
| Salmaggi, A | 1 |
| Broggi, G | 1 |
| Silvani, A | 1 |
| Hung, CF | 1 |
| Lewandowicz, GM | 1 |
| Harding, B | 1 |
| Harkness, W | 1 |
| Hayward, R | 1 |
| Uhm, JH | 1 |
| Choucair, A | 1 |
| Flynn, PJ | 1 |
| Hess, KR | 2 |
| Deininger, MH | 1 |
| Grote, E | 1 |
| Wickboldt, J | 1 |
| Lesser, GJ | 1 |
| Wara, W | 3 |
| Edwards, M | 1 |
| Malec, M | 1 |
| Ramsay, D | 1 |
| Smith, A | 1 |
| Bethune, CR | 1 |
| Geyer, RJ | 1 |
| Spence, AM | 1 |
| Noël, G | 1 |
| Röhn, TA | 1 |
| Wagenknecht, B | 1 |
| Roth, W | 1 |
| Naumann, U | 1 |
| Gulbins, E | 1 |
| Krammer, PH | 1 |
| Walczak, H | 1 |
| Maleniak, TC | 1 |
| Lowenstein, PR | 1 |
| Castro, MG | 1 |
| Qin, D | 2 |
| Ou, G | 2 |
| Mo, H | 2 |
| Song, Y | 1 |
| Kang, G | 1 |
| Hu, Y | 1 |
| Gu, X | 1 |
| Diabira, S | 1 |
| Rousselet, MC | 1 |
| Gamelin, E | 1 |
| Soulier, P | 1 |
| Jadaud, E | 1 |
| Menei, P | 1 |
| Kyritsis, A | 1 |
| Meyers, CA | 1 |
| Ictech, SA | 1 |
| Chang, E | 1 |
| Kochi, M | 1 |
| Ushio, Y | 1 |
| Croteau, D | 1 |
| Gangji, D | 1 |
| Nouwynck, C | 1 |
| Machin, D | 1 |
| Greiner, RH | 1 |
| Zimmerman, A | 1 |
| Walker, MD | 5 |
| Taylor, SG | 1 |
| Nelson, L | 1 |
| Baxter, D | 1 |
| Rosenbaum, C | 1 |
| Sponzo, RW | 1 |
| Cunningham, TJ | 1 |
| Olson, KB | 1 |
| Horton, J | 1 |
| Reagan, TJ | 1 |
| Bisel, HF | 1 |
| Childs, DS | 1 |
| Layton, DD | 1 |
| Rhoton, AL | 1 |
| Taylor, WF | 1 |
| Drafts, D | 1 |
| Enot, KJ | 2 |
| Pouillart, P | 8 |
| Mathé, G | 4 |
| Huguenin, P | 5 |
| M'orin, P | 1 |
| Buge, A | 4 |
| Palangie, T | 3 |
| Parrot, R | 4 |
| Philippon, J | 1 |
| van Effenterre, R | 1 |
| Racadot, J | 1 |
| Sichez, JP | 1 |
| Ertel, IJ | 2 |
| Boesel, C | 2 |
| Williams, CJ | 1 |
| Heiss, WD | 2 |
| Turnheim, M | 1 |
| Mamoli, B | 1 |
| Monfardini, S | 2 |
| Brambilla, C | 2 |
| Solero, CL | 2 |
| Vaghi, A | 2 |
| Valagussa, P | 2 |
| Morello, G | 2 |
| Bonadonna, G | 2 |
| Paillas, JE | 2 |
| Prince, MA | 1 |
| Hassoun, J | 1 |
| Pellet, W | 2 |
| Peragut, JC | 1 |
| Bleher, EA | 1 |
| Creech, RH | 1 |
| Mietlowski, WL | 1 |
| Perez, CA | 1 |
| Costanza, M | 1 |
| Buechler, M | 1 |
| Munzenreider, J | 1 |
| Emami, B | 1 |
| Mukherji, B | 1 |
| Shucart, W | 1 |
| Scott, M | 1 |
| Nathanson, L | 1 |
| Rudders, R | 1 |
| Stein, B | 1 |
| Post, K | 1 |
| Piro, A | 1 |
| Kung, FH | 1 |
| Nythan, WL | 1 |
| Cuttner, J | 1 |
| Falkson, G | 1 |
| Lanzkowsky, P | 1 |
| Del Duca, V | 1 |
| Nawabi, IU | 1 |
| Koch, K | 1 |
| Pluess, H | 1 |
| Freeman, A | 1 |
| Burgert, EO | 1 |
| Leone, LA | 1 |
| Ruymann, F | 1 |
| Patterson, RB | 1 |
| Degnan, T | 1 |
| Hakami, N | 1 |
| Pajak, TF | 1 |
| Holland, J | 1 |
| Lheritier, J | 3 |
| Gautier, H | 3 |
| Morin, P | 4 |
| Garrett, MJ | 2 |
| Hughes, HJ | 2 |
| Freedman, LS | 2 |
| Strada, MR | 1 |
| Schulz, U | 1 |
| Lapukins, Z | 1 |
| Baldini, M | 1 |
| Princi, L | 1 |
| Hasegawa, H | 1 |
| Posner, JB | 1 |
| Tamura, M | 1 |
| Vassella, F | 2 |
| Oster, MW | 1 |
| Bataini, JP | 2 |
| Mashaly, R | 2 |
| Pertuiset, BF | 2 |
| Metzger, J | 2 |
| Hauw, JJ | 1 |
| Williams, ME | 1 |
| Jackson, DV | 1 |
| Richards, F | 1 |
| Cooper, MR | 1 |
| Ferree, C | 1 |
| Muss, HB | 1 |
| White, DR | 1 |
| Spurr, CL | 1 |
| Imbach, P | 1 |
| Wagner, HP | 1 |
| Hilton, J | 3 |
| Fumagalli, R | 3 |
| Weiss, JF | 1 |
| Pezzotta, S | 3 |
| Racca, AR | 2 |
| Crafts, DC | 2 |
| Townsend, J | 1 |
| Waterfield, WC | 1 |
| Tashima, CK | 1 |
| Hortobagyi, GN | 1 |
| Blumenschein, GR | 1 |
| Buzdar, AU | 1 |
| Burgess, MA | 1 |
| Pischer, TL | 1 |
| Waldbaur, H | 1 |
| Kuschnir, H | 1 |
| Engelmann, U | 1 |
| Schmidt, H | 1 |
| Schmack, B | 1 |
| Ward, HW | 1 |
| Bloom, HJ | 1 |
| Neidhardt, MK | 1 |
| Loubrieu, G | 1 |
| Elie, A | 1 |
| Ribadeau Dumas, JL | 1 |
| Kabra, PA | 1 |
| Freeman-Dove, MA | 1 |
| Stearns, J | 1 |
| Byrd, A | 1 |
| Finn, A | 1 |
| Pollet, JF | 1 |
| D'Estienne d'Orves, JF | 1 |
| Thy, HT | 1 |
| Ommaya, AK | 1 |
| Ziegler, JL | 1 |
| Magrath, IT | 1 |
| Bluming, AZ | 1 |
| Day, A | 1 |
| Ng, R | 1 |
| Liberman, L | 1 |
| Terheggen, HG | 1 |
| Fein, VJ | 1 |
| Allan, AE | 1 |
| Rottman, A | 1 |
| Brihaye, J | 2 |
| Weir, B | 1 |
| Band, P | 1 |
| Blain, G | 1 |
| Mclean, D | 1 |
| Wilson, F | 1 |
| Mielke, B | 2 |
| Grace, M | 1 |
| Bramlet, D | 1 |
| Giliberti, J | 1 |
| Bender, J | 1 |
| Brisman, R | 1 |
| Housepian, EM | 1 |
| Chang, C | 1 |
| Duffy, P | 1 |
| Balis, E | 1 |
| Young, DF | 1 |
| Maker, HS | 1 |
| Syed, H | 1 |
| Whetsell, W | 1 |
| Lehrer, GM | 1 |
| Thy, TH | 1 |
| Gauthier, H | 1 |
| Wasserman, TH | 1 |
| Slavik, M | 1 |
| Carter, SK | 1 |
| Kumar, AR | 1 |
| Levin, V | 2 |
| Powell, M | 1 |
| Ryall, RD | 1 |
| Wagenknecht, L | 1 |
| Michel, J | 1 |
| Kenis, Y | 1 |
| Jovanovic, D | 1 |
| Djuric, LJ | 1 |
| Jevremovic, S | 1 |
| Mijatovic, LJ | 1 |
| Fulton, DS | 2 |
| Urtasun, RC | 2 |
| Scott-Brown, I | 1 |
| Johnson, ES | 1 |
| Curry, B | 1 |
| Huyser-Wierenga, D | 1 |
| Hanson, J | 1 |
| Feldstein, M | 1 |
| Sneed, PK | 2 |
| Weaver, KA | 2 |
| Larson, DA | 2 |
| Pyrich, M | 2 |
| Gościński, I | 3 |
| Krzyszkowski, T | 2 |
| Hildebrand, JG | 1 |
| Massin, F | 1 |
| Coudert, B | 1 |
| Foucher, P | 1 |
| Lombard, JN | 1 |
| Reybet-Degat, O | 1 |
| Jeannin, L | 1 |
| Camus, P | 1 |
| Israel, L | 1 |
| Breau, JL | 1 |
| Morere, JF | 1 |
| Boaziz, C | 1 |
| Glass, J | 1 |
| Gruber, ML | 1 |
| Smith, D | 1 |
| Rattner, B | 1 |
| Leibel, SA | 1 |
| Silver, P | 3 |
| Ahn, DK | 1 |
| Flam, MS | 1 |
| Wong, KH | 1 |
| Osterlind, K | 1 |
| Sörenson, S | 1 |
| Pedersen, AG | 1 |
| Ogilvy-Stuart, AL | 1 |
| Shalet, SM | 3 |
| Gattamaneni, HR | 1 |
| Fulton, LM | 1 |
| Steinberg, HS | 1 |
| Hannigan, J | 1 |
| Arena, G | 1 |
| Abbondandolo, A | 1 |
| Rossi, O | 1 |
| Gentile, SL | 1 |
| Bruzzone, E | 1 |
| Francaviglia, N | 1 |
| Capellini, C | 1 |
| Bradford, R | 1 |
| Trojanowski, T | 3 |
| Turowski, K | 3 |
| Peszyński, J | 3 |
| Koźniewska, H | 1 |
| Gaetani, P | 1 |
| Assietti, R | 1 |
| Gaspar, LE | 1 |
| Jenkin, RD | 2 |
| Boesel, CP | 1 |
| Venes, JL | 1 |
| Ortega, JA | 1 |
| Hammond, D | 1 |
| Constantinovici, A | 1 |
| Cristescu, AM | 1 |
| Markiewicz, P | 1 |
| Bielawski, A | 2 |
| Bendarzewska, B | 1 |
| Szymona, J | 1 |
| Dabrowska, A | 1 |
| Lopatkiewicz, J | 1 |
| Clayton, PE | 2 |
| Price, DA | 2 |
| Jones, PH | 1 |
| Livesey, EA | 2 |
| Brook, CG | 2 |
| Friedman, HS | 1 |
| Schold, SC | 1 |
| Djang, WT | 1 |
| Kurtzberg, J | 1 |
| Longee, DC | 1 |
| Halperin, EC | 1 |
| Falletta, JM | 1 |
| Coleman, RE | 1 |
| Oakes, WJ | 1 |
| McDermott, M | 1 |
| Krouwer, D | 1 |
| Wilson, C | 2 |
| Evans, CG | 1 |
| Bodell, WJ | 1 |
| Tokuda, K | 1 |
| Doane-Setzer, P | 1 |
| Smith, MT | 1 |
| Lichter, AS | 1 |
| Bunn, PA | 1 |
| Ihde, DC | 1 |
| Cohen, MH | 1 |
| Makuch, RW | 1 |
| Carney, DN | 1 |
| Johnston-Early, A | 1 |
| Minna, JD | 1 |
| Glatstein, E | 1 |
| Kapp, JP | 1 |
| Vance, RB | 1 |
| Steinbok, P | 1 |
| Dolman, CL | 1 |
| Goldie, JH | 1 |
| Hatlevoll, R | 1 |
| Lindegaard, KF | 1 |
| Kristiansen, K | 1 |
| Nesbakken, R | 1 |
| Torvik, A | 1 |
| Ganz, JC | 1 |
| Mella, O | 1 |
| Rosengren, B | 1 |
| Ringkjöb, R | 1 |
| Müller, H | 1 |
| Brock, M | 1 |
| Ernst, H | 1 |
| Gerosa, MA | 1 |
| Rosenblum, ML | 1 |
| Stevanoni, G | 1 |
| Licata, C | 1 |
| Della Corte, V | 1 |
| Marcon, C | 1 |
| Bricolo, A | 1 |
| Tridente, G | 1 |
| Chak, LY | 1 |
| Zatz, LM | 1 |
| Wasserstein, P | 1 |
| Cox, RS | 1 |
| Kushlan, PD | 1 |
| Porzig, KJ | 1 |
| Sikic, BI | 1 |
| Wilson, WB | 1 |
| Perez, GM | 1 |
| Kleinschmidt-Demasters, BK | 1 |
| McKinnon, S | 1 |
| Tanasichuk, H | 1 |
| Pendergrass, TW | 1 |
| Mulne, AF | 1 |
| Kosnik, EJ | 1 |
| Morris, JD | 1 |
| Heideman, RL | 1 |
| Ruymann, FB | 1 |
| Stuntz, JT | 1 |
| Bleyer, WA | 1 |
| Kamiński, S | 1 |
| Reinfus, M | 1 |
| Leszczyk, C | 1 |
| Campbell, RH | 1 |
| Siegel, KR | 2 |
| D'Angio, G | 1 |
| Bunin, GR | 1 |
| Schut, L | 2 |
| Lefkowitz, IB | 1 |
| Bruce, DA | 1 |
| Retsas, S | 1 |
| Gershuny, AR | 1 |
| Rodriguez, LA | 1 |
| Arkhipov, AI | 1 |
| Vilenskiĭ, BS | 1 |
| Chastagner, P | 1 |
| Olive, D | 1 |
| Philip, T | 1 |
| Zucker, JM | 1 |
| Czorny, A | 1 |
| Lapras, C | 1 |
| Brunat-Mentigny, M | 1 |
| Carcavilla, LI | 1 |
| Gómez Perún, J | 1 |
| Alberdi, J | 1 |
| Eiras, J | 1 |
| Arana, T | 1 |
| Pisón, J | 1 |
| Linfoot, PA | 1 |
| Gray, JW | 1 |
| Dean, PN | 1 |
| Hoag, G | 1 |
| Sima, AA | 1 |
| Rozdilsky, B | 1 |
| McKenney, SA | 1 |
| Fehir, KM | 1 |
| Kerpel-Fronius, S | 1 |
| Hellwig, D | 1 |
| Simon, H | 1 |
| Ertel, I | 1 |
| Evans, A | 1 |
| Hittle, R | 1 |
| Anderson, J | 1 |
| Sulis, E | 1 |
| Floris, C | 1 |
| Chessa, A | 1 |
| Desogus, A | 1 |
| Muggiano, A | 1 |
| Tedde, A | 1 |
| Turno, R | 1 |
| Repetto, L | 1 |
| Grimaldi, A | 1 |
| Ardizzoni, A | 1 |
| Sertoli, MR | 1 |
| Rosso, R | 1 |
| Roberts, JT | 1 |
| Paul, EA | 1 |
| Mott, TJ | 1 |
| Godlee, JN | 1 |
| Tobias, JS | 1 |
| Capra, LG | 1 |
| Collins, CD | 1 |
| Mooney, C | 1 |
| Bozek, T | 1 |
| Ellis, ME | 1 |
| Kuperminc, M | 1 |
| Oi, S | 1 |
| Matsumoto, S | 1 |
| Raimondi, AJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Improvement of Functional Outcome for Patients With Newly Diagnosed Grade II or III Glioma With Co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 Trial[NCT05331521] | Phase 3 | 406 participants (Anticipated) | Interventional | 2021-04-07 | Recruiting | ||
| INTELLANCE-2: ABT-414 Alone or ABT-414 Plus Temozolomide Versus Lomustine or Temozolomide for Recurrent Glioblastoma: A Randomized Phase 2 Study of the EORTC Brain Tumor Group[NCT02343406] | Phase 2 | 266 participants (Actual) | Interventional | 2015-02-17 | Completed | ||
| Phase III Trial of CCNU/Temozolomide (TMZ) Combination Therapy vs. Standard TMZ Therapy for Newly Diagnosed MGMT-methylated Glioblastoma Patients[NCT01149109] | Phase 3 | 141 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma[NCT02414165] | Phase 2/Phase 3 | 403 participants (Actual) | Interventional | 2015-11-30 | Terminated (stopped due to Sponsor Decision) | ||
| Phase III Trial Exploring the Combination of Bevacizumab and Lomustine in Patients With First Recurrence of a Glioblastoma[NCT01290939] | Phase 3 | 592 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| Evaluation of ex Vivo Drug Combination Optimization Platform in Recurrent High Grade Astrocytic Glioma[NCT05532397] | 10 participants (Anticipated) | Interventional | 2023-02-17 | Recruiting | |||
| A Phase III, Randomised, Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Patients to Compare the Efficacy of Cediranib [RECENTIN™, AZD2171] Monotherapy and the Combination of Cediranib With Lomustine to the Efficacy of Lomustine Alone[NCT00777153] | Phase 3 | 423 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| Precoce Medical Care by the Mobil Support for Patients With Glioblastoma Receiving Specific Medical Oncology Treatment[NCT04516733] | 35 participants (Actual) | Interventional | 2019-05-10 | Completed | |||
| A Phase II Study of Observation in Favorable Low-Grade Glioma and a Phase II Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma[NCT00003375] | Phase 2/Phase 3 | 370 participants (Actual) | Interventional | 1998-10-31 | Completed | ||
| Phase II Study of Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma[NCT02698280] | Phase 2 | 23 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Temozolomide Plus Bevacizumab Chemotherapy in Supratentorial Glioblastoma in 70 Years and Older Patients With an Impaired Functional Status (KPS<70)[NCT02898012] | Phase 2 | 70 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| A Phase 2 Study of LY2157299 Monohydrate Monotherapy or LY2157299 Monohydrate Plus Lomustine Therapy Compared to Lomustine Monotherapy in Patients With Recurrent Glioblastoma[NCT01582269] | Phase 2 | 180 participants (Anticipated) | Interventional | 2012-04-26 | Active, not recruiting | ||
| PHASE III STUDY OF ADJUVANT PROCARBAZINE, CCNU AND VINCRISTINE CHEMOTHERAPY IN PATIENTS WITH HIGHLY ANAPLASTIC OLIGODENDROGLIOMA[NCT00002840] | Phase 3 | 350 participants (Anticipated) | Interventional | 1996-08-31 | Completed | ||
| Phase III Intergroup Randomized Comparison of Radiation Alone vs. Pre-Radiation Chemotherapy for Pure and Mixed Anaplastic Oligodendrogliomas[NCT00002569] | Phase 3 | 299 participants (Actual) | Interventional | 1994-07-31 | Completed | ||
| Randomized Phase 3 Open Label Study - Enzastaurin vs. Lomustine in Glioblastoma[NCT00295815] | Phase 3 | 397 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| Chemotherapy for Progressive Low Grade Astrocytoma in Children Less Than Ten Years Old[NCT00002944] | Phase 3 | 428 participants (Actual) | Interventional | 1997-04-30 | Completed | ||
| A Prospective Cohort to Study the Effect of Postoperative Upfront Temozolomide Chemotherapy on IDH Mutational Low Grade Gliomas in Eloquent Areas[NCT02209428] | Phase 2 | 54 participants (Actual) | Interventional | 2014-06-30 | Active, not recruiting | ||
| PHASE II STUDY OF PREIRRADIATION PCV CHEMOTHERAPY IN PATIENTS WITH SUPRATENTORIAL LOW-GRADE GLIOMAS[NCT00002806] | Phase 2 | 43 participants (Actual) | Interventional | 1996-07-31 | Completed | ||
| Second Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors After PCV-Chemotherapy[NCT00003304] | Phase 2 | 29 participants (Anticipated) | Interventional | 1998-04-30 | Completed | ||
| A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent Gliomas[NCT01445119] | Phase 1 | 58 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| A Phase I Study of Temozolomide and CCNU in Pediatric Patients With Newly Diagnosed Incompletely Resected Non-Brainstem High-Grade Gliomas[NCT00006024] | Phase 1 | 32 participants (Actual) | Interventional | 2000-11-30 | Completed | ||
| Phase II, Single Arm, Open Label Clinical Trial With Irinotecan in Combination With Cisplatin in Pediatric Patients With Unfavorable Prognosis Gliomas[NCT01574092] | Phase 2 | 39 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| A Phase I Trial of Lenalidomide and Radiotherapy in Children With Diffuse Intrinsic Pontine Gliomas and High-grade Gliomas[NCT01222754] | Phase 1 | 29 participants (Actual) | Interventional | 2010-11-23 | Completed | ||
| A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-Ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors[NCT00994071] | Phase 1 | 9 participants (Actual) | Interventional | 2009-09-22 | Completed | ||
| Does Varenicline Influence Alcohol Consumption in Alcohol Dependent Individuals?[NCT00846859] | Phase 2 | 162 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas[NCT01837862] | Phase 1/Phase 2 | 36 participants (Anticipated) | Interventional | 2013-10-22 | Recruiting | ||
| A Prospective National Study to Molecularly and Genetically Characterize Human Gliomas: The Glioma Molecular Diagnostic Initiative[NCT00031538] | 674 participants (Actual) | Observational | 2002-03-01 | Terminated | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The objective response rate (ORR) included best overall responses - complete response (CR) and partial response (PR) - assessed by the independent review committee per response assessment in neurooncology criteria (RANO) criteria from the date of randomization until disease progression or death, whichever came first. All objective responses (CR and PR) must be have been confirmed by repeat MRI 4 weeks after the first time when CR or PR is identified. Any subject who did not meet CR or PR including those who did not have post-baseline radiological assessments was considered a nonresponder. (NCT02343406)
Timeframe: Every 8 weeks at each assessment of disease, up to 28 months
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-414/Temozolomide | 14.3 |
| ABT-414_adult | 7.7 |
| Control (Temozolomide/Lomustine) | 4.4 |
AUC is a measure of how long and how much drug is present in the body after dosing. The AUC of depatuxizumab mafodotin (ABT-414) in the pediatric population was measured following treatment to confirm that this was comparable to adults, and that the dosing levels are appropriate for a pediatric population. (NCT02343406)
Timeframe: Samples collected Cycle 1 Days 1, 2,3,5,8,15; Cycle 2 Day 1; Cycle 3 Day 1; Cycle 5 Day 1; Day 1 of every two cycles starting with Cycle 5; and 35 days after the last dose
| Intervention | µg*h/mL (Mean) |
|---|---|
| ABT-414_ Pediatric | 3170 |
AUC is a measure of how long and how much drug or drug metabolite is present in the body after dosing. The AUC of Cys-mcMMAF, a toxic metabolite of depatuxizumab mafodotin, in the pediatric population was measured following treatment to confirm that this was comparable to adults, and that the dosing levels are appropriate for a pediatric population. (NCT02343406)
Timeframe: Samples collected Cycle 1 Days 1, 2, 3, 5, 8
| Intervention | ng*h/mL (Mean) |
|---|---|
| ABT-414_ Pediatric | 14.1 |
Half-life is the calculated time it takes for half of the drug to leave the body. (NCT02343406)
Timeframe: Samples collected Cycle 1 Days 1, 2,3,5,8,15; Cycle 2 Day 1; Cycle 3 Day 1; Cycle 5 Day 1; Day 1 of every two cycles starting with Cycle 5; and 35 days after the last dose
| Intervention | days (Mean) |
|---|---|
| ABT-414_ Pediatric | 9.0 |
Half-life is the calculated time it takes for half of the drug or drug metabolite to leave the body. CysmcMMAF is a toxic metabolite of depatuxizumab mafodotin. (NCT02343406)
Timeframe: Samples collected Cycle 1 Days 1, 2, 3, 5, 8
| Intervention | days (Mean) |
|---|---|
| ABT-414_ Pediatric | 11.2 |
Cmax is the peak concentration that a drug or drug metabolite achieves in a specified compartment after the drug has been administrated and before administration of a second dose. Cys-mcMMAF is a toxic metabolite of depatuxizumab mafodotin. (NCT02343406)
Timeframe: Samples collected Cycle 1 Days 1, 2, 3, 5, 8
| Intervention | ng/mL (Mean) |
|---|---|
| ABT-414_ Pediatric | 0.272 |
Cmax is the peak concentration that a drug achieves in a specified compartment after the drug has been administrated and before administration of a second dose. (NCT02343406)
Timeframe: Samples collected Cycle 1 Days 1, 2,3,5,8,15; Cycle 2 Day 1; Cycle 3 Day 1; Cycle 5 Day 1; Day 1 of every two cycles starting with Cycle 5; and 35 days after the last dose
| Intervention | µg/mL (Mean) |
|---|---|
| ABT-414_ Pediatric | 31.4 |
The severity of each adverse event was rated according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE Version 4.0) (NCT02343406)
Timeframe: From participant's first visit until 49 days after the participant's last dose of study drug, up to 63 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-414_ Pediatric | 100 |
Overall Survival (OS) was defined as time from randomization to death due to any cause, regardless of whether the event occurred on or off study drug (depatuxizumab mafodotin/temozolomide/lomustine). (NCT02343406)
Timeframe: From the date of randomization up to the date of participant's death; participants who completed treatment were to be assessed every 12 weeks, up to 28 months.
| Intervention | months (Number) | ||
|---|---|---|---|
| 25th quartile | 50th quartile | 75th quartile | |
| ABT-414_adult | 4.6 | 7.9 | 15.5 |
| ABT-414/Temozolomide | 5.7 | 9.6 | 16.9 |
| Control (Temozolomide/Lomustine) | 4.9 | 8.2 | 12.6 |
Overall Survival (OS) was defined as time from randomization to death due to any cause, regardless of whether the event occurred on or off study drug (depatuxizumab mafodotin/temozolomide/lomustine) for all randomized participants that had the Epidermal Growth Factor Receptor (EGFRvIII) mutation. (NCT02343406)
Timeframe: From the date of randomization up to the date of participant's death; participants who completed treatment were to be assessed every 12 weeks, up to 28 months
| Intervention | months (Number) | ||
|---|---|---|---|
| 25th quartile | 50th quartile | 75th quartile | |
| ABT-414_adult | 5.0 | 8.4 | 13.9 |
| ABT-414/Temozolomide | 6.3 | 9.4 | 14.4 |
| Control (Temozolomide/Lomustine) | 4.7 | 7.5 | 12.4 |
Progression-free survival was assessed per response assessment in neuro-oncology criteria (RANO) criteria and assessed by an independent review committee and was defined as the length of time during and after the treatment of a disease, that the participant lived with the disease but did not get worse. (NCT02343406)
Timeframe: Measured every 8 weeks from date of randomization until the date of first objective progression or subject's death, whichever occurred first, up to 2 years
| Intervention | months (Number) | ||
|---|---|---|---|
| 25th quartile | 50th quartile | 75th quartile | |
| ABT-414_adult | 1.5 | 1.9 | 3.5 |
| ABT-414/Temozolomide | 1.8 | 2.7 | 4.9 |
| Control (Temozolomide/Lomustine) | 1.6 | 1.9 | 4.2 |
Proportion of patients alive and progression free at 6 months (based on central review) as estimated from Kaplan-Meier techniques. Values are percentages. (NCT00777153)
Timeframe: 6 Months
| Intervention | % of patients alive and progression free (Number) |
|---|---|
| Cediranib 30mg | 16.2 |
| Cediranib 20mg + Lomustine 100mg | 34.5 |
| Lomustine 100mg | 24.5 |
The mean steroid dosage prior to treatment will be considered as the patient's baseline. The percent change in average daily steroid dosage from baseline is calculated by following formula: PC = (md - bm)/bm*100; where PC is the percent change in average daily steroid dosage from baseline; md the mean daily steroid dosage recorded from the first day of therapy to progression; and bm the baseline mean. (NCT00777153)
Timeframe: Baseline to the date of first documented progression or date of death or study discontinuation, whichever came first, assed up to 2014-April-25
| Intervention | percentage of change (Number) |
|---|---|
| Cediranib 30mg | -17.6 |
| Cediranib 20mg + Lomustine 110mg | -1.8 |
| Lomustine 110mg | 36.6 |
Number of months from randomisation to the date of death from any cause (NCT00777153)
Timeframe: Baseline through to date of death up to 25th April 2010
| Intervention | Months (Median) |
|---|---|
| Cediranib 30mg | 8.0 |
| Cediranib 20mg + Lomustine 110mg | 9.4 |
| Lomustine 110mg | 9.8 |
"For patients with measurable disease at entry (at least one lesion that has a shortest diameter~≥10 mm at baseline on 2 axial slices), PFS will be defined as the earliest time that:~The sum of the products of the largest perpendicular diameters of contrast enhancement for all lesions has increased by a greater than or equal to 25% in comparison to the nadir scan as long as the shortest diameter is ≥15 mm. If the dose of steroids has been reduced within the 10 days prior to the scan being conducted, progression will be based on a follow-up scan performed after the dose of steroids has been stabilized for 10 days.~The patient has died from any cause.~A new lesion is detected that is outside the original tumor volume and has a shortest diameter ≥10 mm." (NCT00777153)
Timeframe: Baseline at 6 weeks and then every 6 weeks to discontinuation
| Intervention | Days (Median) |
|---|---|
| Cediranib 30mg | 92 |
| Cediranib 20mg+ Lomustine 110mg | 125 |
| Lomustine 110mg | 82 |
"An individual visit response of PR was defined as a greater than or equal to 50% reduction in the sum of the products of the largest perpendicular diameters of contrast enhancement for all lesions compared to baseline as long as the steroid dose has not been increased within the previous 10 days and no new lesions are present.~An individual visit response of CR was defined as the complete disappearance of all tumor on MRI scan." (NCT00777153)
Timeframe: Baseline at 6 weeks and then every 6 weeks to discontinuation
| Intervention | Participants (Number) |
|---|---|
| Cediranib 30mg | 18 |
| Cediranib 20mg + Lomustine 110mg | 21 |
| Lomustine 110mg | 5 |
Number of days known not to have used any steroids prior to progression (NCT00777153)
Timeframe: Baseline to the date of first documented progression or date of death or study discontinuation, whichever came first, assessed up to 2014-April-25
| Intervention | Days (Mean) |
|---|---|
| Cediranib 30mg | 75.8 |
| Cediranib 20mg + Lomustine 119mg | 74.8 |
| Lomustine 110mg | 92.3 |
47 reviews available for lomustine and Benign Neoplasms, Brain
| Article | Year |
|---|---|
Treatment options for progression or recurrence of glioblastoma: a network meta-analysis.
Topics: Brain Neoplasms; Glioblastoma; Humans; Lomustine; Neoplasm Recurrence, Local; Network Meta-Analysis | 2021 |
Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Brain Neoplasms; Glioblastoma; Humans; Lomustine; Ne | 2023 |
Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Chemoradiotherapy, Adjuvant; | 2020 |
How did lomustine become standard of care in recurrent glioblastoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Glioblastoma; Humans; Lomustine; Ne | 2020 |
Is chemotherapy alone an option as initial treatment for low-grade oligodendrogliomas?
Topics: Antineoplastic Agents; Brain Neoplasms; Humans; Lomustine; Oligodendroglioma; Temozolomide; Treatmen | 2020 |
Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytarabine; Dacarbazine; Dis | 2017 |
Anti-angiogenic therapy for high-grade glioma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brai | 2018 |
[Management of gliomas].
Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Co | 2014 |
Antiangiogenic therapy for high-grade glioma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brai | 2014 |
Practice changing mature results of RTOG study 9802: another positive PCV trial makes adjuvant chemotherapy part of standard of care in low-grade glioma.
Topics: Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Clinical Trials, Phase III as T | 2014 |
Low-grade gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; | 2015 |
Procarbazine, lomustine and vincristine or temozolomide: which is the better regimen?
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Humans; Lomustine; Ol | 2015 |
Procarbazine--a traditional drug in the treatment of malignant gliomas.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cli | 2008 |
[Clinicopathological diagnosis of gliomas by genotype analysis].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2009 |
[Treatment of glioma with temozolomide].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2009 |
Chemotherapy for diffuse low-grade gliomas in adults.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chemother | 2011 |
Chemotherapy in low-grade gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Clinical Trials | 2012 |
Integrated phase II/III clinical trials in oncology: a case study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2012 |
Conformal irradiation for pure and mixed oligodendroglioma: the experience of Centre Leon Berard Lyon.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Damage, Chronic; Brain Injuries | 2003 |
Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2003 |
The role of PCV chemotherapy in the treatment of central neurocytoma: illustration of a case and review of the literature.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Humans; Lomusti | 2003 |
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Artifacts; Astrocytoma; Brain Edema; Brain Neoplasms | 2004 |
[The molecular genetics of oligodendroglioma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromos | 2004 |
[Brief review of the neuro oncology for recent three decades in Japan].
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain; Brain Neoplasms; Humans; | 2005 |
Anaplastic oligodendroglioma and oligoastrocytoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brai | 2007 |
[Clinical significance of mustoforan in management of malignant glioma].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Astrocytoma; Blood-Brain Barr | 2007 |
High dose chemotherapy with autologous bone marrow rescue for high grade gliomas of the brain: a potential for improvement in therapeutic results.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brain Neoplasms; Carmus | 1984 |
Management of small cell cancer: radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Combined Mod | 1984 |
Carcinogenic N-nitroso compounds and their environmental significance.
Topics: Alkylation; Animals; Brain Neoplasms; Carcinogens; Carcinogens, Environmental; Carmustine; Dimethyln | 1984 |
Treatment of neuroectodermal brain tumors.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms; | 1982 |
The nitrosoureas: carmustine (BCNU) and lomustine (CCNU).
Topics: Bone Marrow; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Gastrointestinal Neoplasms; Hod | 1982 |
Aggressive oligodendroglioma: a chemosensitive tumor.
Topics: Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Ad | 1994 |
Acute leukemia following treatment of malignant glioma.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Fatal Outcome | 1998 |
Chemotherapy of low-grade gliomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chi | 2001 |
Multidisciplinary management of adult anaplastic oligodendrogliomas and anaplastic mixed oligo-astrocytomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; G | 2001 |
PCV chemotherapy for oligodendroglioma: response analyzed on T2 weighted-MRI.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined M | 2001 |
[Chemo-radiotherapy for malignant brain tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Central Nervous System | 2002 |
Adults with newly diagnosed high-grade gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Antioxidan | 2001 |
Immunotherapy of gliomas: a review.
Topics: Adult; Animals; Azaguanine; BCG Vaccine; Brain; Brain Neoplasms; Child; Disease Models, Animal; Glio | 1976 |
A pharmacologic basis for brain tumor chemotherapy.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Division; Doxorubicin; Drug Interactions; Huma | 1975 |
Chemotherapy: the agents in current use.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Dacarbazine; Drug Therapy, Combination; Glioma; | 1975 |
Clinical comparison of the nitrosoureas.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Carmustine; Chemical Phenomena; C | 1975 |
[Nitrosourea-induced lung diseases].
Topics: Adult; Brain Neoplasms; Carmustine; Child; Drug Therapy, Combination; Female; Humans; Iatrogenic Dis | 1992 |
Aggressive oligodendroglioma: a chemosensitive tumor.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Crani | 1992 |
Preliminary study of lomustine in the treatment of intracranial masses in dogs following localization by imaging techniques.
Topics: Animals; Brain Neoplasms; Dog Diseases; Dogs; Lomustine; Magnetic Resonance Imaging; Tomography, X-R | 1990 |
The role of radiation therapy in the treatment of small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Clinical Tri | 1985 |
Chemotherapy of primary brain tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Brain Stem; Child; Efl | 1985 |
149 trials available for lomustine and Benign Neoplasms, Brain
| Article | Year |
|---|---|
Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Humans; Lomustine; Neoplasm | 2022 |
Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Feasibility Studies; G | 2023 |
Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Feasibility Studies; G | 2023 |
Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Feasibility Studies; G | 2023 |
Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Feasibility Studies; G | 2023 |
Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Feasibility Studies; G | 2023 |
Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Feasibility Studies; G | 2023 |
Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Feasibility Studies; G | 2023 |
Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Feasibility Studies; G | 2023 |
Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Feasibility Studies; G | 2023 |
Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Lomus | 2023 |
Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial.
Topics: Bevacizumab; Biomarkers; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DNA Repair E | 2023 |
INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Brain Neoplasms; ErbB Receptor | 2020 |
Phosphorylated Acetyl-CoA Carboxylase Is Associated with Clinical Benefit with Regorafenib in Relapsed Glioblastoma: REGOMA Trial Biomarker Analysis.
Topics: Acetyl-CoA Carboxylase; Biomarkers, Tumor; Brain; Brain Neoplasms; Chemotherapy, Adjuvant; Female; G | 2020 |
Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Contrast M | 2020 |
MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA-09 trial.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor | 2021 |
Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neop | 2020 |
Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating | 2018 |
Lomustine and Bevacizumab in Progressive Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2017 |
Lomustine and Bevacizumab in Progressive Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2017 |
Lomustine and Bevacizumab in Progressive Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2017 |
Lomustine and Bevacizumab in Progressive Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2017 |
New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brai
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Biomarkers, Tu | 2013 |
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Follow-Up Studies; Glioblas | 2013 |
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Follow-Up Studies; Glioblas | 2013 |
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Follow-Up Studies; Glioblas | 2013 |
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Follow-Up Studies; Glioblas | 2013 |
Effect of the addition of chemotherapy to radiotherapy on cognitive function in patients with low-grade glioma: secondary analysis of RTOG 98-02.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy, Adjuvant; | 2014 |
Upfront chemotherapy with CCNU alone for adults' low-grade gliomas: a clinical analysis.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease-Free Survival; Female | 2014 |
Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chi-Square Distr | 2014 |
Patients with primary brain tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Che | 2014 |
Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial.
Topics: Antineoplastic Agents; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dac | 2014 |
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
Topics: Administration, Oral; Adolescent; Adult; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neopl | 2014 |
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
Topics: Administration, Oral; Adolescent; Adult; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neopl | 2014 |
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
Topics: Administration, Oral; Adolescent; Adult; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neopl | 2014 |
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
Topics: Administration, Oral; Adolescent; Adult; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neopl | 2014 |
Joint modeling of longitudinal health-related quality of life data and survival.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Hu | 2015 |
The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2015 |
Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antigens, CD; Antineoplastic Combined Chemotherapy P | 2015 |
Sunitinib Malate plus Lomustine for Patients with Temozolomide-refractory Recurrent Anaplastic or Low-grade Glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2015 |
The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Dacarbazin | 2016 |
Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; B | 2016 |
A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease-Free Survival; Drug Therapy, Combination | 2016 |
Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Axitinib; Bevacizumab; Brai | 2016 |
Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chil | 2016 |
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Combined Modali | 2016 |
[Not Available].
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chemoradiotherapy; Dis | 2016 |
A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Dose-Response Relationship, Drug; | 2016 |
Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Contrast Media; Gliobl | 2017 |
[Postoperative chemoradiotherapy for cerebral glioblastoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemothera | 2008 |
Phase II study of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037) in the treatment of brain tumors.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Brain Neoplasms; Humans; Lomustine; Neoplas | 1972 |
Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Cell Proliferation; Ch | 2009 |
Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cognition; Combined Mo | 2010 |
MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant | 2009 |
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2009 |
Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Carbopl | 2010 |
Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.
Topics: Adult; Aged; Brain Neoplasms; Female; Glioblastoma; Humans; Indoles; Lomustine; Male; Middle Aged; N | 2010 |
IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined M | 2010 |
Impact of adjuvant chemotherapy for gliomatosis cerebri.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 2010 |
Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Chr | 2011 |
Alpha-internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy: European organization for research and treatment of cancer trial 26951.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Combined | 2011 |
Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Central Nervous System | 2012 |
Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Disease-Fre | 2013 |
Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chromosomes, Hum | 2013 |
EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dasatinib; Disease-Fre | 2012 |
Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC stu
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemothera | 2013 |
Concurrent modified PCV chemotherapy and radiotherapy in newly diagnosed grade IV astrocytoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Combined Modali | 2002 |
Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chromosome Aber | 2003 |
Feasibility and toxicity of CCNU therapy in elderly patients with glioblastoma multiforme.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease Progression; Fe | 2003 |
Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2003 |
Tolerance of nitrosurea-based multiagent chemotherapy regime for low-grade pediatric gliomas.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Child; Chi | 2003 |
Outcome of children with centrally reviewed low-grade gliomas treated with chemotherapy with or without radiotherapy on Children's Cancer Group high-grade glioma study CCG-945.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Pr | 2003 |
High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combin | 2003 |
Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2004 |
Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Bromodeoxyuridine; Che | 2004 |
Initial chemotherapy in gliomatosis cerebri.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combin | 2004 |
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Artifacts; Astrocytoma; Brain Edema; Brain Neoplasms | 2004 |
Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytom | 2004 |
Phase I study of temozolomide and lomustine in the treatment of high grade malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2006 |
Oligodendroglial tumor chemotherapy using "decreased-dose-intensity" PCV: a Singapore experience.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; | 2006 |
PCV chemotherapy for recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Progression; D | 2006 |
High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brai | 2006 |
A pilot study of dose-intensified procarbazine, CCNU, vincristine for poor prognosis brain tumors utilizing fibronectin-assisted, retroviral-mediated modification of CD34+ peripheral blood cells with O6-methylguanine DNA methyltransferase.
Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2006 |
Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant | 2006 |
Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer p
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant | 2006 |
Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2006 |
A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarb | 2007 |
Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Progression; Disease | 2007 |
Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo | 2007 |
A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Busulfan; Combi | 2008 |
A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2008 |
Randomized comparisons of radiotherapy and CCNU versus radiotherapy, CCNU plus procarbazine for the treatment of malignant gliomas following surgery. A Southwest Oncology Group Report.
Topics: Brain Neoplasms; Combined Modality Therapy; Drug Therapy, Combination; Female; Glioblastoma; Humans; | 1983 |
CCNU-chemotherapy of hemispheric supratentorial glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Bone Marrow; Brain Neoplasms; Clinical Trials as Topic; Female; Glioblastom | 1980 |
Adjuvant chemotherapy with VM 26 and CCNU after operation and radiotherapy of high-grade supratentorial astrocytomas.
Topics: Adult; Aged; Brain Neoplasms; Drug Therapy, Combination; Female; Glioblastoma; Humans; Lomustine; Ma | 1980 |
Combination chemotherapy for small cell carcinoma of the lung: continuous versus alternating non-cross-resistant combinations.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Small Cell; Cyclophosphamide; Doxoru | 1982 |
Combined radiotherapy and chemotherapy with dibromodulcitol and CCNU in the postoperative treatment of malignant gliomas.
Topics: Brain Neoplasms; Drug Therapy, Combination; Glioblastoma; Humans; Lomustine; Mitolactol; Nitrosourea | 1983 |
Combined modality treatment of regional small cell undifferentiated carcinoma of the lung: a cooperative study of the RTOG and ECOG.
Topics: Brain Neoplasms; Carcinoma, Small Cell; Clinical Trials as Topic; Cyclophosphamide; Female; Humans; | 1983 |
Radio-chemo-immunotherapy (CCNU plus levamisole) for treatment of metastatic brain tumors. A pilot study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Humans; | 1984 |
Treatment of neuroectodermal brain tumors.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms; | 1982 |
Prophylactic irradiation in bronchogenic small cell anaplastic carcinoma. A comparative trial of localized versus extensive radiotherapy including prophylactic brain irradiation in patients receiving combination chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Bronchogenic; Clinical Trials as Top | 1980 |
Evaluation of CCNU, VM-26 plus CCNU, and procarbazine in supratentorial brain gliomas. Final evaluation of a randomized study. European Organization for Research on Treatment of Cancer (EORTC) Brain Tumor Group.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Drug Therapy, Combination; Female; | 1981 |
Primary intracranial gliomas: clinical studies and treatment regimens of the Brain Tumor Research Center, University of California, San Francisco, 1977-1979.
Topics: Antineoplastic Agents; Brain Neoplasms; California; Carmustine; Clinical Trials as Topic; Drug Thera | 1981 |
A review of studies of the EORTC brain tumor group.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Dexamethasone; Drug Administration | 1981 |
[VM-26 plus CCNU in the prevention of brain metastasis in lung cancer patients].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcin | 1995 |
Prognostic factors and treatment results for supratentorial primitive neuroectodermal tumors in children using radiation and chemotherapy: a Childrens Cancer Group randomized trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool; Combined M | 1995 |
Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Chemother | 1995 |
Pre-irradiation chemotherapy in children with high-grade astrocytoma: tumor response to two cycles of the '8-drugs-in-1-day' regimen. A Childrens Cancer Group study, CCG-945.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Che | 1994 |
Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasm | 1995 |
Survival and prognostic factors following radiation and/or chemotherapy for primitive neuroectodermal tumors of the pineal region in infants and children: a report of the Childrens Cancer Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Pr | 1995 |
Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens Cancer Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Che | 1995 |
Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Canada; Ce | 1994 |
Results of a pilot study of low-dose craniospinal radiation therapy plus chemotherapy for children younger than 5 years with primitive neuroectodermal tumors.
Topics: Brain Neoplasms; Chemotherapy, Adjuvant; Child, Preschool; Cisplatin; Cranial Fossa, Posterior; Cran | 1993 |
A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study.
Topics: Adult; Aged; Brain Neoplasms; Combined Modality Therapy; Female; Glioma; Humans; Lomustine; Male; Mi | 1993 |
Ototoxicity in children with malignant brain tumors treated with the "8 in 1" chemotherapy protocol.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; | 1996 |
Adjuvant chemotherapy of childhood posterior fossa ependymoma: cranio-spinal irradiation with or without adjuvant CCNU, vincristine, and prednisone: a Childrens Cancer Group study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; | 1996 |
Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool | 1997 |
TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 1997 |
Activity of combination chemotherapy in brain metastases from breast and lung adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phyt | 1997 |
Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study.
Topics: Abdominal Neoplasms; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 1997 |
Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas.
Topics: Adult; Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; | 1997 |
Synchronous radiochemotherapy in unfavorable brain tumors of children and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Che | 1998 |
Dose-intensification of procarbazine, CCNU (lomustine), vincristine (PCV) with peripheral blood stem cell support in young patients with gliomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Pr | 1998 |
A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Brain | 1999 |
Combined treatment modality for anaplastic oligodendroglioma: a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; D | 1999 |
A phase 3 randomized study of radiotherapy plus procarbazine, CCNU, and vincristine (PCV) with or without BUdR for the treatment of anaplastic astrocytoma: a preliminary report of RTOG 9404.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Bromodeoxyuridine; Che | 1999 |
Quantitative 201Tl SPET imaging in the follow-up of treatment for brain tumour: a sensitive tool for the early identification of response to chemotherapy?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Female; Follow- | 2000 |
A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antin | 2000 |
Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; | 2000 |
Phase II study of 6-thioguanine, procarbazine, dibromodulcitol, lomustine, and vincristine chemotherapy with radiotherapy for treating malignant glioma in children.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Pr | 2000 |
[Therapeutic effect on glioblastoma of chemotherapy on the basis of brain irradiation].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Carmustine; Chil | 2001 |
Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasm | 2002 |
Enhancement of bone marrow toxicity of VM-26-CCNU combination by bleomycin.
Topics: Adult; Aged; Bleomycin; Bone Marrow; Brain Neoplasms; Clinical Trials as Topic; Drug Therapy, Combin | 1977 |
Chemotherapy: adjuvant to surgery and radiation therapy.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Fluorouracil; Glioma; | 1975 |
Controlled study of CCNU and radiation therapy in malignant astrocytoma.
Topics: Adult; Aged; Brain Neoplasms; Digestive System; Drug Evaluation; Glioblastoma; Hematopoiesis; Humans | 1976 |
Controlled study with BCNU vs. CCNU as adjuvant chemotherapy following surgery plus radiotherapy for glioblastoma multiforme.
Topics: Brain Neoplasms; Carmustine; Clinical Trials as Topic; Female; Glioblastoma; Humans; Lomustine; Male | 1979 |
Preliminary report of a cooperative randomized study for the treatment of localized small cell lung carcinoma.
Topics: Bone Marrow; Brain Neoplasms; Carcinoma, Small Cell; Clinical Trials as Topic; Cyclophosphamide; Dru | 1979 |
Radiation plus adjuvant CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) vs CCNU, hpydroxyurea and vincristine in the treatment of malignant glioma.
Topics: Adolescent; Adult; Aged; Bone Marrow; Brain Neoplasms; Clinical Trials as Topic; Drug Therapy, Combi | 1979 |
Vincristine, prednisone and L-asparaginase in the induction of remission in children with acute lymphoblastic leukemia following relapse.
Topics: Adolescent; Adult; Antineoplastic Agents; Asparaginase; Bone Marrow; Brain Neoplasms; Carmustine; Ch | 1978 |
Treatment of malignant gliomas and brain metastases in adults using a combination of adriamycine, VM 26, and CCNU. Results of a type II trial.
Topics: Adult; Aged; Brain Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Drug Therapy, | 1977 |
A comparison of radiotherapy alone with radiotherapy and CCNU in cerebral glioma.
Topics: Adult; Age Factors; Aged; Brain Neoplasms; Clinical Trials as Topic; Evaluation Studies as Topic; Fe | 1978 |
Multidisciplinary treatment for central nervous system tumours with nitrosourea compounds.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Female; Humans; Lomu | 1978 |
Effect of CCNU on survival rate of objective remission and duration of free interval in patients with malignant brain glioma--final evaluation. E.O.R.T.C. Brain Tumor Group.
Topics: Brain Neoplasms; Clinical Trials as Topic; Female; Glioma; Humans; Lomustine; Male; Neoplasm Recurre | 1978 |
[A study of the use of sequential chemotherapy in 176 cases of glioblastoma (author's transl)].
Topics: Adult; Brain Neoplasms; Clinical Trials as Topic; Doxorubicin; Drug Therapy, Combination; Follow-Up | 1978 |
[Combined postoperative therapy of glial brain tumors. Initial results of the pilot study].
Topics: Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Cobalt Radioisotopes; Glioma; Humans; Lomust | 1978 |
Prophylactic cranial irradiation in small cell carcinoma of the lung. A randomized study.
Topics: Adult; Aged; Brain; Brain Neoplasms; Carcinoma; Cyclophosphamide; Doxorubicin; Drug Therapy, Combina | 1977 |
[Letter: Chemotherapy of operated malignant brain gliomas using a combination of VM 26 and CCNU].
Topics: Brain Neoplasms; Clinical Trials as Topic; Drug Therapy, Combination; Follow-Up Studies; Glioma; Hum | 1976 |
[Trial treatment of glioblastomas in adults and cerebral metastais by adriamycin, VM 26 and CCNU combination. Result of a type II trial].
Topics: Adult; Aged; Brain Neoplasms; Clinical Trials as Topic; Doxorubicin; Drug Evaluation; Drug Therapy, | 1976 |
Radiotherapy and CCNU in the treatment of high-grade supratentorial astrocytomas.
Topics: Astrocytoma; Brain Neoplasms; Drug Evaluation; Female; Humans; Lomustine; Male; Nitrosourea Compound | 1976 |
Adjuvant nitrosourea therapy for glioblastoma.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Carmustine; Child; Child, Preschool; Drug Evaluation; Fema | 1976 |
Effect of CCNU on survival, rate of objective remission and duration of free interval in patients with malignant brain glioma--first evaluation.
Topics: Brain Neoplasms; Dexamethasone; Glioma; Humans; Lomustine; Neoplasm Recurrence, Local; Nitrosourea C | 1976 |
Advantage of post-radiotherapy chemotherapy with CCNU, procarbazine, and vincristine (mPCV) over chemotherapy with VM-26 and CCNU for malignant gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Combined | 1992 |
Increasing radiation dose intensity using hyperfractionation in patients with malignant glioma. Final report of a prospective phase I-II dose response study.
Topics: Adolescent; Adult; Age Factors; Aged; Astrocytoma; Brain; Brain Neoplasms; Cobalt Radioisotopes; Com | 1992 |
[Chemotherapy of malignant glioma. Results of studies of the EORTC group of brain tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Combined Modality Therap | 1992 |
External irradiation followed by an interstitial high activity iodine-125 implant "boost" in the initial treatment of malignant gliomas: NCOG study 6G-82-2.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Brain Neoplasms; Combine | 1991 |
Evaluation of bromodeoxyuridine in glioblastoma multiforme: a Northern California Cancer Center Phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Bro | 1991 |
Combination chemotherapy of limited-stage small-cell lung cancer. A controlled trial on 221 patients comparing two alternating regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; | 1991 |
Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 1990 |
A randomized study of CCNU with and without benznidazole in the treatment of recurrent grades 3 and 4 astrocytoma. Report to the Medical Research Council by the Brain Tumor Working Party.
Topics: Adolescent; Adult; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Double-Blin | 1989 |
The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chi | 1989 |
Quality of survival of patients with brain gliomas treated with postoperative CCNU and radiation therapy.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Disab | 1989 |
The role of radiation therapy in the treatment of small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Clinical Tri | 1985 |
Combined modality treatment of operated astrocytomas grade 3 and 4. A prospective and randomized study of misonidazole and radiotherapy with two different radiation schedules and subsequent CCNU chemotherapy. Stage II of a prospective multicenter trial of
Topics: Actuarial Analysis; Adult; Aged; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Therap | 1985 |
Long-term survival and recurrence-free interval in combined surgical, radio- and chemotherapy of malignant brain gliomas.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Child; Child, Preschool; Clinical Trials as Topic; Combine | 1985 |
Postoperative radiotherapy and radiotherapy combined with CCNU chemotherapy for treatment of brain gliomas.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Clinical Trials as Topic; Female; Glioma; Humans; Lomustin | 1988 |
Brain-stem tumors in childhood: a prospective randomized trial of irradiation with and without adjuvant CCNU, VCR, and prednisone. A report of the Childrens Cancer Study Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Brain Stem; Chil | 1987 |
Benznidazole with CCNU: a clinical phase I toxicity study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Brain Neoplasms; Drug Evaluation; | 1985 |
295 other studies available for lomustine and Benign Neoplasms, Brain
| Article | Year |
|---|---|
Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; DNA Modification Methylases; DNA Repair Enzymes; Dr | 2021 |
Viability fingerprint of glioblastoma cell lines: roles of mitotic, proliferative, and epigenetic targets.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Brain Neoplasms; Cell Cycle; Cell Line, | 2021 |
Early Postoperative Treatment versus Initial Observation in CNS WHO Grade 2 and 3 Oligodendroglioma: Clinical Outcomes and DNA Methylation Patterns.
Topics: Adult; Brain Neoplasms; DNA Methylation; Humans; Isocitrate Dehydrogenase; Lomustine; Methyltransfer | 2022 |
Current therapeutic options for glioblastoma and future perspectives.
Topics: Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Glioblas | 2022 |
Prediction of response to lomustine-based chemotherapy in glioma patients at recurrence using MRI and FET PET.
Topics: Adult; Brain Neoplasms; Glioma; Humans; Lomustine; Magnetic Resonance Imaging; Positron-Emission Tom | 2023 |
Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line; Cell Line, Tumor; DNA Modification Me | 2023 |
T2-Fluid-attenuated inversion recovery (FLAIR) pseudoprogression in patients with anaplastic oligodendrogliomas treated with procarbazine, lomustine and vincristine (PCV) chemotherapy alone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Humans; Lomustine; Magnetic Resonan | 2023 |
Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Lomustine; Ma | 2023 |
Pediatric glioblastoma in the setting of constitutional mismatch-repair deficiency treated with upfront lomustine and nivolumab.
Topics: Brain Neoplasms; Child; Colorectal Neoplasms; Glioblastoma; Humans; Lomustine; Nivolumab | 2024 |
Craniotomy for recurrent glioblastoma: Is it justified? A comparative cohort study with outcomes over 10 years.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immu | 2020 |
Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Com | 2020 |
A troublesome burden, the amplification of EGFR in glioblastoma!
Topics: Antibodies, Monoclonal, Humanized; Brain Neoplasms; ErbB Receptors; Glioblastoma; Humans; Lomustine; | 2020 |
Salvage chemotherapy after failure of targeted therapy in a child with BRAF V600E low-grade glioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child, Preschool; Glioma; Humans; L | 2021 |
Microangiopathy, lomustine, and karyomegalic mesangial cells.
Topics: Brain Neoplasms; Humans; Lomustine; Mesangial Cells | 2020 |
A comparative study of the effectiveness and safety of combined procarbazine, lomustine, and vincristine as a therapeutic method for recurrent high-grade glioma: A protocol for systematic review and meta-analysis.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Glioma; Humans; | 2020 |
Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for IDH-Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Humans; Lomustine; Pro | 2021 |
One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Drug-Related Side Effects an | 2021 |
PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Humans; Lomustine; Neoplasm Staging | 2021 |
Diagnosis of Pseudoprogression Following Lomustine-Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2021 |
Increased infiltration of CD8 T cells in recurrent glioblastoma patients is a useful biomarker for assessing the response to combined bevacizumab and lomustine therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizu | 2021 |
Combination chemotherapy versus temozolomide for patients with methylated MGMT (m-MGMT) glioblastoma: results of computational biological modeling to predict the magnitude of treatment benefit.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Artificial Intell | 2021 |
Cost-effectiveness of radiation and chemotherapy for high-risk low-grade glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Cost-Bene | 2017 |
Estrogen and soy isoflavonoids decrease sensitivity of medulloblastoma and central nervous system primitive neuroectodermal tumor cells to chemotherapeutic cytotoxicity.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Cisplatin; Equol; Estradiol | 2017 |
Targeting glioma stem-like cell survival and chemoresistance through inhibition of lysine-specific histone demethylase KDM2B.
Topics: Antineoplastic Agents; Apoptosis; Astrocytes; Brain Neoplasms; Cell Line; DNA Damage; Drug Resistanc | 2018 |
Regimen of procarbazine, lomustine, and vincristine versus temozolomide for gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2018 |
Survival times in dogs with presumptive intracranial gliomas treated with oral lomustine: A comparative retrospective study (2008-2017).
Topics: Administration, Oral; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dog Diseases; Dog | 2018 |
Achievable Central Nervous System Concentrations of the Green Tea Catechin EGCG Induce Stress in Glioblastoma Cells in Vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Brain Neoplasms; Catechin; Cen | 2018 |
OIP5 Expression Sensitize Glioblastoma Cells to Lomustine Treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Chromosom | 2018 |
Radiotherapy plus temozolomide or PCV in patients with anaplastic oligodendroglioma 1p19q codeleted.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2018 |
Improving survival in molecularly selected glioblastoma.
Topics: Adult; Brain Neoplasms; Combined Modality Therapy; DNA Modification Methylases; DNA Repair Enzymes; | 2019 |
Lomustine-temozolomide combination efficacious in newly diagnosed glioblastoma.
Topics: Brain Neoplasms; Clinical Trials, Phase III as Topic; DNA Methylation; DNA Modification Methylases; | 2019 |
A Real-World Claims Analysis of Costs and Patterns of Care in Treated Patients with Glioblastoma Multiforme in the United States.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasm | 2019 |
Imaging necrosis during treatment is associated with worse survival in EORTC 26101 study.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Clinical T | 2019 |
PCV for anaplastic oligodendrogliomas: back to the future or a step backwards? A point/counterpoint discussion.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Clinical Trials, Phase III as Topic | 2013 |
How to use molecular markers when caring for a patient with brain cancer: 1P/19Q as a predictive and prognostic marker in the neuro-oncology clinic.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chromosome Deletion; Chromosomes, H | 2013 |
Anaplastic oligodendroglioma: a new treatment paradigm and current controversies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Female; | 2013 |
Addition of lomustine for bevacizumab-refractory recurrent glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemo | 2014 |
Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Renewing interest in targeting angiogenesis in glioblastoma.
Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Female; Glioblastoma; Humans; Lomus | 2014 |
CNS cancer: it takes two to tango.
Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Female; Glioblastoma; Humans; Lomus | 2014 |
Neuro-oncology: It takes two to tango.
Topics: Antibodies, Monoclonal, Humanized; Brain Neoplasms; Female; Glioblastoma; Humans; Lomustine; Male; N | 2014 |
Bevacizumab alone or in combination with chemotherapy in glioblastomas?
Topics: Antibodies, Monoclonal, Humanized; Brain Neoplasms; Female; Glioblastoma; Humans; Lomustine; Male; N | 2014 |
Bevacizumab alone or in combination with chemotherapy in glioblastomas?--authors' reply.
Topics: Antibodies, Monoclonal, Humanized; Brain Neoplasms; Female; Glioblastoma; Humans; Lomustine; Male; N | 2014 |
Treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study with growth kinetics.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Disease Progression; Drug Therapy, Combination; Femal | 2015 |
Enhanced anticancer properties of lomustine in conjunction with docosahexaenoic acid in glioblastoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; | 2015 |
Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Dacarbazi | 2015 |
Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkyla | 2015 |
Comparative efficacy of bevacizumab and PCV chemotherapy in recurrent glioblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Glioblastoma; Humans; | 2015 |
The role of bevacizumab in recurrent glioblastoma: new insights from randomized trials.
Topics: Antibodies, Monoclonal, Humanized; Brain Neoplasms; Female; Glioblastoma; Humans; Lomustine; Male; N | 2015 |
Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for PCV.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2015 |
Kinetic evaluation of low-grade gliomas in adults before and after treatment with CCNU alone.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy | 2015 |
Second-Line Chemotherapy in Recurrent Glioblastoma: A 2-Cohort Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothe | 2015 |
PC or PCV, That Is the Question: Primary Anaplastic Oligodendroglial Tumors Treated with Procarbazine and CCNU With and Without Vincristine.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astr | 2015 |
Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Female; Follow- | 2016 |
High-grade glioma in children and adolescents: a single-center experience.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astro | 2016 |
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of High-Grade Glioma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Beva | 2015 |
Increasing the Time Interval between PCV Chemotherapy Cycles as a Strategy to Improve Duration of Response in Low-Grade Gliomas: Results from a Model-Based Clinical Trial Simulation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Clinical Protocols; Clinical | 2015 |
Lomustine Nanoparticles Enable Both Bone Marrow Sparing and High Brain Drug Levels - A Strategy for Brain Cancer Treatments.
Topics: Animals; Antineoplastic Agents, Alkylating; Bone Marrow; Brain; Brain Neoplasms; Cell Line, Tumor; D | 2016 |
Chemotherapy for intracranial ependymoma in adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Dis | 2016 |
Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytosine Deaminase; Diseas | 2016 |
Case of a miniature dachshund with a primitive neuroectodermal tumor confined to the forebrain region treated with a combination of surgery and chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dog Diseases | 2016 |
Inhibition of histone deacetylases sensitizes glioblastoma cells to lomustine.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western | 2017 |
Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A 1H-Magnetic Resonance Spectroscopy Study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Brain N | 2016 |
Nitrosoureas inhibit the stathmin-mediated migration and invasion of malignant glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Movement; Glioma; Lomustine; Mice; | 2008 |
Low-grade glioma: a challenge in therapeutic options: the role of radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2008 |
Procarbazine and CCNU as initial treatment in gliomatosis cerebri.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease-Free Survival; | 2008 |
[Clinical features and combined treatment of the central nervous system in Hodgkin's disease].
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2008 |
Assessment of cetuximab efficacy by bioluminescence monitoring of intracranial glioblastoma xenograft in mouse.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineopl | 2009 |
Retrospective analysis of treatment outcome in 315 patients with oligodendroglial brain tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Chi | 2009 |
De novo germline TP53 mutation presenting with synchronous malignancies of the central nervous system.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma; Choroid Plex | 2009 |
Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2009 |
Bevacizumab is active as a single agent against recurrent malignant gliomas.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Glioma; Humans; Lomustine; | 2010 |
Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Capecitabine; Celecoxi | 2011 |
HPLC method validation for the quantification of lomustine to study pharmacokinetics of thermosensitive liposome-encapsulated lomustine containing iohexol for CT imaging in C6 glioma rats.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Brain Neoplasms; Calibration; Cell Line, Tumor; Ch | 2011 |
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chr | 2011 |
[Brain metastasis in breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Antineopl | 2011 |
[Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2012 |
Late and prolonged pseudoprogression in glioblastoma after treatment with lomustine and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2012 |
Comparison between symptomatic treatment and lomustine supplementation in 71 dogs with intracranial, space-occupying lesions.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dog Diseases; Dogs; Female; Lomustine; | 2014 |
Chemotherapy and radiotherapy combination extends survival for patients with oligodendroglial tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Proliferation; Chemoradiothera | 2012 |
Cervicothoracic syringohydromyelia associated with a prosencephalic mass in a dog.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2012 |
Intensified PCV-chemotherapy with optional stem cell support in recurrent malignant oligodendroglioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Brain Neoplasms; Female | 2002 |
Complete response of a recurrent, multicentric malignant glioma in a patient treated with phenylbutyrate.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Femal | 2002 |
Dramatic response to chemotherapy in oligodendroglial gliomatosis cerebri.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Corpus Callosum; Fro | 2003 |
Long-term sequelae in children treated for brain tumors: impairments, disability, and handicap.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Atrophy; Brain; Brain Damage, Chronic; B | 2003 |
Glioma treatment, radionecrosis, and growth factors. In regard to Levin et al., IJROBP 2002;53:58-66.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Diseases; Brain Neoplasms; Carbop | 2003 |
Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chromosome Aberrations; Chromosomes | 2003 |
Interobserver variability in the radiological assessment of response to chemotherapy in glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carboplat | 2003 |
Survival improvement in patients with glioblastoma multiforme during the last 20 years in a single tertiary-care center.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating | 2003 |
Malignant transformation of a dysembryoplastic neuroepithelial tumor after radiation and chemotherapy.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Cell | 2003 |
[Use of modern technologies in the diagnosis and combined treatment of brain stem tumors].
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2003 |
Monitoring individual response to brain-tumour chemotherapy: proton MR spectroscopy in a patient with recurrent glioma after stereotactic radiotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Astrocytoma; Brain Neoplasms; | 2004 |
Long-term outcome of oligodendrogliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Ci | 2004 |
[Neoadjuvant chemotherapy for symptomatic non operable grade II fibrillary astrocytoma in adults].
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Astrocytom | 2004 |
Gliomatosis cerebri: better definition, better treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Astrocyt | 2004 |
Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neo | 2005 |
Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Humans; Lomust | 2005 |
Combination chemotherapy with carmustine and cisplatin followed by procarbazine, lomustine, and vincristine for adult high-grade astrocytoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasm | 2005 |
P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents; Blood Cell Count; Brain Neop | 2005 |
Complete remission of brain metastases in three patients with stage IV melanoma treated with BOLD and G-CSF.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Dacarbazine | 2005 |
Effects of lipid association on lomustine (CCNU) administered intracerebrally to syngeneic 36B-10 rat brain tumors.
Topics: Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Ethylni | 2006 |
Toxic epidermal necrolysis after PCV combination chemotherapy for relapsed B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Humans; Lomustine; Lymphoma, B-Cell | 2006 |
Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Case-Control Studies; | 2006 |
Anaplastic oligodendroglial tumors: a tale of two trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Tr | 2006 |
[Palliative therapy in glioblastoma multiforme: a multimodal concept].
Topics: Aged; Brain Neoplasms; Catheters, Indwelling; Chemotherapy, Adjuvant; Combined Modality Therapy; Cra | 2006 |
Gliomatosis cerebri treatment in 11 elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined M | 2006 |
Re-evaluation of the cost effectiveness of temozolomide for malignant gliomas in British Columbia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; British Columbia | 2006 |
Genetic and metabolic predictors of chemosensitivity in oligodendroglial neoplasms.
Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chromosomes, | 2006 |
Astrocytic tumors in children: treatment results from a single institution.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Child; Chi | 2007 |
[Long-term outcome in patients with symptomatic low-grade oligodendrogliomatous tumors treated by cytotoxic agents].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemo | 2006 |
Radiotherapy plus concurrent and adjuvant procarbazine, lomustine, and vincristine chemotherapy for patients with malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemothera | 2007 |
Nitrosourea efficacy in high-grade glioma: a survival gain analysis summarizing 504 cohorts with 24193 patients.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; | 2008 |
Cryptococcal meningitis in patients with glioma: a report of two cases.
Topics: Adult; Aged; Amphotericin B; Anti-Inflammatory Agents; Antifungal Agents; Antineoplastic Agents, Alk | 2008 |
5-Fluorouracil and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) followed by hydroxyurea, misonidazole, and irradiation for brain stem gliomas: a pilot study of the Brain Tumor Research Center and the Childrens Cancer Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Bra | 1984 |
Radiation therapy for brain metastases from malignant melanoma.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Radiation; Female; Humans; Lo | 1984 |
[What is safe in the treatment of small-cell bronchial carcinoma?].
Topics: Brain Neoplasms; Bronchial Neoplasms; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Drug The | 1980 |
Late results of multimodality therapy of high-grade supratentorial astrocytomas.
Topics: Adult; Antineoplastic Agents; Astrocytoma; Bleomycin; Brain Neoplasms; Drug Therapy, Combination; Fe | 1981 |
Therapeutic evaluation of five nitrosoureas in a human melanoma xenograft system.
Topics: Animals; Bone Marrow; Brain Neoplasms; Carmustine; Dose-Response Relationship, Drug; Female; Humans; | 1983 |
Multimodality treatment of malignant gliomas. Comparison of several adjuvant approaches.
Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Drug Therapy, Combination; Ependymoma; Glioblastoma; | 1981 |
[Postoperative treatment of malignant glial tumors of the brain with CCNU].
Topics: Astrocytoma; Brain Neoplasms; Follow-Up Studies; Glioblastoma; Humans; Lomustine; Nitrosourea Compou | 1981 |
Methotrexate in the chemotherapy of lung cancer.
Topics: Brain Neoplasms; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cyclophos | 1981 |
Combination chemotherapy for metastatic brain tumors.
Topics: Adenocarcinoma; Brain Neoplasms; Breast Neoplasms; Carcinoma, Small Cell; Doxorubicin; Drug Therapy, | 1981 |
Clinical toxicity of combined modality treatment with nitrosourea derivatives for central nervous system tumors.
Topics: Bone Marrow Diseases; Brain Neoplasms; Carmustine; Gastrointestinal Diseases; Glioblastoma; Glioma; | 1982 |
[Glioblastoma multiforme. Postoperative therapy].
Topics: Adult; Aged; Brain Neoplasms; Drug Therapy, Combination; Female; Glioblastoma; Humans; Lomustine; Ma | 1983 |
[Antimitotic chemotherapy of supratentorial cerebral glioma in adults. Apropos of 56 cases].
Topics: Adult; Aged; Brain Neoplasms; Drug Therapy, Combination; Female; Glioma; Humans; Lomustine; Male; Mi | 1983 |
[Prognostic value of gliofibrillary protein assay in malignant gliomas treated with chemo- and radiotherapy].
Topics: Adolescent; Adult; Brain Neoplasms; Drug Therapy, Combination; Female; Follow-Up Studies; Glial Fibr | 1983 |
[Irradiation of the brain in the combined treatment of small-cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; | 1983 |
Megadose chemotherapy with bone marrow rescue.
Topics: Animals; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioma | 1984 |
Influence of polyamine depletion caused by alpha-difluoromethylornithine, an enzyme-activated irreversible inhibitor of ornithine decarboxylase, on alkylation- and carbamoylation-induced cytotoxicity in 9L rat brain tumor cells in vitro.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carboxy-Lyases; Carmustine; Cell Line; Cell Surviva | 1983 |
Procarbazine, CCNU and vincristine (PCV) combination chemotherapy for brain tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Combined Modali | 1984 |
Hypoxic cells and in situ chemopotentiation of the nitrosoureas by misonidazole.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Survival; Dose-Response Relationship, Drug; Drug Synergis | 1984 |
Use of phenobarbital and high doses of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea in the treatment of brain tumor-bearing mice.
Topics: Animals; Brain Neoplasms; Cell Survival; Dose-Response Relationship, Drug; Drug Interactions; Female | 1983 |
Treatment of brain giomas with high dose of CCNU and autologous bone marrow transplantation.
Topics: Bone Marrow Transplantation; Brain Neoplasms; Glioma; Hematologic Diseases; Humans; Lomustine; Nitro | 1980 |
Quantitative dose-response relations for the cytotoxic activity of chloroethylnitrosoureas in cell culture.
Topics: Animals; Biotransformation; Brain Neoplasms; Carmustine; Cell Survival; Cells, Cultured; Dose-Respon | 1982 |
[The effects of combined chemotherapy (adriamycin/VM/26/CCNU) in brian tumours in adults and animal experiments (author's transl)].
Topics: Adult; Aged; Animals; Brain Neoplasms; Doxorubicin; Drug Therapy, Combination; Ethylnitrosourea; Fem | 1982 |
Pulmonary fibrosis associated with lomustine (CCNU): a case report.
Topics: Astrocytoma; Brain; Brain Neoplasms; Child; Humans; Lomustine; Male; Nitrosourea Compounds; Pulmonar | 1982 |
[Analysis of long-term effects of CCNU on gliomas of the brain].
Topics: Adolescent; Adult; Brain Neoplasms; Child; Female; Glioma; Humans; Lomustine; Male; Middle Aged; Nit | 1982 |
[Results of combined modality treatment of malignant gliomas. Comparison of postoperative irradiation, chemotherapy, and combined radio-polychemotherapy (author's transl)].
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Drug Therapy, Combination; Female; Glioma; Huma | 1981 |
Nephrotoxicity of nitrosoureas.
Topics: Adolescent; Adult; Aged; Biopsy; Blood Urea Nitrogen; Brain Neoplasms; Carmustine; Child; Creatinine | 1981 |
The effect of phenobarbital on the toxicity and tumoricidal activity of CCNU in a murine brain tumor model.
Topics: Animals; Brain Neoplasms; Drug Therapy, Combination; Ependymoma; Female; Lomustine; Mice; Mice, Inbr | 1980 |
Cell growth rate of human brain tumours in vitro.
Topics: Brain Neoplasms; Humans; In Vitro Techniques; Lomustine | 1980 |
[Progressive insufficiency after CCNU therapy].
Topics: Adult; Brain Neoplasms; Glomerulosclerosis, Focal Segmental; Humans; Kidney Failure, Chronic; Lomust | 1980 |
Synergistic effect of combined hyperthermia and a nitrosourea in treatment of a murine ependymoblastoma.
Topics: Animals; Brain Neoplasms; Ependymoma; Female; Hot Temperature; Lomustine; Mice; Neoplasm Transplanta | 1980 |
Combination chemotherapy with VM 26 and CCNU in primary malignant brain tumors of children.
Topics: Adolescent; Brain Neoplasms; Child; Child, Preschool; Drug Therapy, Combination; Female; Humans; Lom | 1980 |
CCNU chemotherapy in adult patients with tumors of the basal ganglia and brain stem.
Topics: Adolescent; Adult; Aged; Basal Ganglia Diseases; Brain Neoplasms; Brain Stem; Female; Humans; Lomust | 1980 |
CCNU therapy in basal germinomas.
Topics: Brain Neoplasms; Dysgerminoma; Humans; Lomustine; Nitrosourea Compounds | 1981 |
The effect of topical CCNU(1-(2-chloroethyl)-3 cyclohexyl 1 nitrosurea) treatment on lipid peroxidation of glial tumours transplanted on rat brain.
Topics: Administration, Topical; Animals; Brain; Brain Neoplasms; Glioma; Injections, Intralesional; Lipid P | 1995 |
Multiorgan failure associated with lomustine overdose.
Topics: Adult; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; Drug Overdose; Female; Frontal Lobe; | 1995 |
Response and control: lessons from oligodendroglioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Humans; Lomustine; Oligodendrogliom | 1995 |
Chemoradiation and adjuvant chemotherapy for glioblastoma: why does so much therapy yield so little improvement in survival?
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Chemotherapy, Adjuvant | 1995 |
Interleukin-2 gene therapy in a patient with glioblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cells, Cultured; Combined Modality | 1995 |
Restrictive lung disease following treatment for malignant brain tumors: a potential late effect of craniospinal irradiation.
Topics: Adolescent; Adult; Brain Neoplasms; Child; Child, Preschool; Cranial Irradiation; Female; Humans; Lo | 1995 |
Brain tumor chemotherapy trials: slow start, but quickly gaining.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Clinical Trials as Topic; Humans; L | 1994 |
Consolidative thoracic radiotherapy and prophylactic cranial irradiation in limited disease small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Small Cell; | 1993 |
Long survival in patients with acquired immune deficiency syndrome-related primary central nervous system lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; C | 1994 |
Aplastic anemia induced by cyclohexylchloroethylnitrousurea.
Topics: Adult; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Blood Cell Cou | 1994 |
Low-grade oligodendroglioma responds to chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Humans; Lomustine; M | 1996 |
Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas.
Topics: Adult; Astrocytoma; Brain Neoplasms; Female; Humans; Lomustine; Male; Middle Aged; Procarbazine; Pro | 1996 |
Quantitative DNA analysis of an intracerebrally transplanted brain tumour model after experimental chemotherapy with BCNU and CCNU.
Topics: Animals; Brain Neoplasms; Brain Tissue Transplantation; Carmustine; Cell Division; Cytophotometry; D | 1995 |
Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Pr | 1996 |
Radiation and chemotherapy improve outcome in oligodendroglioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1997 |
Intracranial Hodgkin's disease in two patients with familial Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modalit | 1997 |
Retreatment of patients with intracranial gliomas by external beam radiotherapy and cytotoxic chemotherapy.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Case-Control Studies; Child; Combined Modality Therap | 1997 |
Pretreatment prediction of the chemotherapeutic response of human glioma cell cultures using nuclear magnetic resonance spectroscopy and artificial neural networks.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Drug Resistance, Neoplasm; Drug S | 1997 |
[Assessment of procarbazine, vincristine and lomustine association (PCV protocol) in oligodendroglioma and mixed glioma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Gl | 1997 |
Neurotoxicity of combination chemotherapy with procarbazine, CCNU and vincristine (PCV) for recurrent glioma.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 1998 |
Bihemispheric malignant glioma: one size does not fit all.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Fatal Outcome; Glioblastoma; | 1998 |
CCNU overdose during PCV chemotherapy for anaplastic astrocytoma.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neo | 1998 |
Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Co | 1998 |
A retrospective study of the value of chemotherapy as adjuvant therapy to surgery and radiotherapy in grade 3 and 4 gliomas.
Topics: Administration, Oral; Adult; Age Distribution; Antineoplastic Combined Chemotherapy Protocols; Brain | 1998 |
The efficacy of CCNU in non-small cell lung carcinoma presenting with cranial metastases.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Sur | 1998 |
Reirradiation and lomustine in patients with relapsed high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Disease | 1999 |
Sensitivity of short-term cultures derived from human malignant glioma to the anti-cancer drug temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Dose-Response R | 1999 |
Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Fem | 1999 |
BUdR radiosensitization in anaplastic astrocytoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Bromodeoxyuridine; Che | 1999 |
Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors.
Topics: Adult; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carbamazepi | 1999 |
Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Carmustine; Chemotherapy | 1999 |
Effects of carmustine and lomustine on arylamine N-acetyltransferase activity and 2-aminofluorene-DNA adducts in rat glial tumor cells.
Topics: Animals; Arylamine N-Acetyltransferase; Brain Neoplasms; Carmustine; DNA Adducts; Fluorenes; Glioma; | 2000 |
Chemosensitivity in childhood brain tumours in vitro: evidence of differential sensitivity to lomustine (CCNU) and vincristine.
Topics: Adult; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Child; Dose-Response Relationship, Drug; | 2000 |
Chemotherapy for aggressive or anaplastic high grade oligodendrogliomas and oligoastrocytomas: better than a salvage treatment.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasm | 1998 |
Distinct radiochemotherapy protocols differentially influence cellular proliferation and expression of p53 and Bcl-2 in glioblastoma multiforme relapses in vivo.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apop | 2000 |
Myeloablative chemotherapy for recurrent aggressive oligodendroglioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplanta | 2000 |
Lipid association improves the therapeutic index of lomustine [1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea] to suppress 36B-10 tumor growth in rats.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Cell Division; Dose-Respon | 2001 |
[Post-operative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of German prospective randomised trial HIT'91].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; | 2001 |
PCV chemotherapy for recurrent glioblastoma multiforme.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Progression; Female; Gliobl | 2001 |
CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Brai | 2001 |
Adenovirus-mediated expression of HSV1-TK or Fas ligand induces cell death in primary human glioma-derived cell cultures that are resistant to the chemotherapeutic agent CCNU.
Topics: Adenoviridae; Antineoplastic Agents, Alkylating; Apoptosis; beta-Galactosidase; Brain Neoplasms; Com | 2001 |
Medical Research Council adjuvant trial in high-grade gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant | 2001 |
Improved efficacy of chemotherapy for glioblastoma by radiation-induced opening of blood-brain barrier: clinical results.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Ch | 2001 |
Radiotherapy combined with procarbazine, bleomycin, and CCNU in the treatment of high-grade supratentorial astrocytomas.
Topics: Adolescent; Adult; Aged; Astrocytoma; Bleomycin; Brain Neoplasms; Child; Drug Therapy, Combination; | 1978 |
Treatment of grade III and IV astrocytoma with dimethyl triazeno imidazole carboxamide (DTIC, NSC-45388) alone and in combination with CCNU (NSC-79037) or methyl CCNU (MeCCNU, NSC-95441).
Topics: Adult; Brain Neoplasms; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Female; Glioblastom | 1975 |
Single-agent chemotherapy of brain tumors. A five-year review.
Topics: Astrocytoma; Bone Marrow Diseases; Brain Neoplasms; Carmustine; Glioma; Humans; Imidazoles; Lomustin | 1976 |
[Treatment of inoperable glioblastomas using a combination of adriamycin, VM 26 and CCNU].
Topics: Adult; Aged; Brain Neoplasms; Doxorubicin; Drug Therapy, Combination; Drug Tolerance; Glioblastoma; | 1977 |
[Polychemotherapy of glioblastoma multiforme].
Topics: Adult; Brain Neoplasms; Carmustine; Glioblastoma; Humans; Lomustine; Male | 1977 |
Cerebral pseudocysts following chemotherapy of glioblastomas.
Topics: Adult; Astrocytoma; Brain Diseases; Brain Neoplasms; Cysts; Glioblastoma; Humans; Lomustine; Male; M | 1977 |
Brain tumors in children.
Topics: Adolescent; Astrocytoma; Brain; Brain Neoplasms; Child; Diagnosis, Differential; Ependymoma; Female; | 1978 |
Prevention of brain extension in small-cell carcinoma of the bronchus.
Topics: Antineoplastic Agents; Brain Neoplasms; Bronchial Neoplasms; Carcinoma, Small Cell; Drug Therapy, Co | 1978 |
Combination chemotherapy of malignant glioma. Effect of postoperative treatment with CCNU, vincristine, amethopterine and procarbazine.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Drug Therapy, Combination; Glioma; Humans; Lomustine; Meth | 1978 |
Adjuvant chemotherapy with nitrosourea compounds following surgery plus radiotherapy in glioblastoma multiforme.
Topics: Brain Neoplasms; Carmustine; Glioblastoma; Humans; Lomustine; Nitrosourea Compounds; Semustine | 1978 |
[Value of chemotherapy associated with conventional treatment of malignant gliomas of the brain. Study of 95 cases with histological verification and follow-up of 1 to 6 years 9 months].
Topics: Administration, Oral; Adult; Brain Neoplasms; Carmustine; Drug Evaluation; Drug Therapy, Combination | 1979 |
Preoperative radiotherapy and chemotherapy in hypervascular, high-grade supratentorial astrocytomas.
Topics: Adult; Aged; Brain Neoplasms; Drug Therapy, Combination; Female; Glioblastoma; Humans; Lomustine; Ma | 1979 |
Delayed response to brain tumor chemotherapy.
Topics: Adult; Brain Neoplasms; Glioma; Humans; Lomustine; Male; Middle Aged; Nitrosourea Compounds; Prednis | 1979 |
Treatment of primitive malignant tumors of the central nervous system. Clinical evaluation of 91 cases.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Ependymoma; Glioma; Humans; Lomustine; Oligodendroglioma | 1979 |
Chemotherapy of experimental metastatic brain tumors in female Wistar rats.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carcinoma 256, Walker; Carotid Arteries; Cells, Cul | 1979 |
Brain tumor chemotherapy using a rat glioma model.
Topics: Animals; Bone Marrow; Brain Neoplasms; Cell Nucleus; Disease Models, Animal; Dose-Response Relations | 1979 |
Combination chemotherapy with VM 26 and CCNU in primary malignant brain tumors.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Child; Drug Therapy, Combination; Female; Humans; Lomustin | 1979 |
Combination chemotherapy for extracranial metastases of a primary malignant cerebral neoplasm.
Topics: Adult; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Cisplatin; Cyclophosphamide; Doxorubi | 1979 |
Malignant gliomas treated after surgery by combination chemotherapy and delayed irradiation. Part I: Analysis of results.
Topics: Adolescent; Adult; Aged; Astrocytoma; Brain Neoplasms; Cobalt Radioisotopes; Drug Therapy, Combinati | 1979 |
Malignant gliomas treated after surgery by combination chemotherapy and delayed radiation therapy. Part II. Tolerance to irradiation after chemotherapy.
Topics: Brain; Brain Neoplasms; Drug Therapy, Combination; Glioma; Humans; Lomustine; Neoplasm Recurrence, L | 1979 |
Comparison of the CCNU and BCNU modification of the in vitro radiation response in 9L brain tumor cells of rats.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Survival; Cells, Cultured; Dose-Response Relationship, Dr | 1979 |
Adjuvant chemotherapy with intraventricular methotrexate and CCNU after surgery and radiotherapy of medulloblastomas.
Topics: Brain Neoplasms; Humans; Injections, Spinal; Lomustine; Medulloblastoma; Methotrexate; Nitrosourea C | 1978 |
Experimental brain tumor chemotherapy: DNA damage in the rat gliosarcoma 9L treated with CCNU.
Topics: Animals; Brain Neoplasms; DNA, Neoplasm; DNA, Single-Stranded; Drug Evaluation, Preclinical; Glioma; | 1977 |
Desmosterol: a biochemical marker of glioma growth.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Cholesterol; Chromatography, Gas; Desmosterol; Diagnosis, | 1977 |
Chemotherapy of human nervous system tumors: influence on cerebrospinal fluid sterols.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Carmustine; Cholesterol; Desmosterol; Female; Humans; | 1977 |
Development of Hodgkin's disease in a patient receiving procarbazine, CCNU, and vincristine therapy for a gemistocytic astrocytoma.
Topics: Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Drug Therapy, Combination; Female; Hodgkin Dise | 1978 |
Adriamycin and 1-(2-chlorethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Bone Marrow; Brain Neoplasms; Breast Neoplasms; Doxorubicin; Drug Therapy, Combination; | 1978 |
The effect of amphotericin B on the survival of brain-tumor-bearing mice treated with CCNU.
Topics: Amphotericin B; Animals; Brain Neoplasms; Drug Synergism; Female; Lomustine; Mice; Neoplasm Transpla | 1978 |
Chemotherapy of recurrent medulloblastoma with combined procarbazine, CCNU, and vincristine.
Topics: Adolescent; Adult; Brain Neoplasms; Child; Child, Preschool; Drug Therapy, Combination; Humans; Lomu | 1978 |
Experiments on the chemotheraphy of a transplantable glioblastoma in the rat, employing 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).
Topics: Animals; Brain Neoplasms; Glioma; Lomustine; Male; Methylnitrosourea; Neoplasm Transplantation; Neop | 1978 |
Chemotherapy of malignant gliomas: comparison of the effect of polychemo- and CCNU-therapy.
Topics: Adult; Aged; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Drug Therapy, Combination; Humans; | 1978 |
The contemporary role of chemotherapy in the treatment of malignant brain tumor.
Topics: Adrenal Cortex Hormones; Animals; Brain Neoplasms; Carmustine; Dose-Response Relationship, Drug; Dru | 1978 |
Central nervous system tumors of childhood treated with CCNU, vincristine, and radiation.
Topics: Adolescent; Astrocytoma; Bone Marrow; Brain Neoplasms; Child; Child, Preschool; Drug Therapy, Combin | 1978 |
[Interim results of the SIOP study (author's transl)].
Topics: Adolescent; Brain Neoplasms; Child; Ependymoma; Humans; Lomustine; Medulloblastoma; Methods; Vincris | 1978 |
[Neurogliale cerebral tumors: test of chemotherapy treatment. Forty five cases (author's transl)].
Topics: Adult; Aged; Brain Neoplasms; Child, Preschool; Drug Therapy, Combination; Echoencephalography; Elec | 1978 |
Relationship of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) pharmacokinetics of uptake, distribution, and tissue/plasma partitioning in rat organs and intracerebral tumors.
Topics: Animals; Brain Neoplasms; Carmustine; DNA; Kinetics; Lomustine; Male; Neoplasm Proteins; Nitrosourea | 1978 |
Treatment of adult malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Drug Administration Schedule; Drug Therapy, Com | 1978 |
Adjuvant chemotherapy in malignant brain gliomas.
Topics: Brain Neoplasms; Drug Administration Schedule; Glioma; Humans; Lomustine | 1978 |
The effect of phenobarbital pretreatment on the antitumor activity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl-1-nitrosourea (PCNU), and on the plasma p
Topics: Alkylating Agents; Animals; Biotransformation; Brain Neoplasms; Carmustine; Dexamethasone; Drug Inte | 1979 |
Management of Burkitt's lymphoma involving the central nervous system.
Topics: Antineoplastic Agents; Brain Neoplasms; Burkitt Lymphoma; Child; Cyclophosphamide; Cytarabine; Human | 1976 |
Chemotherapy of an experimental glioma with nitrosoureas.
Topics: Animals; Brain Neoplasms; Drug Administration Schedule; Ependymoma; Female; Glioma; Injections; Inje | 1977 |
Intraneoplastic injection of CCNU for experimental brain tumor chemotherapy.
Topics: Animals; Brain Neoplasms; Drug Evaluation, Preclinical; Ependymoma; Female; Lomustine; Mice; Neoplas | 1977 |
[Therapy of medulloblastoma and ependymoma in childhood].
Topics: Age Factors; Brain Neoplasms; Child; Child, Preschool; Ependymoma; Humans; Infant; Lomustine; Medull | 1977 |
DNA damage in the intracerebral rat gliosarcoma 9L treated with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.
Topics: Animals; Brain Neoplasms; Centrifugation, Density Gradient; DNA Repair; DNA, Neoplasm; DNA, Single-S | 1977 |
Letter: Effects of CCNU.
Topics: Brain Neoplasms; Drug Evaluation; Humans; Lomustine; Nitrosourea Compounds | 1976 |
Chemotherapy of brain tumors.
Topics: Brain Neoplasms; Carmustine; Drug Combinations; Glioma; Humans; Lomustine; Methotrexate; Podophyllot | 1976 |
Meningeal carcinomatosis. Case report and review of the literature.
Topics: Adult; Brain Neoplasms; Breast Neoplasms; Carcinoma; Female; Humans; Lomustine; Meninges; Methotrexa | 1976 |
Nitrosourea pharmacodynamics in relation to the central nervous system.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Glioma; Humans; Lomustine; Mice; Molecula | 1976 |
Nitrosourea chemotherapy for primary malignant gliomas.
Topics: Brain Neoplasms; Carmustine; Drug Therapy, Combination; Fluorouracil; Glioma; Humans; Lomustine; Neo | 1976 |
Lomustine (CeeNU).
Topics: Brain Neoplasms; Glioma; Hodgkin Disease; Humans; Lomustine; Nitrosourea Compounds | 1976 |
Sterols in cerebrospinal fluid during nitrosourea chemotherapy of human brain tumors.
Topics: Adult; Astrocytoma; Brain Neoplasms; Carmustine; Cholesterol; Desmosterol; Female; Glioma; Humans; I | 1976 |
Chemotherapy of malignant glioma with CCNU alone and CCNU combined with vincristine sulfate and procarbazine hydrochloride.
Topics: Brain Neoplasms; Drug Evaluation; Drug Therapy, Combination; Glioma; Humans; Lomustine; Nitrosourea | 1976 |
Environmental factors modifying the effect of CCNU on glioma in vitro and in vivo.
Topics: Animals; Brain Neoplasms; Cells, Cultured; Glioma; In Vitro Techniques; Lomustine; Mice; Nitrosourea | 1976 |
Treatment of malignant gliomas and brain metastases in adults with a combination of adriamycin, VM 26, and CCNU. Results of a phase II trail.
Topics: Adult; Aged; Brain Neoplasms; Doxorubicin; Drug Therapy, Combination; Drug Tolerance; Female; Glioma | 1976 |
Phase II study of procarbazine, CCNU, and vincristine combination chemotherapy in the treatment of malignant brain tumors.
Topics: Brain Neoplasms; Drug Therapy, Combination; Evaluation Studies as Topic; Humans; Lomustine; Neoplasm | 1975 |
CCNU in brain tumours.
Topics: Adolescent; Adult; Brain Neoplasms; Bronchial Neoplasms; Cerebellar Neoplasms; Child, Preschool; Fem | 1975 |
Combination chemotherapy with CCNU, vincristine and methotrexate in primary and metastatic brain tumors.
Topics: Brain Neoplasms; Drug Therapy, Combination; Humans; Lomustine; Methotrexate; Neoplasm Metastasis; Ni | 1975 |
Brachytherapy of brain tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Brain Neoplasms; Child; Combined Moda | 1992 |
[Diagnosis and treatment of recurrent brain glioma].
Topics: Adult; Brain Neoplasms; Cobalt Radioisotopes; Female; Glioma; Humans; Lomustine; Male; Middle Aged; | 1992 |
[Rapid complete regression of liver, brain and bone metastases from previously treated breast cancer, with combination of platin, fluorouracil and lomustine].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Breast Neopl | 1992 |
The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Drug Admi | 1992 |
2-Nitroimidazole potentiation of nitrosourea induced cytotoxicity in subcutaneous implants of rat 9L brain tumor cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Car | 1991 |
Thyroid function after treatment of brain tumors in children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine | 1991 |
Chemotherapy for oligodendroglioma. Progress report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Humans; Lomustine; Neoplasm Recurre | 1991 |
[Possible role of 06-methylguanine-DNA-transferase in the response of patients with primary tumor of the brain to chemotherapy using chloro-ethyl-nitroso-urea: results of a current study].
Topics: Astrocytoma; Brain Neoplasms; Female; Glioblastoma; Humans; Lomustine; Male; Methyltransferases; Neo | 1990 |
The chemotherapeutic response of a murine (VM) model of human glioma.
Topics: Animals; Astrocytoma; Brain Neoplasms; Carmustine; Disease Models, Animal; Lomustine; Mice; Mice, In | 1990 |
Postoperative radiotherapy and radiotherapy combined with CCNU chemotherapy for treatment of brain gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Glioma; Humans; Lomustine | 1990 |
Chemotherapy for malignant gliomas of the brain: a review of ten-years experience.
Topics: Antineoplastic Agents; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Cyclohexenes; Glioma; | 1990 |
Successful chemotherapy for newly diagnosed aggressive oligodendroglioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Humans; Lomustine; M | 1990 |
Efficiency of the radio-chemo-surgical. Treatment in cerebral astrocytomas.
Topics: Adult; Astrocytoma; Brain Neoplasms; Cobalt Radioisotopes; Combined Modality Therapy; Female; Gliobl | 1989 |
Ovarian function following chemotherapy for childhood brain tumours.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Child; Chil | 1989 |
Thyroid dysfunction after radiotherapy and chemotherapy of brain tumours.
Topics: Brain Neoplasms; Child; Combined Modality Therapy; Growth Hormone; Humans; Lomustine; Radiotherapy; | 1989 |
Criteria for termination of phase II chemotherapy for patients with progressive or recurrent brain tumor.
Topics: Adolescent; Antineoplastic Agents; Astrocytoma; Aziridines; Benzoquinones; Brain Neoplasms; Cohort S | 1989 |
Irradiation and CCNU in glioma therapy.
Topics: Brain Neoplasms; Combined Modality Therapy; Glioma; Humans; Lomustine | 1989 |
Glutathione and related enzymes in rat brain tumor cell resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea and nitrogen mustard.
Topics: Animals; Brain Neoplasms; Buthionine Sulfoximine; Carmustine; Cell Line; Cell Survival; Chromatograp | 1987 |
Supraophthalmic carotid infusion for recurrent glioma: rationale, technique, and preliminary results for cisplatin and BCNU.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Car | 1985 |
Variation in response to CCNU of glioblastoma multiforme in brain and cervical lymph node. Case report.
Topics: Adult; Brain Neoplasms; Female; Glioblastoma; Humans; Lomustine; Lymphatic Metastasis | 1985 |
[Multimodal treatment of undifferentiated astrocytomas of the cerebrum. Indications for chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Glioblas | 1985 |
In vitro analysis of BCNU-sensitivity in human malignant gliomas. II. Cross-resistance studies with cisplatinum and nitrosoureas.
Topics: Brain Neoplasms; Carmustine; Cells, Cultured; Cisplatin; Drug Resistance; Glioblastoma; Humans; Lomu | 1986 |
Neurologic dysfunction in patients treated for small cell carcinoma of the lung: a clinical and radiological study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Diseases; Brain Neoplasms; | 1986 |
Sudden onset of blindness in patients treated with oral CCNU and low-dose cranial irradiation.
Topics: Administration, Oral; Aged; Blindness; Brain; Brain Neoplasms; Carcinoma, Small Cell; Combined Modal | 1987 |
Misonidazole and CCNU chemotherapy for recurrent primary brain tumor.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bone Marrow Diseases; Brain Neop | 1987 |
Eight drugs in one day chemotherapy for brain tumors: experience in 107 children and rationale for preradiation chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Child; Cisplatin; Comb | 1987 |
Testicular damage after chemotherapy for childhood brain tumors.
Topics: Adolescent; Adult; Brain Neoplasms; Carmustine; Child; Follicle Stimulating Hormone; Follow-Up Studi | 1988 |
[New developments in chemotherapy for experimental brain metastasis].
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Daunorubicin; Doxorubicin; Flo | 1985 |
Efficacy of adjuvant chemotherapy for patients with poor-risk medulloblastoma: a preliminary report.
Topics: Adolescent; Adult; Brain Neoplasms; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; D | 1988 |
Results of the treatment of children with recurrent gliomas with lomustine and vincristine.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool | 1988 |
Central nervous system involvement in malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Dexameth | 1988 |
Treatment of recurrent brain stem gliomas and other central nervous system tumors with 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Brain Stem; Chil | 1988 |
[Use of nitrosourea derivatives in the treatment of patients with Hodgkin's disease with lesions of the central nervous system].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Drug Evaluation; | 1988 |
Successful chemotherapy for recurrent malignant oligodendroglioma.
Topics: Adult; Antineoplastic Agents; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Female; Humans | 1988 |
Gonadal dysfunction after treatment of intracranial tumours.
Topics: Adolescent; Brain Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Female; Gonadotropi | 1988 |
[Efficacy of the "8 drugs in a day" protocol in brain tumors in children].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Cer | 1988 |
[Abdominal metastasis of a pineal germinoma in a child with a ventriculo-peritoneal shunt].
Topics: Abdominal Neoplasms; Brain Neoplasms; Cerebrospinal Fluid Shunts; Child; Humans; Liver Neoplasms; Lo | 1987 |
Effect of cell cycle position on the survival of 9L cells treated with nitrosoureas that alkylate, cross-link, and carbamoylate.
Topics: Alkylating Agents; Animals; Brain Neoplasms; Carbamates; Carmustine; Cell Cycle; Cell Line; Cell Sur | 1986 |
Astroblastoma revisited: a report of three cases.
Topics: Adult; Aged; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; Electroencephalography; Female | 1986 |
Myelofibrosis following treatment with a nitrosourea for malignant glioma.
Topics: Brain Neoplasms; Glioma; Humans; Lomustine; Male; Middle Aged; Primary Myelofibrosis | 1986 |
Dibromodulcitol-based combined postoperative chemotherapy of malignant astrocytomas and glioblastomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Combined | 1986 |
Chemotherapy in intracerebrally transplanted tumors induced with transplacental administration of ethylnitrosourea in rats.
Topics: Animals; Brain Neoplasms; Drug Administration Schedule; Ethylnitrosourea; Female; Lomustine; Methyln | 1986 |
Sequential treatment with interferon and chemotherapy of metastatic malignant melanoma. Total remission of cutaneous and visceral metastasis, but not of cerebral metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carmus | 1987 |
Metastatic malignant melanoma treated with procarbazine, vincristine and lomustine (POC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Female | 1987 |
Assay of anti-cancer drugs in tissue culture: relationship of relapse free interval (RFI) and in vitro chemosensitivity in patients with malignant cerebral glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cells, Cultured; Female; Gli | 1985 |
Nephrotoxicity of lomustine. A case report and literature review.
Topics: Adult; Astrocytoma; Brain Neoplasms; Humans; Kidney Diseases; Kidney Glomerulus; Lomustine; Male | 1985 |
Chemosensitivity testing in the treatment of malignant gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Glioma; Humans; Lomustine; Procarba | 1985 |
[Brain tumors in infants and children--factors affecting prognosis, (Part-3). Mode of metastasis and prognosis in medulloblastoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Brain Stem; Cerebellar Neoplasms; C | 1985 |